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ABSTRACT
Methods/Measurements: A cross-sectional correlational design explored the
relationships between symptoms, functional status, health perceptions and QoL in women with
CVD. The aims of the study were: 1) to determine the relationship of symptoms
(depression/anxiety) to functional status (health-promoting behaviors), health perceptions (illness
perception), and QoL; and 2) to determine whether age is a factor contributing to negative mood
symptoms, functional status, health perceptions, and QoL after controlling for social support.
Measurements were collected at one time-point to address these aims that included the
following: biological function (Framingham Recurrent Risk Model and Functional Comorbidity
Index), symptoms (Patient Health Questionnaire-8 and Generalized Anxiety Disorder-7),
functional status (Health-Promoting Lifestyle Profile-II), general health perceptions (Illness
Perception Questionnaire-Revised-Cardiac version), QoL (Quality of Life Index-Cardiac
version) and social support (Medical Outcomes Study-Social Support Survey). A convenience
sample of 81 women aged 35-78 years with CVD were recruited from two cardiology clinic sites
within a single health care system in the Chicago west suburbs. The study was approved by the
institutional review boards from Advocate Health Care and Loyola University Chicago.
Data Analysis: The primary study hypothesis was that negative mood symptoms
(depression/anxiety) will be associated with fewer health-promoting behaviors, less perception of
risk (illness), and poorer QoL. SPSS Statistics version 25 was used to perform all the analyses.
To test the primary hypothesis, the analysis included descriptive statistics on all study variables,
xvii

correlations, and multiple regression.
Correlational analyses demonstrated the following: (1) more depressive symptoms were
associated with greater anxiety symptoms (r = .689, p < .01), less health promoting behaviors (r
= -.366, p < .01), poorer QoL (r = -.673, p < .01), less social support (r = -.380, p < .01), and
greater functional comorbidities (r = .431, p < .01), (2) symptoms of higher anxiety were
associated with less health promoting behaviors (r = -.328, p < .01), poorer QoL (r = -.687, p <
.01), less social support (r = -.431, p < .01) and greater functional comorbidities (r = .345, p <
.01), (3) better QoL was significantly associated with more health promoting behaviors (r = .535,
p < .01). When examining illness perception, correlations indicated that greater depressive and
anxiety symptoms were associated with: (1) greater number of CVD symptoms (r = .274, p <
.05; r = .246, p < .05), (2) less understanding of CVD (r = -.340, p < .01; r = -.322, p < .01), and
that (3) CVD caused distress (r = .431, p < .01; r = .522, p < .01).
Stepwise multiple regression method was used to determine the variables that predict
QoL. Anxiety symptoms ( = -.324 (SE = .120, t = -3.69, p < .001), health promoting behaviors
( = .292 (SE = .014, t = 4.08, p < .001), functional comorbidities ( = -.257 (SE = .119, t = 3.68, p < .001), illness perception CVD caused distress ( = -.215 (SE = .067, t = -2.80, p < .01),
and social support ( = .152 (SE = .026, t = 2.03, p < .05), were significant predictors of QoL.
Greater anxiety symptoms, greater functional comorbidities, and the belief that CVD caused
distress predicted poorer QoL. Greater health promoting behaviors and greater social support
predicted greater QoL. Although depressive symptoms were not a predictor of QoL, there was a
trend ( = -.178 (t = -1.85, p = .069) toward poorer QoL. An important finding is that anxiety
symptoms ( = -.324) were a greater predictor of poorer QoL than depressive symptoms ( = .178) in this sample of women.
xviii

The secondary hypothesis was that women who are younger will have more negative
symptoms, fewer health-promoting behaviors, less perception of illness, and lower QoL than
women who are older. In order to test this hypothesis, Analysis of covariance (ANCOVA) for
social support was used to examine differences between age groups (less than 65 or 65 and older)
among the key study variables. The analysis results found that younger women had lower QoL
compared to the older women (F(1,78) = 5.81, p < .05). In addition, there was a trend for
younger women to have more anxiety symptoms (F(1,78) = 3.41, p = .068) and perceive more
emotional distress related to CVD (F(1,78) = 3.86, p = .053).
In summary, younger women with CVD reported worse outcomes than older women.
These findings support the importance to target the younger women to treatments, such as
antidepressant/anti-anxiety medications, education on CVD illness, and health promoting
behaviors to increase their overall QoL.
Nursing and Healthcare Implications: Overall, findings from this study support the
need to identify early detection of negative mood symptoms and implement interventions to
promote healthy behaviors, address illness perceptions to improve QoL. Collaborative care
models, managed by advanced practice nurses, have been shown to be more effective in
improving negative mood, healthy behaviors, and QoL in patients with CVD. Ultimately,
advanced practice nurses have the opportunity to develop evidence-based practice guidelines to
develop and implement a collaborative care approach to improve women’s CVD health and QoL.
The overall benefit could potentially reduce CVD secondary events that translate to cost savings
to the health care system.
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CHAPTER ONE
INTRODUCTION
Magnitude and Importance of the Problem
Cardiovascular disease (CVD) is a widespread chronic illness that is a major cause of
morbidity and mortality in the United States. CVD is the leading cause of death for females in
the United States accounting for 289,758 deaths in 2013 (American Heart Association, 2015;
Kochanek, Xu, Murphy, Minino, & Kung, 2011; Mozaffarin et al., 2015; Roger et al., 2012; Xu,
Murphy, Kochanek, & Bastian, 2016). One out of every three female deaths is due to CVD and
the mortality rate continues to grow (American Heart Association, 2015). Statistics support the
claim that heart disease has a significant impact on health care costs across the nation (Centers
for Disease Control (CDC), 2014; Mozaffarin et al., 2015). In 2011, the estimated direct and
indirect costs for CVD were approximately 320 billion dollars (National Heart Lung Blood
Institute, 2012). Over the past decade there has been an increased awareness of women and heart
disease through campaigns such as “Go Red for Women”, although there remains an underrepresentation of women in clinical trials examining CVD prevention (Low, Thurston, &
Matthews, 2010). There is a need to continue to study women with heart disease due to the
increase in mortality rate in women as compared to men and the significant cost to health care.
Depression
Depression is common and often unrecognized in CVD patients (Huffman, Celano,
Beach, Motiwala, & Januzzi, 2013). Over the past two decades, research has found depression is
1
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prevalent in individuals with CVD and has a significant association with increased morbidity and
mortality rates, independent of traditional CVD risk factors (Lichtman et al., 2014; Meijer et al.
2011; Rutledge et al., 2006.) Studies have found that depressed CVD patients have an increased
risk for cardiac events (Gan et al., 2014; Huffman et al., 2013). These cardiac events have been
attributed to poor adherence to healthy behaviors including exercise, diet modification, and
smoking cessation (Kronish et al., 2006; Lichtman et al., 2014). Depression is present in 7.6% of
the general population (Pratt & Brody, 2014) and may be as high as 20-40% in patients with
CVD (Celano & Huffman, 2011). Furthermore, 15-20% of patients with CVD meet the criteria
for major depressive disorder (MDD) (Carney & Freedland, 2008; Lesperance, Frasure-Smith,
Juneau, & Theroux, 2000; Thombs, Bass et al., 2006; Thombs, de Jonge et al., 2008). In
conjunction with CVD demonstrating inflated levels of depression, reports suggest females are
generally more susceptible to depression (Pratt & Brody, 2014; Vaccarino, 2010).
Research data has shown that depression is often chronic and recurrent in individuals
with stable CVD (Rudledge, Reis, Linke, Greenberg, & Mills, 2006). Depression is a comorbid
disorder that is significantly associated with worse illness perception and increased perceived
symptoms in individuals with CVD (Mommersteeg, Pot, Aarnoudse, Denollet, & Widdershoven,
2013; Rogerson, Murphy, Bird, & Morris, 2012). Depression can worsen adherence to healthy
behaviors making medication compliance, exercise, diet modification, and smoking cessation
challenging for the patient (Bigger & Glassman, 2010; Pozuelo et al., 2009; Tsu, 2012).
Anxiety
Concomitant with depression are also increased levels of anxiety. Anxiety is a negative
emotion that may impair healthy behaviors in individuals with CVD. Anxiety disorders affect
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approximately 19 million adults in the US annually and have been associated with impaired
QoL, increased adverse health behaviors, and poor outcomes related to chronic illness (Strine,
Chapman, Kobau, & Balluz, 2005). This suggests an individual’s emotional response may have
an effect on behavioral changes. A meta-analysis of twenty studies found anxiety to be an
independent risk factor for CVD and cardiac mortality (Roest, Martin, de Jonge, & Denollet,
2010). Anxious individuals had a 26 % increased risk of CVD and a 48 % increased risk for
mortality (Roest et al., 2010). Anxiety has been associated with progressive atherosclerosis,
ventricular arrhythmias, and decreased heart rate variability (Martens, Nyklíček, Szsabó, &
Kupper, 2008; Paterniti et al., 2001; Van den Broek et al., 2009). Anxiety has also been
associated with an increase in mortality risk for middle aged women (Denollet, Maas,
Knottnerus, Keyzer, & Pop, 2009). Brezinka and Kittel (1996) reviewed nine studies examining
emotional responses in men and women post myocardial infarction (MI). Eight of the nine
studies found anxiety and depression to be greater in women compared to men. Unhealthy
lifestyle behaviors, including decreased physical activity, smoking, and increased weight, were
found in individuals with anxiety.
Anxiety can alter an individual’s perception by creating an overwhelming feeling
accompanied by a health threat message. The health threat message alters the individual’s
internal emotional response and creates a negative mood that becomes a barrier to healthy
behavior. The individual adopts unhealthy behaviors in attempt to reduce the negative mood and
reduce the anxiety (Rozanski, 2005). The unhealthy behaviors used to reduce anxiety may
include smoking, physical inactivity, or stress-related eating. These harmful behaviors increase
the individual’s risk for CVD events. Evidence strongly supports depression and anxiety as mood
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symptoms that adversely affect the health of individuals with CVD. However, the link between
mood and the illness perception in individuals with chronic CVD has yet to be clearly
understood.
Health-Promoting Behaviors
Healthy behaviors are self-care behaviors that contribute to a significant reduction in
CVD risk through prevention and management of the disease. Healthy behaviors include diet,
physical exercise, weight reduction, medication adherence, and smoking cessation. Unhealthy
lifestyle behaviors contribute to increased cardiovascular risk in women. Although risk factors
for heart disease are similar for women and men, women with known CVD have worse outcomes
than men (Pearson, 2010). There is evidence to suggest that women are knowledgeable about
cardiovascular risk reduction behaviors; however, many do not change their health behaviors or
their change in behavior is not sustained (Mosca et al., 2006). Data indicate that women who
acknowledge risk factors for CVD, lack understanding of preventive strategies (Webster &
Heeley, 2010). This may suggest that factors, such as emotional responses, can alter a woman’s
perception of illness, which may influence healthy behaviors for risk reduction. Women who do
not make changes in their health behaviors are at significantly greater risk for MI, stroke, and
death (Hammond et al., 2007; Mosca et al., 2006; Murphy et al., 2005).
There is sufficient evidence to suggest why women are not successful in making
alterations to their health behaviors (Hart, 2005; Thanavaro, 2005). Such behaviors, known as
barriers to change, include family/care-giving responsibilities, multiple role functions, confusion
in the media of preventive strategies, lack of money for health insurance or medications, and
education. The list may be extended to include factors such as lack of knowledge of CVD, lack
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of knowledge regarding relationship between cardiovascular risk factors and CVD, religious
beliefs, stress, and depression (Mochari-Greenberger, Mills, Simpson, & Mosca, 2010). There is
evidence indicating the significant role of negative mood symptoms (depression, anxiety) in
illness perception, which in turn will influence CVD risk perception and self-care behaviors in
individuals with chronic heart disease (McKenzie & Skelly, 2010; Mommersteeg et al., 2013;
Strine et al., 2005).
Unhealthy lifestyle behaviors have placed women at an increased risk for both primary
and secondary CVD events. Unhealthy lifestyle behaviors for CVD include eating patterns (high
saturated and trans fat diets), sedentary lifestyle, overweight/obesity, tobacco use, and
medication non-adherence. Although there is an increase in awareness of healthy lifestyles to
prevent CVD, some women continue to engage in unhealthy behaviors, where others do not.
Barriers to healthy behavior change are plentiful and factual in women’s everyday life. Negative
mood symptoms have been identified as a barrier to healthy behavior change in some
individuals. Illness perception may predict an individual’s ability to adopt healthy behaviors.
However, little research has been conducted regarding whether negative mood symptoms affect
illness perception. Although negative emotions are risk factors for developing CVD and a
barrier to healthy behaviors, these emotions are not routinely screened for nor are they integrated
into cardiology practice guidelines. Learning more about what prevents women from adopting
healthy behaviors for secondary risk reduction for CVD events may have a positive impact on
women’s health in the United States of America.
Illness Perception
Over the past decade there has been an increase awareness of women and heart disease,
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but still only 54% of women recognize heart disease as the major cause of death for the female
gender (Mosca, Mochari-Greenberger, Dolor, Newby, & Robb, 2010). Psychological factors that
influence the prognosis for individuals with CVD is an important area for research (Fennessy,
DeVon, Ryan, Lopez, & Zerwic, 2013; Smith, Pedersen, Van Domburg, & Denollet, 2008).
Illness representation is the individual’s perception of the significance and meaning of a health
threat or disease (Cherrington, Moser, Lennie, & Kennedy, 2004). Illness perception is defined
as an individual acknowledging they have disease, such as CVD, hypertension, heart failure,
hyperlipidemia, arrhythmias, or obesity and/or diabetes. Studies have demonstrated that illness
perception affected patients’ health behaviors and the confidence to maintain long-term
behavioral changes in patients with an acute MI (Steca et al., 2013). There is limited information
on whether negative mood symptoms (depression/anxiety) influence illness perception in
individuals with chronic CVD.
Risk Perception
Risk perception is the degree of understanding one’s risk for illness/disease. Higher
levels of risk perception should increase one’s motivation to adopt healthy behaviors that will
reduce the illness threat. Studies have shown that women with increased risk perception for
CVD do not engage in promoting changes in their healthy behaviors (Galbraith, Mehta, Veledar,
Vaccarino, & Wenger, 2011). Additionally, women with CVD underestimate their risk for
future CVD events (Hart, 2005; Webster, 2010). One factor contributing to an individual’s
decreased perception of risk is optimistic bias (Weinstein, 1982). Optimistic bias is when an
individual overestimates the positivity of a situation. In other words, the individual
underestimates the likelihood that he/she will experience an adverse event, such as an MI or
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stroke. An individual’s perception of risk for CVD is a major consideration in preventing further
development of CVD (Mosca, Ferris, Fabunmi, & Robertson, 2004). There are cognitive,
perceptual, and environmental factors affecting risk perception of CVD in women (Ammouri &
Neuberger, 2008; Dearborn & McCullough, 2008). Cognitive factors include the individual’s
knowledge and understanding of CVD risk factors, the number of current risk factors, and
educational level. Perceptual factors include symptoms, socio-economic variables, belief in a
higher being in charge (God), and unrealistic optimism. Environmental factors affecting risk
perception are communication with healthcare providers, access to health care, media, and
family/friends. The focus on risk reduction for individuals with CVD should remain dynamic to
prevent disease progression and the occurrence of cardiac events (Moore, Kimble, & Minick,
2010). Individual perceptions of risk have been linked to risk reduction behavior, known as
healthy behaviors. Psychological factors, such as depression/anxiety symptoms, may explain
some of the resistance to behavior change seen in individuals with chronic heart disease. There
is limited data about psychological factors and risk perception for heart disease, especially in
women with known CVD.
Quality of Life (QoL) in Women with CVD
QoL has been defined in terms of an individual’s overall satisfaction with life. Healthrelated quality of life (HRQoL) is a subcategory of QoL that conceptualizes and measures QoL
with symptoms of a specific disease (Wilson and Cleary, 1985). HRQoL was developed as a
means of relating health status to satisfaction with life. HRQoL contains three major
characteristics: multidimensional (physiological, psychological, sociological, spiritual),
temporal (individuals can change their self-perceptions of quality of life), and subjective (an
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individual’s own thought or perception) (Ferrans & Powers, 1985; Padilla & Grant, 1985).
HRQoL measures QoL and the way a disease expresses itself in an individual’s daily life. These
include symptoms, functional ability, psychological states, social states, and physical wellness
(Broddadottir, Jensen, Norris, & Graham, 2009). There is no consensus in the healthcare
disciplines on defining QoL and how to measure the concept, other than the general view that
QoL is an important outcome of health care intervention (Anderson & Burckhardt, 1999). This
study used the term QoL to refer to an overall satisfaction with life maintained by the individual
with CVD.
QoL is lower in individuals with CVD compared to individuals without CVD, and
women with CVD have worse QoL when compared to men with CVD (Ford et al., 2004). When
comparing QoL between men and women it has been found that women are worse off in the
following categories: general health, physical functioning, social functioning, well-being, selfesteem, depression levels, anxiety, and social supports (Broddadottir et al., 2009). The effect
that depressive/anxiety symptoms and age may have on QoL in gender comparison studies
remains unclear. Although women with CVD consistently report worse QoL compared to men
with CVD, there is limited and inconsistent understanding of the effect of mood and age on QoL
(Broddadottir et al., 2009).
Social Support
Social support is defined as support provided by tangible tasks, financial support, and
support that is informational, emotional, and structural (Lett, Blumenthal, Babyak, & Strauman,
2005; Sherbourne & Stewart, 1991). Social support consists of two domains: functional support
and structural support. Functional support refers to the encouragement provided by the social
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network that includes providing information, a sense of being loved, and help with tasks.
Structural support describes the characteristics of the social network that includes group
membership, number/frequency of contacts, and marital status (Barth, Schneider, & von Kanel,
2010). This support provides a positive influence for individuals to better cope with stressful
encounters. Social support is a known predictor of CVD etiology and prognosis. Impaired social
support is a known predictor for greater CVD mortality. In addition, social support has been
found to have a positive influence on healthy behaviors and QoL (Lett et al., 2005; Stanuite,
Brozaitiene, & Bunevicius, 2013).
Older Population
The past several decades have shown a significant growth in the number of older adults
in the United States. The first Baby Boomers came to age 65 years in 2011, predicting an
increase in the older population for the next twenty years (West, Cole, Goodkind, & He, 2014).
The older population (> 65 years) is estimated to increase from 12.4% to 20.3% between 2000
and 2030 (West et al., 2014). The subgroup of individuals 85 years and older is expected to
triple by 2050. There is a significant disproportion of older women compared with older men,
with women outnumbering men by 3.6 million among those aged 65 years and over (West et al.,
2014). Studies have found that women develop CVD disease approximately ten years later than
men. Women have a longer life expectancy and develop CVD at an older age resulting in a
higher prevalence of heart disease in women over the age of sixty five years of age. Studies have
indicated 10% to 15% of older patients (age ≥ 65 years) with CVD are depressed and 20% show
symptoms of anxiety (Berkman et al., 2000; Williams et al., 2002). Few studies have evaluated
the impact of negative mood symptoms (depression/anxiety) in older women (≥ 65 years) with
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known heart disease. There may be a difference in negative mood symptoms and illness
perception in women of older age (≥ 65 years) compared with middle-aged populations. Older
aged women with and without CVD have been found to have less depressive symptoms
compared with middle-aged women (Broddadottir et al., 2009; Rutledge et at., 2012; Shah et
al., 2014). Broddadottir et al. (2009) found depressive symptoms were greater in younger
women (32-59 years) compared to middle age (age 60-75 years) or older (age 76–88 years)
women with CVD. Rutledge et al. (2012) studied women (n = 620) with suspected ischemic
heart disease and found depressive symptoms were greater in middle-aged women (mean age 56
years) compared to older (mean age 59 years) women. Shah et al. (2014) studied women with
CVD (n = 1071) and found depressive symptoms were greater in younger women (< 55 years)
compared to middle-aged (56 – 64 years) or older aged (≥ 65 years) women. Mirowsky and
Ross (1992) found depressive symptoms to be most prevalent among younger adults (age 18-39
years) followed by older adults (≥ 65 years) and least prevalent in middle-aged adults (40 - 64
years). Keyes (2004) found depressive symptoms were most prevalent in women with CVD
between the ages of 45 and 74 years. Beckie, Fletcher, Groer, Kip & Ji (2015) examined women
with CAD (n = 252) after acute coronary syndrome (ACS) or MI and found anxiety and
depressive symptoms to be greater in younger women (< 55 years) compared to older women.
Fang et al. (2018) studied anxiety symptoms in men and women post MI and found anxiety
symptoms were greater in younger women and men (age < 65 years) compared to older
individuals. There are limited and inconsistent findings in the literature on individuals with CVD
and the prevalence of depressive and/or anxiety symptoms in age-related populations.
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Theoretical Model
The theoretical framework that guided this study was proposed by Wilson and Cleary
(1995) who integrate biological, psychological, and social facets of health outcomes to examine
HRQoL. Their model was developed to conceptualize the relationships of pertinent clinical
variables to measures of HRQoL. The theory examines causal relationships between multiple
health concepts that affect an individual’s QoL. The model is comprised of individual and
environmental characteristics that influence an individual’s symptoms, functional status, general
health perceptions and overall QoL (Wilson & Cleary, 1995). Individual characteristics include
one’s own preferences or values and environmental characteristics include social, economic, and
psychological support. Wilson-Cleary’s model examines the relationships among five different
levels of patient outcomes: biological and physiological variables, symptoms status, functional
status, health perceptions, and overall QoL. The biological and physiological variables are
medical diagnoses, laboratory values, and physical examination findings that affect an
individual’s health status. The symptom status concept includes physical, emotional, and
cognitive symptoms perceived by the individual. Functional status measures the physical and
social roles and the psychological function of the individual. General health perception is a
subjective rating of all the preceding health concepts, including mental health. Overall QoL is
the individual’s subjective well-being that is assessed by how happy and/or satisfied the
individual is with life as a whole. Wilson-Cleary’s model has provided a framework that was
best suited to guide the proposed study because it identifies the multiple key concepts that affect
an individual’s QoL. The proposed study included Ferrans, Zerwic, Wilbur, & Larson’s (2005)
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revision of the Wilson-Cleary model, which indicates that biological function is influenced by
individual and environmental characteristics.
For the proposed study, the revised Wilson-Cleary’s Model for HRQoL (Figure 1) was
used to examine mood symptoms, general health perception, functional status and QoL. The
characteristics of the individual included age, race/ethnicity, marital status, education,
socioeconomic status, and employment. The biological variables for the proposed study were
cardiovascular risk factors and comorbidities measured by the Framingham Recurrent Risk
Model and the Functional Comorbidity Index tool. Evidence shows that cardiovascular risk
factors and the number of comorbidities influence one’s risk for a secondary CVD event, as well
as mortality (Mozaffarian et al., 2015). Symptom status assessed depressive symptoms (Patient
Health Questionnaire-8, PHQ-8) and anxiety symptoms (Generalized Anxiety Disorder-7, GAD7). Functional status was assessed by health promotion behaviors (Health-Promoting Lifestyle
Profile-II scale, HPLP-II). General health perceptions was assessed by asking women with CVD
their perception of cardiac illness (Illness Perception Questionnaire-Revised Cardiac version,
IPQ-R Cardiac). There is evidence that functional status has an effect on health perceptions, as
health perceptions influence functional status. Consequently, a reciprocal relationship is
indicated on this model with permission of Dr. Carol Ferrans (Personal Communication, June 1,
2016). QoL measured overall satisfaction with life that included the following subscales: health
and functioning, social and economic, psychological and spiritual, and family (Quality of Life
Index-Cardiac version, QLI-Cardiac). Lastly, environmental characteristics included social
support measured by the Medical Outcomes Study Social Support Survey (MOS-SS).
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Figure 1. Study conceptualization using the revised Wilson and Clearly Health-Related Quality
of Life Model (Ferrans et al., 2005)
Characteristics of the Individual
Age, Race, Ethnicity, Marital, Education,
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Purpose of the Study

Purpose of the Study
The purpose of this study was to better understand whether negative mood symptoms
(depression, anxiety) contributed to the lack of successful change in healthy behaviors in women
with known CVD. Negative mood symptoms may impact illness perception which may be
related to a decrease in health-promoting behaviors, which negatively impacts QoL. Therefore,
this study examined the effect of negative mood symptoms on functional status, general health
perceptions, and QoL. For this study, the concept of mood was assessed by examining the
symptoms of depression and anxiety using the PHQ-8 and the GAD-7 instruments.
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Study Aims and Hypotheses
The primary aims and hypotheses were:
Aim 1: To determine the relationship of symptoms (depression, anxiety) to functional
status (health-promoting behaviors), health perceptions (illness perception), and QoL.
Hypothesis: Negative mood symptoms (depression or anxiety) will be associated with
fewer health-promoting behaviors, less perception of risk (illness), and poorer QoL.
Aim 2: To determine whether age is a factor contributing to negative mood symptoms,
functional status, health perceptions, and QoL after controlling for social support.
Hypothesis: Women who are younger will have more negative symptoms, fewer healthpromoting behaviors, less perception of risk, and lower QoL than women who are older (≥ 65
years) after controlling for social support.
The study identified the effect mood had on functional status, health perceptions, and QoL,
and whether age was a contributing factor. This knowledge will benefit nursing practice by
enabling advanced practice nurses (APNs) to target the factors that affect functional status and
QoL. These findings may support the benefits of regular screening for depression and anxiety
symptoms in cardiology clinics. Identifying and treating depression and anxiety symptoms may
promote positive illness perception, which may help improve treatment and disease outcomes in
women with CVD.

CHAPTER TWO
LITERATURE REVIEW
The theoretical framework that guided this study was the revised Wilson and Cleary’s
HRQoL model. As described in the previous chapter, the key components included the
following: individual characteristics, biological function, symptom status, functional status,
general health perception, and environmental factors. Each theoretical component of the HRQoL
model will be presented with its supporting literature to justify its inclusion in this study.
Characteristics of the Individual
Women and Heart Disease
CVD is the leading cause of death for females in the United States, accounting for
289,758 deaths in 2013 (American Heart Association, 2015; Kochanek, Xu, Murphy, Minino, &
Kung, 2011; Mozaffarin et al., 2015; Roger et al., 2012; Xu, Murphy, Kochanek, & Bastian,
2016). One out of every three female deaths is due to CVD and the mortality rate continues to
grow (American Heart Association, 2015). The risk for CVD increases as women become older.
Studies have found women develop CVD approximately ten years later than men. CVD is
present in 69.1% of men and 67.9% of women between the ages of 60-79. Of said percentages,
11.3% of men and 4.2% of women had an MI. There is a higher proportion of CVD in men than
women before the age of 75 years, but after this age the paradigm shifts with women accounting
for the higher proportion of CVD. In the age group exceeding 80 years, CVD is comparable
between genders—84.7% of men and 85.9% of women, and of those percentages, 17.3% of men
15
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and 8.9% of women experienced an MI. Women have a longer life expectancy and develop
CVD at an older age, resulting in a higher prevalence of heart disease over 65 years of age.
Similarly, the mortality rate from an MI increases with age, especially over the age of 80
years. One year after an acute MI, women over the age of 45 years who have had an MI have a
26% mortality rate compared to 19% in men (Mozaffarin et al., 2015). The mortality rate five
years after a first MI is 47% in women and 36% in men (McSweeney et al., 2016). The disparity
in deaths between men and women may be due to the fact that women have MIs at an older age
than do men, and as one ages there is a greater incidence of comorbidities. Diabetes,
hypertension, hypercholesterolemia, and genetic history of heart disease are more prevalent in
women with CVD than men with CVD (Shirato & Swan, 2010). The greater number of
cardiovascular risk factors increases the likelihood for a cardiac event.
There are racial/ethnic variations in CVD in the United States with a higher occurrence in
black women (7%) compared to Hispanic (5.9%) and white (4.6%) women. The same trend is
found with MI (2.2%, 1.7%, and 1.8% respectively) and angina (5.0%, 3.8%, and 2.9%) (Go et
al., 2014). Low income, low educational level and crime-ridden neighborhoods are found to
influence CVD risk reduction behaviors in women without CVD (Finkelstein, Khavjou, Mobley,
Haney, & Will, 2004; Mosca et al., 2006). Low income may influence an unhealthy diet and an
unsafe neighborhood may limit physical activity.
The delay in diagnosis and treatment of MI contributes to an increase in mortality. The
difference in cardiac symptoms between men and women may account for the delay in diagnosis
and treatment for women. Although the most frequent cardiac symptoms prior to an ACS in men
and women are chest pain, shortness of breath, and unusual fatigue, women report more
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indigestion, palpitations, nausea, numbness of the hands, and weakness (Devon, Ryan, Ochs, &
Shapiro, 2008; Eastwood, Johnson, Rutledge, Bittner, Whittaker et al., 2013). The latter
symptoms reported by women are not the typical symptoms associated with ACS and may
contribute to a delay in diagnosis. The World Health Organization (WHO), Northern Sweden
Multinational MONItoring of Trends and Determinants of CArdiovascular Disease (MONICA)
study examined symptoms and time delay to medical presence in men (n = 5072) and women (n
= 1470) with MI over a 15-year period (Isaksson, Holmgren, Lundblad, Brulin, & Eliasson,
2008). There was no gender difference in prehospital delay until after the age of 65. The
individuals 65 and older had a longer time preceding hospitalization and fewer typical MI
symptoms, compared to those under the age of 65. In addition, overall women had longer
prehospital delay compared to men (Isaksson et al., 2008). There are many studies that provide
insight into the delay in seeking care for women. One of the largest contributors to delay in
treatment is women’s inability to identify MI symptoms and promptly seek medical care
(Isaksson, Brulin, Eliasson, Naslung, & Zingmark, 2013). Another contributing factor to delay
care is the healthcare provider’s uncertainty in diagnosing CVD and less aggressive treatment
when women disclose chest symptoms.
Secondary prevention of heart disease involves the long-term management of cardiac risk
factors in women with known CVD. Individuals with CVD are considered to be at high risk for
a secondary event. Individuals ≥ 65 years of age with a first MI will have a recurrent MI or fatal
coronary heart disease (CHD) event within five years. The breakdown of statistics shows 21%
Caucasian men and women, 33% black men, and 26% of black women will experience such
problems (Rogers et al., 2012). Heart failure will develop in 19% of white men, 31% of black
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men, 23% of white women, and 24% of black women within this five year time period (Rogers
et al., 2012). There is a high rate of adverse outcomes in older patients, especially minorities,
with CVD supporting the need for secondary prevention of cardiac events.
Biological Function
Patients with a history of coronary artery disease (CAD) have an increased risk of
subsequent cardiac events, including MI, stroke, or death. Women with CAD are considered to
be at high risk for a secondary cardiac event (Mosca et al., 2010). The American Heart
Association (AHA) and the American College of Cardiology Foundation (ACCF) guidelines for
secondary prevention include healthy lifestyle changes and medication adherence, as well as
blood pressure < 140/90 mmHg, low density lipoprotein (LDL) < 100mg/dL and cardiac
rehabilitation (Smith et al., 2011). The number of cardiac risk factors correlates to the percent of
risk for a secondary cardiac event (D’Agostino et al., 2000). The greater the number of risk
factors, the greater the risk for a secondary event. The traditional risk factors for CVD in women
are comparable to those in men and include tobacco use, inactivity, obesity, dyslipidemia,
hypertension, diabetes mellitus, older age, and family history (Yusuf et al., 2004).
There are specific risk factors for women that increase their risk for a cardiac event. The
female specific risk factors are menopause and depression. Menopause causes the loss of
estrogen and low estrogen levels contributes to endothelial dysfunction (McSweeney et al.,
2016). Although it continues to remain controversial, lack of estrogen may contribute to CAD in
postmenopausal women. There is also a greater occurrence of depression in women compared to
men. Depression contributes to adverse physiological and psychosocial function, increasing the
risk for CVD (Huffman et al., 2013). The AHA recognizes depression as a risk factor for CVD
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and recommends screening and treating depression in cardiac patients to decrease the risk for
secondary events (Lichtman et al., 2008; Smith et al., 2011).
Individuals with CAD typically have other comorbid conditions, such as diabetes,
hypertension, hypercholesterolemia, and tobacco use. This may be partly due to the fact that
CAD usually occurs in an individual at an older age, 60 years or greater. For decades, research
studies have identified that comorbid conditions have been found to have a negative effect on
QoL in individuals with heart disease (Jamieson et al., 2002; Stewart et al., 1989). Patients may
differ significantly in their general health perception due to their comorbid illnesses (Groll et al.,
2005). Some comorbid illnesses, for example arthritis or chronic obstructive pulmonary disease,
may impact physical function, contributing to less engagement in health-promoting behaviors
that require physical exercise. It is essential to adjust for comorbid illnesses when examining the
relationship between negative mood symptoms, illness perception, health-promoting behaviors,
and overall QoL. This is of particular importance in the older populations where more chronic
illnesses are present in the same individual (Groll et al., 2005).
Symptom Status
Depression
Depression is a known risk factor for the development of CVD in healthy individuals and
for recurrent CVD events in patients with known CVD disease (Lichtman et al., 2008; Lichtman
et al., 2014; Low et al., 2010). Gan et al. (2014) conducted a meta-analysis based on thirty
prospective cohort studies to examine the association between depression and the risk of CHD.
The studies included a total of 893,850 participants from both genders during a follow-up
duration range of 2-37 years (Gan et al., 2014). There were a total of forty independent reports
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from the thirty studies, with twenty-seven reports measuring the outcome CHD and thirteen
reports measuring the outcome MI. The pooled relative risks for depression were 1.30, 95% CI
[1.22-1.40] for CHD and 1.30, 95% CI [1.18-1.44] for MI (Gan et al., 2014). The data shows a
positive association between depression and risk for CHD. There was moderate heterogeneity
among the studies.
Most subgroup analyses, which were stratified by sex, mean age at baseline, publication
year, duration of follow-up, study location, and type of depression measure—whether smoking,
body mass index (BMI), diabetes, hypertension, physical activity, cholesterol or socioeconomic
status were controlled or not—found similar associations between depression, CHD, and MI
(Gan et al., 2014). Two major findings from the subgroup analysis were that 1) depression was
an independent risk factor for CHD, and 2) depression increased the risk for CHD in the group
with less than a 15-year follow-up. There was a positive association between depression and
CHD after the subgroup analysis was adjusted for smoking, BMI, hypertension, diabetes,
physical activity, and socioeconomic status. It was found that depression significantly increased
the risk for CHD in the group of less than a 15-year follow-up although not for the group equal
or greater than the 15-year follow-up. It is possible that over time, treated depressive individuals
may weaken the association between depression and CHD risk. Nonetheless, data confirm that
depression is associated with CHD (Gan et al., 2014).
This report also noted that depression, assessed using self-reported measurement scales
rather than structured clinical diagnosis, had a stronger association with CHD. Within the metaanalysis, twenty-two studies administered a validated self-report depressive symptom
questionnaire. The self-report depression instruments included the Beck Depression Inventory
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(BDI), Center of Epidemiology Studies Depression Scale (CES-D), Geriatric Depression Scale
(GDS), General Health Questionnaire (GHQ), General Well-Being Schedule-Depressed Mood
(GWB), Hospital Anxiety Depression Scale-D (HADS-D), Mental Health Index-5 (MHI-5),
Minnesota Multiphasic Personality Inventory-Depression-Obvious Depression Subscale (MMPIOBD), and the Zung Self Rating Depression Scale (ZSDS) (Gan et al., 2014). Self-reported
depression scales will allow the inclusion of individuals with significant depressive symptoms
who fail to meet formal criteria for a diagnostic disorder, which may have been the reason for
this positive association. However, individuals with depressive symptoms are important to
include since there is a large body of evidence that associates depressive symptoms to adverse
functional outcomes, disability, morbidity, and mortality (Lichtman et al., 2008).
Anxiety
There is evidence that anxiety has an adverse effect on prognosis in CVD patients
independent of depression (Grace, Abbey, Irvine, Shnek, & Stewart, 2004; Roest, Zuidersma, &
de Jonge, 2012; Rothenbacher, Hahmann, Wust, Koenig, & Brenner, 2007; Shibeshi, Yound-Xu,
& Blatt, 2007; Strik, Denollet, Lousberg, & Honig, 2003). Although there are several studies
that suggest anxiety is associated with the development of CVD and MI, there are other studies
that found no association. Roest et al. (2010) conducted a meta-analysis using prospective
studies examining the association between anxiety and heart disease in healthy individuals. The
aim of the analysis was to assess the association between common anxiety constructs (anxiety,
panic, phobia, post-traumatic stress, and worry) and the incident of CHD (Roest et al., 2010).
Twenty one studies were included in the meta-analysis. Of these twenty-one studies, twenty
reported on the incidence of CHD in healthy individuals. The twenty studies comprised a total of
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249,846 participants with follow-up periods ranging from 2.0-20.9 years. The mean age at
baseline assessment ranged from 38-72 years. The analysis included studies of males (n = 9),
females (n = 5), and both (n = 6). Findings indicated a positive association between anxiety and
CHD after adjusting for the covariates of demographic variables, biological risk factors, and
health behaviors (Roest et al., 2010). Overall, there was a 26% increase in incident CHD (HR
1.26, 95% CI [1.15-1.38]) and a 48% increase in cardiac mortality (HR 1.48, 95% CI [1.14-1.92]
for cardiac mortality and HR 1.43, 95% CI [0.85-2.40] for nonfatal MI). However, it should be
noted that these results were based on subgroup analysis of only five studies.
Batelaan, Seldenrijk, Bot, van Balkom, and Penninx (2016) conducted a meta-analysis
comprised of thirty seven studies of men and women (n = 1,565,699) to determine the
independent association and causality between anxiety and incident CVD. The follow-up ranged
from 1-24 years. The results found anxiety was associated with a 52% risk for increased
incidence of CVD (HR 1.52, 95% CI [1.36-1.71]). The CVD risk seemed independent of
depression and the traditional CVD risk factors.
Tully, Cosh, and Baune (2013) provided a narrative review of experimental and
observational studies to present psychophysiological and behavioral pathways upon
cardiovascular function. These pathways illustrated the involvement of worry and generalized
anxiety disorder (GAD). The review included studies from 1975-2011 that examined GAD and
worry on cardiac function in individuals with and without CVD. Excessive and uncontrollable
worry is the hallmark clinical symptom of GAD (Andrews et al., 2010). The review identified
that worry had physiological effects of diminished heart rate variability and elevated heart rate
suggesting increased sympathetic activity and decreased parasympathetic activity (Hammel et
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al., 2011). GAD and worry were found to be associated with hypertension and use of
hypertension medications, but independent of depression. Individuals with established CAD and
GAD showed an increased risk for major cardiac events independent of depression (FrasureSmith & Lesperance, 2008; Martens et al., 2010; Tully et al., 2011).
Frasure-Smith and Lesperance (2008) examined the effect that major depression and
GAD had on major adverse cardiac events in stable CAD patients (n = 804) two years after the
initial CAD event. MDD (OR 2.55, 95% CI [1.38-4.73]), GAD (OR 2.47, 95% CI [1.23-4.97]),
the elevated Beck Depression Inventory-II (BDI-II) (OR 1.66, 95% CI [1.20-2.73]), and the
elevated Hospital Anxiety and Depression Scale-Anxiety (HADS-A) scale (OR 1.66, 95% CI
[1.12-2.47]) all predicted major adverse cardiac events. The results of the study suggest that
GAD is associated with adverse cardiac outcomes independent of MDD. Martens et al. (2010)
examined the effect of GAD on subsequent cardiovascular events (n = 1015) in stable outpatient
CHD patients. GAD was associated with a 62% higher rate of cardiovascular events (HR 1.62,
95% CI [1.11 – 2.37]) after adjusting for demographics, comorbid conditions (including major
depression), cardiac disease severity, and medication use. Patients with CHD and GAD were
frequent smokers, practiced less adherence to medications, and performed less physical activity.
Tully et al. (2011) examined depression and anxiety in relation to cardiac surgery
morbidity (n = 158). Cardiac morbidity included stroke, renal failure, ventilation > 24 hours,
deep sternal wound infection, reoperation, arrhythmia, and 30-day mortality. GAD was
associated with increased cardiac morbidity (OR = 3.26, 95% CI [1.10-9.67], p = 0.03).
One study found individuals with CAD and GAD (n = 436) had a lower risk for major
cardiac events (Parker, Hyett, Hadzi-Pavlovic, Brotchie, & Walsh, 2011). Parker et al. (2011)
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conducted a longitudinal study that examined the effect GAD had on cardiac outcome five years
after the initial CAD event. Cardiac outcome was a composite measure of cardiac admission,
cardiac death, and/or a cardiac event between the one month and five year review. GAD was
associated with a reduced risk for cardiac outcome (OR = .35, 95% CI [.17-.75]). GAD was
believed to be associated with constructive worry that may influence seeking out medical care
for symptoms and participating in cardiac rehabilitation programs (Parker et al., 2011). Worry
was not shown to be beneficial for promoting healthy behaviors in individuals with CVD.
Low et al. (2010) conducted a literature review (1995-2009) examining the relationship
between psychosocial risk factors and CHD in women. The psychosocial risk factors included
negative mood (depression, anxiety, hostility, and anger suppression), stress, social relationships,
and positive psychological factors (optimism, positive well-being, sense of vitality, and
emotional control). The two negative moods, depression and anxiety, will be reported because
these two moods will be examined in the research proposal. Depression was twice as common
among women compared to men and was a consistent predictor of both initial and recurrent
CHD among women. Fifteen studies examined depression and incident CHD and 75% of the
studies found depression was related to incident CHD in women (RR 1.03-3.00, with most less
than 2.0). Seven studies examined the association between depression and recurrent CHD and
found that depression was associated with recurrent cardiac events. Seven studies found anxiety
was associated with increased risk for CHD in healthy men and women (RR 1.30-4.20). Two
studies examined the association between anxiety and recurrent cardiac events. One study found
that anxiety in patients with CHD predicted cardiac mortality one year post-MI for men but not
women (OR 2.58, 95% CI [1.06-6.30], p = .038) (Frasure-Smith, Lesperance Juneau, Talajic, &
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Bourassa, 1999). Another study found anxiety and depression to predict greater major adverse
cardiac events (cardiac death, MI, cardiac arrest, or non-elective revascularization) in men and
women within two years after hospital discharge for ACS (Frasure-Smith & Lesperance, 2008).
Overall, evidence indicates that depression and anxiety are independently associated with
increased CHD and recurrent cardiac events.
Functional Status
For this study, the variable of functional status will be examined relative to healthpromoting behaviors. Several studies have identified that women are less likely to engage in
healthy behaviors to reduce the risk for CVD even though they are knowledgeable about CVD
(Hart, 2005; Mochari-Greenberger et al., 2010; Mosca et al., 2006; Tanavaro, 2005). There are
several studies examining the lack of CVD risk-reduction behaviors in women who are
knowledgeable on heart disease. The findings from these studies support examining whether
negative mood symptoms contribute to decreased healthy behaviors.
There is a strong link between depression and CVD with depression contributing to
adverse physiological and behavioral factors, such as lower adherence to health-promoting
behaviors. Huffman et al. (2013) summarized findings from a literature review on depression
and cardiac disease. The summary included associations between depression and cardiac
outcomes and whether healthy behaviors mediated the link. Studies have found that individuals
with depression are less likely to engage in healthy behaviors. Depressed patients are less likely
to eat a low-salt low-fat diet, exercise regularly, adhere to medications, reduce stress, and
complete cardiac rehabilitation programs following an MI (Bauer et al., 2012; Casey, Hughes,
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Waechter, Josephson, & Rosneck, 2008; May et al., 2010; McGrady, McGinnis, Badenhop,
Bentle, & Rajput, 2009; Whooley et al., 2008; Ziegelstein et al., 2000).
Bauer et al. (2012) examined the association between improvements in depression and
anxiety and adherence to healthy behaviors in depressed patients with heart disease (acute
coronary syndrome, heart failure, or arrhythmia). The Medical Outcomes Study Specific
Adherence Scale (MOS-SAS) questionnaire was used to measure adherence to healthy behaviors
using a 5-point Likert scale with 0 = never and 5 = always. Four items were used to measure
adherence to healthy behaviors. Total scores range from 0-20, with higher scores indicating
better adherence. The healthy behaviors assessed were adherence to a low-salt low-fat diet,
exercise, stress reduction, and medications. The study consisted of 134 participants, men (n =
65) and women (n = 69), with a mean age of 61.49, who were enrolled in a randomized trial of
collaborative depression management care. The depression collaborative care was a twelve-week
intervention that was guided by a psychiatrist’s recommendation of depression care and a case
manager who provided serial assessments of depression. Adherence to healthy behaviors was
measured at six weeks, twelve weeks, and six months in both groups. The depressed individuals
had significantly less healthy behavior adherence compared to the non-depressed with significant
(p < 0.001) between-group differences at all three time points. Patients receiving the
collaborative care intervention had significantly greater decreases in depression and anxiety at
six and twelve weeks compared to those in usual care. Adherence scores at six weeks in the
depressed patients versus the non-depressed patients were 14.4 versus 16.5 (t = 4.19, p < 0.001).
Scores at twelve weeks were depressed 14.2 and non-depressed 16.7 (t = 4.08, p < 0.001) and six
month scores were depressed 14.1 and non-depressed 16.5 (t = 3.98, p < 0.001). There was a
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strong and significant relation between change in depression score and adherence at six months
(β 0.263, p < 0.001). Anxiety score changes at six months were not associated with adherence.
Results of the study concluded that an improvement in depression was associated with an
improvement in healthy behavior adherence. Anxiety patients with an improvement in their
anxiety symptoms had an improvement in healthy behaviors at six weeks, but no improvement at
twelve weeks or six months. Less improvement in anxiety compared to depression may be due
to the intervention which focused on depression and not anxiety. Adequate adherence to healthy
behaviors has been shown to improve cardiac risk factors and decrease cardiac events in ACS
patients (Chow et al., 2010; Gehi, Ali, Na, & Whooley, 2007). Symptoms of anxiety may have a
lesser impact on adherence to healthy behaviors. Some patients with anxiety may be more
focused on health concerns that may lead to greater adherence to healthy behaviors. However,
other patients with anxiety may be restrained by the anxious symptoms and unable to adhere to
healthy behaviors.
Ziegelstein et al. (2000) studied men (n = 116) and women (n = 88) post-MI to determine
whether depression affects adherence to healthy behaviors for CVD risk reduction. Depression
was measured by interview and the BDI scale three to four days following their MI. The
Medical Outcomes Study Specific Adherence Scale (MOS-SAS) questionnaire was used to
measure healthy adherence behaviors four months after admission to the hospital. The behaviors
are diets consisting of low sodium, fat, and cholesterol; medication adherence; exercise; stress
reduction; carrying medical supplies (e.g., nitroglycerine); diabetic diet for diabetic patients;
smoking cessation; and social support. Patients with mild to moderate depression or major
depression reported lower adherence than patients who were not depressed to the following: a
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low-fat diet (F1,197 = 3.82, p = .046), regular exercise (F1,197 = 6.88, p < .01), reducing stress
(F1,158 = 8.42, p < .004), and increasing social support at four months (F1,158 = 4.11, p < .04).
Patients with major depression and/or dysthymia also reported poor medication adherence (F 1,197
= 4.82, p <.03). Overall, the results of the study found that depressed patients post-MI had poor
adherence to recommended healthy cardiac behaviors.
The Heart and Soul Study found that behaviors, particularly physical inactivity, explained
the association between depression and adverse CVD events (Whooley et al., 2008). The
purpose of the Heart and Soul Study was to examine why depressive symptoms are associated
with a greater risk for CVD events. The participants were men and women (n = 1017) with
established CAD (MI, 50% stenosis in one or more coronary arteries, exercise induced ischemia,
history of coronary revascularization or diagnosis of CAD) included in the study and 201 (20%)
had depressive symptoms (Whooley et al., 2008). Individuals with depressive symptoms
compared to those without depressive symptoms reported greater symptom burden, physical
inactivity, decreased QoL, and worse health status. Exercise is a healthy behavior that is
recommended for individuals with CVD to prevent worsening of their chronic illness, prevent
secondary events, and improve mood.
Benyamini et al. (2013) conducted a longitudinal study in Israel with post-MI patients (n
= 540) focusing on predictors of QoL. Participants included in the study were both men (n =
437) and women (n = 103) with an age ≤ 65 years. The study examined whether negative mood
(depression and anxiety) due to an MI diagnosis were related to QoL ten years later and the
degree to which these associations are mediated by health behaviors reported five years post-MI.
While controlling for age, gender, social economic status, MI severity, and health status it was
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found that negative moods were significantly related to health behaviors. Anxiety was
associated with greater health behaviors and depression associated with worse health behaviors
at five years post MI. Both anxiety and depression were related to decreased QoL ten years postMI.
The effect of anxiety on healthy behaviors in individuals post-MI is not as widely studied
as depression. Some researchers have suggested that anxiety can have positive, motivating
effects while others have suggested that anxiety produces avoidant and restrictive behaviors
(Herrmann, Brand-Driehorst, Buss and Ruger, 2000). Kuhl, Fauerbach, Bush, and Ziegelstein
(2009) conducted a study similar to their previously reported study examining depression. Kuhl
et al. (2009) studied the association between anxiety and adherence to healthy behaviors after
MI. The participants for the study were male (n = 158) and female (n = 120) patients who were
assessed for anxiety and adherence to healthy behaviors in the hospital post-MI and four months
after hospital discharge. The MOS-SAS questionnaire was used to measure behavior adherence.
Results of the study found that women had greater anxiety compared to men and that anxiety
symptoms were significantly greater at the four-month follow-up. Baseline anxiety was
associated with a lower adherence to regular exercise, stress reduction, smoking cessation, and
better adherence to carrying medical supplies. There was no significant association between
baseline anxiety and diet. Anxiety measured at four months was associated with lower
adherence to a low-sodium diet (p = 0.021), low fat diet (p = 0.013), regular exercise (p < 0.001),
stress reduction (p = 0.001), socialization (p = 0.003), and overall adherence (p < 0.001). The
summary scores for anxiety were associated with worse adherence to exercise (r = -0.16, p =
0.027), stress reduction (r = -0.28, p = <0.000), increasing socialization (r = -0.20, p = 0.01),
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smoking cessation (r = -0.26, p = 0.001), and better adherence to carrying medication (r = 0.15, p
= 0.041). Anxiety independently predicted poor adherence to smoking cessation and increasing
socialization. Living alone was not associated with anxiety at baseline, but was associated with
anxiety at four months. Overall, in post-MI patients, anxiety during the hospitalization and four
months later was associated with decreased adherence to several healthy behaviors for CVD risk
reduction. There may be an optimal level of anxiety in post-MI patients where it becomes
motivating rather than a debilitating factor.
General Health Perceptions
General health perceptions are a strong predictor of the use of medical and mental health
services, as well as a strong predictor of mortality (Wilson & Cleary, 1995). Those individuals
who assess their health as poor are more likely to die sooner than those who perceive their health
as good (Benyamini, Leventhal, & Leventhal, 2000). Health perceptions are purely subjective
and are influenced by biological variables, symptom status, and functional status. Although
health perceptions are influenced by these other concepts, they nonetheless are different and
require a separate measurement component (Ferrans et al., 2005). A major component of an
individual’s perception of their overall general health is the influence exerted by the individual’s
perception of illness or disease (Weinman, Petrie, Moss-Morris, & Horne, 1996). For this study,
the variable of general health perceptions will be examined relative to illness perceptions.
Illness Perception
Illness perceptions are an individual’s beliefs and expectations, based on a variety of
sources, regarding their illness. These perceptions have been shown to relate to functional status,
adherence behaviors, and emotional distress among many chronic health conditions (Petrie et al.,
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2002). Individuals who have negative illness perceptions have more depressive symptoms,
poorer adherence behaviors, and poorer functional status. A review of the literature found
studies examining whether illness perception influenced negative mood symptoms (depression
and/or anxiety) in individuals with CAD.
Foxwell, Morley, and Frizelle (2013) conducted a narrative review of quantitative peerreviewed research studies (n = 21) that measured illness perception and either QoL or mood
(depression and/or anxiety) in individuals over the age of eighteen years with CHD. The aim of
the review was to examine the relationship between illness perceptions, QoL, and mood in CHD
populations. The studies included both male and female genders although there was a greater
representation of males (72.72%) compared to females (27.28%). The mean age across the
studies was 62.43 years. The majority of the studies used the Illness Perception QuestionnaireRevised (IPQ-R) measurement tool that measures illness perception using six subscales:
identity, timeline, cause, coherence, consequences, and control. The review found a consistent
relationship between negative illness perceptions and elevated depression and anxiety across the
CHD (MI, angina, CAD, percutaneous coronary artery angioplasty (PTCA) or coronary artery
bypass graft (CABG) population. Lack of illness understanding led to a perception of greater
negative consequences, and low personal and treatment control had the strongest relationship to
elevated depression and anxiety. The findings from this narrative review will be broken down
and reported according to the IPQ-R subscales.
In terms of the IPQ-R, the identity subscale has not shown any significant relationships
relative to depression (Foxwell et al., 2013). However, one study found a positive correlation and
significant differences in the identity scores for anxious and non-anxious individuals (Ratcliffe,
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Macleod, & Sensky, 2006). Anxious individuals thought that they were at greater risk for a
subsequent MI and had more cardiac symptoms on the identity scale (Ratcliffe et al., 2006).
In terms of the negative consequences subscale, the majority of the studies found a
significant correlation between increased negative consequences and elevated depression (Aalto
et al., 2006; Cherrington et al., 2004; Grace et al., 2005). One study found perceived
consequences to significantly predict changes in depression using regression analysis (Stafford,
Berk, & Jackson, 2009). Stafford et al. (2009) examined the association of illness perceptions
about CAD on depression symptoms and HRQoL in hospitalized CAD patients (n = 193). The
results concluded that negative illness perceptions were significantly associated with greater
depressive symptoms and positive illness perceptions were significantly associated with greater
HRQoL at three and nine months. Ratcliffe et al. (2006) found anxious individuals with CAD to
perceive their heart problem to have more serious consequences.
The coherence subscale represents the individual’s perceived personal understanding of
the illness and risk factor beliefs (Moss-Morris et al., 2002). In terms of the coherence subscale,
studies reported that lower illness coherence was significantly correlated with elevated
depression and anxiety (Bergman, Malm, Karlsson, & Bertero, 2008; Hermele, Olivo, Namerow,
& Oz, 2007; Juergens, Seekatz, Moosdorf, Petrie, & Reif, 2010). Lower illness coherence means
there is less understanding of the illness. However, one study found lower illness coherence did
not correlate to elevated depression and anxiety levels using the Antonovsky’s Sense of
Coherence measurement scale (Karlsson, Berglin, & Larsson, 2000). Karlsson et al. (2000)
examined the relations between sense of coherence and emotional states (depression, anxiety,
loneliness, and stress) in patients post-coronary artery bypass surgery. Individuals reporting
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lower illness coherence correlated with increasing levels of loneliness. An increase in illness
coherence was found in individuals with less depression, anxiety, stress, and loneliness. Studies
did not use regression analysis to examine causality nor did they examine other factors that may
have affected the depression and anxiety level.
In terms of the control subscale, the majority of the studies reported a consistent
significant correlation between lower perceived control and elevated depression and/or anxiety
(Grace et al., 2005; Hermele et al., 2007; Juergens et al., 2010; Stafford, Berk, & Jackson, 2009).
In addition, Stafford et al. (2009) found that older (> 65 years) individuals perceived lower
control over their CAD illness and that poorer personal control was associated with greater
depressive symptoms. One study found patients who perceived their illness to be governed by
fate, luck, or chance showed the strongest relationship with depression and anxiety (Singh &
Dixit, 2009). Singh and Dixit’s (2009) study enrolled only male participants therefore the results
of the study are not reflective of female perceived control of illness. Ratcliffe et al. (2006) found
significant differences between anxious and non-anxious patients for control, whereas anxious
individuals had significantly lower perceived illness control. One study found no significant
relationship between lower control and anxiety (Hermele et al., 2007).
In terms of the timeline subscales, it is used to determine whether the illness is perceived
as acute or chronic. The timeline-cyclical subscale examines whether the illness is perceived as
fluctuating over time. The subscale timeline examines whether one perceives the illness as
acute/chronic or cyclical. The Foxwell et al. (2013) review found that increased perception of
CAD chronicity was significantly related to elevated depression and anxiety. The correlation
between negative timeline, depression, and anxiety varied depending on whether the CHD
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patient was recruited in the hospital or the outpatient setting. One study that recruited
hospitalized patients with an initial MI reported that perceived illness chronicity was
significantly correlated to elevated depression and anxiety (Juergens et al., 2010). Grace et al.
(2005) recruited male (n = 504) and female (n = 157) CAD patients from the outpatient setting
and did not find a significant relationship between chronicity timeline and depression and
anxiety. There were no consistent findings that increased perception of variability (cyclical) was
significantly correlated to elevated depression and anxiety; although women with CAD,
compared to men with CAD, were found to perceive their illness as more chronic and cyclical.
With the use of the causal subscale, studies can gain perspective on perceived causes of
the illness. The causal subscale was not analyzed in all of the studies (n = 6) due to small sample
size (Hermele et al., 2007; Juergens et al., 2010) or unstated reason (Alsen, Brink, Persson,
Brandstrom, & Karlson, 2010; Dickens et al., 2008; Ratcliffe et al., 2006 Stafford et al., 2009).
Two studies found personality and stress were significantly related to depression (Dunkel,
Kendel, Lehmkuhl, Hetzer, & Regitz-Zagrosek, 2011; Grace et al., 2005). Grace et al. (2005)
reported causal factors of stress, worry, mental attitude, and feeling overworked were
significantly related to elevated depression. Dunkel et al. (2011) found stress and mental attitude
led to elevated depression. No studies examined the relationship between perceived causes and
anxiety.
The literature review of Foxwell et al. (2010) included a study by Grace et al. (2005) that
examined differences in IPQ-R subscales between genders. There was no significant difference
in depressive symptoms between genders, although there was a trend that women experienced
greater symptoms than men (p <.08) (Grace et al., 2005). Women perceived the illness to be
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chronic with more cyclic episodes (p <.001). Men perceived themselves to have more control
over the illness. Greater depression symptoms in men were related to illness perception of a
chronic time course, greater consequences, and lower treatment control. Women with greater
depression symptoms perceived the illness as a chronic time course. Grace et al. (2005) found
illness perceptions to be related to depressive symptoms.
In summary, illness perceptions were found to predict negative mood and QoL in CAD
patients. Specifically, the subscales illness coherence, perceived control, and perception of
illness timeline are important determinants of mood and QoL. Individuals with lower illness
coherence, perceived lack of control, and perceived disease chronicity correlated to elevated
depression and anxiety. The results of this review support that illness perceptions are important
and should be assessed by the health care provider. Identifying illness perceptions related to
negative mood or poorer QoL can be modified through interventions, such as cardiac
rehabilitation, cognitive behavioral therapy, and self- management programs.
CVD Risk Perception
Individuals with heart disease are at a high risk for a recurrent cardiac event or worsening
of their heart function. Women with CVD often do not perceive themselves at risk for secondary
cardiac events. Moore et al. (2010) used a qualitative method to examine the perception of risk
for CHD and perceptions of risk reducing behaviors in women (n = 7) with CHD. CHD was
defined as myocardial infarction, coronary artery stenting, or coronary artery bypass surgery.
Seven women with CHD participated in the study with a sample mean age of 69.1 years. Three
major themes emerged from the data: (1) the absence of symptoms was perceived as absence of
disease, (2) the desire for a relationship with their physician in which they can have an open
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discussion about their heart disease, and (3) a fear of the effects their heart disease may have on
their daily lives and relationships. In addition to the three themes, women did not perceive their
heart disease as chronic and thought the disease was corrected by the intervention. Therefore
they did not require risk reduction behaviors for a recurrent cardiac event. Women expressed a
desire to return to normal and not focus on the disease. They believed their patient-physician
relationship lacked open dialogue and there was no discussion of heart disease and risk-reduction
behaviors. This lack of discussion about risk-reduction behaviors supported their belief that
there was no need for behavior change. Women also believed their concerns were not taken
seriously because of their sex. All women experienced fear. Many feared not knowing when
something was wrong with their heart and others feared the effects of CHD on their
relationships. One participant reported her fear was a motivator for engaging in risk reduction
behaviors.
Mosca, Hammond, Mochari-Greenberger, Towfighi and Albert (2013) conducted a crosssectional survey of healthy women (n = 2432) age 24-65 years to assess their awareness,
knowledge, and perceptions of CVD risk and prevention. The data collected in 2012 were
compared to data collected in 1997. Awareness of heart disease as the leading cause of death was
significantly higher in 2012 compared with 1997 (56% versus 30%, p < 0.001). However, the
rate of awareness was lower among younger women (24-34 years). Awareness of atypical signs
of a heart attack was significantly greater in 2012 versus 1997 (18% versus 10%, p < 0.001).
Chest pain was less frequently identified as a warning sign of a heart attack in 2012 versus 1997
(56% versus 67%, p < 0.001). Communication from physician to patient about heart disease risk
was 21% in 2012. The communication was lower for young women compared with older age
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groups (6% for those age 25-34 years, 16% for age 35-44 years, 23% for age 45-64, 33% for age
> 65 years). There was a high level of self-reported depression (26%) among the participants and
more prevalent in the age groups 35-44 years and 45-64 years. The lack of communication on
heart disease risk and the negative emotion of depression may contribute to women’s perception
of their risk for heart disease. The most frequent potential barrier to preventive action was that
only one third of women reported they lead a heart-healthy lifestyle (35%), with the greatest
response among women ≥ 65 years (48%). Other more common barriers preventing healthy
heart behaviors among the women in 2012 were lack of money or insurance (16%), lack of selfconfidence to change behaviors (14%), time constraints (13%), stress (12%), lack of knowledge
(11%), family obligations (11%), decrease perception of risk (9%), not want to change lifestyle
(9%), depression (8%), and confusion in the media about what to do (8%). Younger women (2444 years) reported different barriers to prevention of heart disease compared with older women
and these barriers included financial burden, time constraints, depression/stress, and low
perception of risk. Older women (≥ 65 years) identified lack of self-confidence to change
behaviors and lack of willingness to change lifestyle, although 10% did not perceive themselves
at risk for heart disease. A low perception of risk for heart disease was identified as a barrier to
healthy heart behaviors, although more prevalent in younger women compared to older women.
Oliver-McNeil and Artinian (2002) used a descriptive study to describe perceptions of
risk factors and risk-reducing behaviors among women with CHD. The study included women
(n = 33) age 36-85 years with a mean age of 65.64 years. The results of the study identified that
women had a decreased awareness of their cardiac risk. Women with controlled hypertension on
medication did not perceive hypertension as a continued risk factor for heart disease.
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Overweight women did not perceive themselves as overweight. The risk factors least identified
were age, menopause, and physical inactivity. There was no significant relationship between
perceived risk and risk-reducing behaviors (r = 0.055, p = 0.82) and no significant relationship
between knowledge of risk and risk-reducing behaviors (r = -0.011, p = 0.95). The study
examined women’s perceived risk of cardiac risk factors and knowledge of risk factors and not
the perceived risk of a secondary cardiac event. Risk-perception beliefs are included in one’s
perception of their illness.
Quality of Life
HRQoL relates specifically to an individual’s health status and the way a disease
expresses itself in an individual’s daily life, including symptoms, functional ability,
psychological, and social and physical states (Broddadottir et al., 2009; Ferrans et al., 2005;
Wilson and Cleary, 1995). Individuals with CHD have worse HRQoL compared to those
without CHD, and women with CHD consistently report worse HRQoL compared to men with
CHD (Broddadottir et al., 2009; Ford et al., 2008).
Ford et al. (2008) performed a cross-sectional analysis of data from the Behavioral Risk
Factor Surveillance System (BRFSS) conducted in 2004. The analysis included data from ten
states with male (n = 19,852) and female (n = 30,721) participants. The mean age of these
individuals was 45.8 years and all had a record of MI, angina or CHD, and/or diabetes. There
were three aims of the study. The first aim was to compare HRQoL between individuals with
and without CHD. The second aim was to examine whether HRQoL differed between
individuals with only diabetes, only CHD, or both diabetes and CHD. The third aim was to
examine whether there were gender differences in HRQoL. The HRQoL measurement tool
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consisted of four items that measured general health, physical health, mental health, and activity
limitation days. Physical health included physical illness or injury, and mental health included
stress, depression, and problems with emotions. Activity limitation days included usual activity
of daily life, such as self-care, work, or recreation. Individuals with CHD reported significantly
increased physically unhealthy days, mentally unhealthy days, and activity limitation days
compared with individuals who did not have CHD. Women with CHD compared to women
without CHD reported ≥ fourteen physically unhealthy days (absolute difference = 9%, p <
0.001), ≥ fourteen mentally unhealthy days (absolute difference = 4.1%, p = 0.010), and ≥
fourteen activity limitation days (absolute difference = 4.8%, p < 0.001) during the past thirty
days. Women with CHD compared to men with CHD had greater physically unhealthy days
(absolute difference = 6.4%, p < 0.001) and greater mentally unhealthy days (absolute difference
= 5.8%, p = 0.002), with no difference in activity limitation days (absolute difference = 2.0%, p
= 0.090. Impaired HRQoL was significantly greater in individuals with CHD compared to
individuals without CHD. Women with CHD had worse HRQoL compared to men with CHD.
Women with CHD have higher levels of depression than men with CHD. HRQoL can be
significantly affected by depression.
Broddadottir et al. (2009) examined the effect of age and depression on HRQoL in
women with CAD. Participants were women (n = 437) with CAD from the Alberta Provencial
Project for Outcome Assessment in Coronary Heart Disease (APPROACH) database from 20042005. HRQoL was measured using the Seattle Angina Questionnaire (SAQ) and the EuroQoL 5
Dimensional Instrument (EQ-5D). The SAQ items were physical limitations, angina stability,
angina frequency, treatment satisfaction, and disease satisfaction, and the EQ-5D items
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addressed mobility, self-care, usual activities, pain/discomfort, and depression/anxiety.
Depressive symptoms were a significant predictor of HRQoL in all the categories of the SAQ
and EQ-5D. Younger women reported the most depressive symptoms. Increased age was
predictive of greater physical limitations, although not significant (p = 0.028), and of a
significantly greater positive perception of disease (p = 0.011).
Stafford, Berk, Reddy and Jackson (2007) conducted a literature review (1995-2006) of
seventeen cross-sectional and prospective studies to examine the impact of depression and its
treatment on the HRQoL of individuals with CAD. The literature review included a study by
Ruo et al. (2003) who conducted a cross-sectional study of patients (n = 1204) with CAD and
compared the effects of heart disease severity and depressive symptoms on HRQoL. Depressive
symptoms were strongly associated with greater symptom burden (OR 1.8, 95% CI [1.3-2.7]; p =
.002), greater physical limitation (OR 3.1, 95% CI [2.1-4.6]; p < .001), worse QoL (OR 3.1, 95%
CI [2.2-4.6]; p < .001), and worse overall health (OR 2.0, 95% CI [1.3-2.9]; p < .001). Disease
severity was not associated with symptom burden, physical limitation, diminished QoL, or worse
overall health. Similar results were found in cross-sectional studies of patients with acute MI
and unstable angina. The Sertraline Antidepressant Heart Attack Randomized Trial
(SADHART) included patients (n = 369) with ACS and depression. The results of the study
concluded that depression was the strongest predictor of impaired HRQoL at baseline and that
disease severity had little effect on HRQoL scores. The literature review of several prospective
studies found that depression and anxiety have a negative effect on HRQoL in CAD patients.
The overall findings from the studies found that depression and anxiety diminish HRQoL in
CAD patients.
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Women with CVD report worse QoL and greater depression compared to men with CVD.
Norris et al. (2008) examined gender and sex discrepancies in HRQoL among patients with
CAD. Sex refers to biology and anatomy and gender refers to the behavioral, psychological, and
cultural traits associated with one sex. The study included male (n = 1872) and female (n = 522)
patients with CAD from the Alberta Provincial Project for Outcome Assessment in Coronary
Heart Disease (APPROACH) database. Women reported significantly more depressive
symptoms compared to men at the time of angiography and one year later. Men reported less
angina at one year (men 92.3 versus women 89.8, p ≤ 0.001) and higher treatment satisfaction
(men 91.5 versus women 88.9, p = 0.001) and a better physical limitation score (men 83.6 versus
80.2, p ≤ 0.001). The discrepancies in the scores are only partially accounted for by sex
differences in depression and social support. Both at the time of angiography and one year later,
women scored greater depressive symptoms and worse HRQoL compared to men. Therefore,
gender roles and perception may contribute to the differences in HRQOL in men and women
with CAD.
Characteristics of the Environment
Social Support
Prata, Ramos, Martins, Rocha-Goncalves, and Coelho (2014) conducted a systematic
review examining the gender differences in psychosocial domains in individuals with CAD. The
meta-analysis included examining the relationship between social support and CAD and
secondary events. Social support was divided into two domains: functional support and
structural support. Functional support describes the encouragement of the social network (help
with tasks, sense of being loved, providing information) and structural support includes the
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characteristics of the social network (number/frequency of contacts, marital status, group
membership). The literature review included a meta-analysis of thirty-two studies examining the
role of social support in the development and outcome of CAD and MI (Barth et al., 2010). The
results of the analysis found low functional support was associated with increased risk of CAD
(HR 1.53, 95% CI [1.02-2.28]) and increased risk of mortality (HR 1.59, 95% CI [1.17-2.16]) in
patients with CAD. Low structural support was not associated with an increased risk for CAD or
mortality in patients with CAD (RR, 1.56, 95% CI [0.94-2.58]).
Leifheit-Limson et al. (2010) conducted a large prospective study with MI patients (n =
2411) examining whether baseline social support predicted patient outcomes (poorer angina,
disease-related QoL, physical and mental functioning, and depressive symptoms) within one year
of MI recovery. Patients with the lowest social support had increased risk of angina (RR 1.27,
95% CI [1.10, 1.48]), lower disease specific QoL (β -3.33, 95% CI [-5.25, -1.41]), lower mental
functioning (β -1.72, 95% CI [-2.65, -0.79]), and greater depressive symptoms (β 0.94, 95% CI
[0.51, 1.38]). There was a non-significant risk toward lower physical functioning (β -.087, 95%
CI [-1.95, 0.20]). There was a stronger negative relationship between social support and
outcomes in women compared to men. Lower social support was associated with greater
depressive symptoms and worse health status, particularly in women.
Compare et al. (2013) conducted a narrative review of five quantitative studies (3
prospective cohorts, 1 case-control study, 1 randomized controlled trial) examining the
relationship between social support, depression, and health outcomes in patients with heart
disease. The majority of findings suggest that low social support, being unmarried, and
depression are risk factors for poor cardiac outcomes. Being unmarried was significantly
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associated with an increase in sudden cardiac death while controlling for depression. Unmarried
individuals were less likely to receive preventive care, seek timely health care for symptoms,
adhere to medication, or do physical activity. Therefore, being unmarried was associated with
greater depressive levels.
Lett et al. (2007) conducted a randomized controlled trial comparing the impact of
network support and perceived functional support on all-cause mortality or non-fatal reinfarction
in patients with a recent MI. Network support included the mean number of close friends and
relatives, married, and living with others; whereas functional support includes instrumental (help
getting tasks done), financial (economic support), informational (providing needed information),
appraisal (help evaluating a situation), and emotional (feelings of being loved) support.
Participants were men (n = 1389) and women (n = 1092) with depression or low social support
that were recruited from the Enhancing Recovery in Coronary Heart Disease (ENRICHD) trial
and randomized to a cognitive behavioral intervention or to a usual care control group. The
average age of the participants was 61 years. Higher levels of perceived social support were
associated with improved outcome for patients without elevated depression, although this was
not found in patients with high levels of depression. High levels of depression regardless of the
level of support were associated with increased risk of mortality. Perceived support and network
support were not associated with improved health outcomes regardless of the level of depression.
The narrative review concludes that depressive symptoms and the absence of marital or social
support are significant risk factors for worse prognosis and may predict adverse outcomes in
patients with heart disease.
Wang, Mittleman, and Orth-Gomer (2005) conducted a three year longitudinal study
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examining whether social support influenced progression of coronary artery disease in women
with CAD (n = 102). Social support included emotional support, social integration, and
interpersonal social relations. Emotion support refers to deep emotional relationships or
attachment that describes the availability of close family and friend support. Social integration
refers to one’s social network that is determined by the number and frequency of contacts.
Interpersonal social relations include belongingness, appraisal support, and tangible support.
Progression of disease was determined by a change in coronary luminal diameter at baseline and
three years later that was measured by coronary artery angiogram. At baseline, women with low
levels of social integration and low emotional support were more likely to have a diagnosis of MI
compared to those women with high levels of social support. Women with higher levels of
interpersonal support were more likely to have severe angina symptoms (77.8% vs.48.3%, p <
.01). There may be various causes for this finding. Women with frequent symptoms may
receive more attention from family and close friends or these women experiencing severe angina
symptoms may be more proactive in seeking out help concerning the disease from others
therefore receive more interpersonal support (Wang, Mittleman, & Orth-Gomer, 2005). Three
years later, women with low levels of social support had greater coronary artery luminal
narrowing than women with high levels. Women with low levels of emotional support showed a
progression of 0.14 mm in coronary artery luminal narrowing compared to women with high
levels of emotional support who showed a progression of 0.06 mm ( p = 0.02). Women with low
levels of social integration and interpersonal social relations showed a progression of 0.16 mm
and 0.12 mm coronary artery luminal narrowing compared to women with high levels of social
integration and interpersonal social relations who showed a progression of 0.06 mm (p < 0.007
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and 0.05 mm (p < 0.03). The results of the study found women with CAD and low social
support, emotional support, social integration, and interpersonal social relations, were associated
with significantly increased progression of coronary atherosclerosis. The associations were
independent of age, BMI, menopausal status, tobacco use, educational level, marital status,
sedentary lifestyle, alcohol intake, fibrinogen, total/high density lipoprotein cholesterol ratio,
systolic blood pressure, left ventricular dysfunction, angina severity, diabetes, medications, or
family history of CHD. The study findings support that a direct pathophysiological mechanism
involving the psycho-neuro-endocrine pathway may link social support with CHD (Wang,
Mittleman, & Orth-Gomer, 2005). The results of the study did not find that social support had an
influence on healthy behaviors.
Summary
In summary, this literature review provides evidence that supports the relationship
between negative mood symptoms (depression, anxiety) to CVD and the risk for secondary
cardiac events, functional status, illness perception, and QoL in women. Depression has been
identified as an independent risk factor for CVD and poor adherence to healthy behaviors.
Anxiety has been identified as an independent risk factor for CVD, although the relationship
between anxiety and adherence to healthy behaviors is inconsistent. Anxiety has been found to
promote healthy behaviors in some individuals and proved to be a debilitating factor for healthy
behaviors in others.
Depressive and anxiety symptoms may influence an individual’s illness perception.
These symptoms may negatively alter an individual’s perception of their illness, perceiving the
illness to be more severe, chronic, and uncontrollable. The negative illness perception
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significantly correlated with worse QoL. QoL is diminished by depressive and anxiety
symptoms, as well as poor social support. However, what has not been investigated is how
negative emotions relate to healthy behaviors, illness perception, and QoL and whether illness
perception has an effect on healthy behaviors. In addition, the literature review found a lack of a
consensus on whether age is a contributing factor to negative emotions, healthy behaviors, illness
perception, and QoL. Some studies report negative emotions to be more prevalent in younger
women compared with older women and vice versa in other studies. Overall, there are few
studies that examine the relationship of these concepts in women with CVD.
Therefore, this study will make a unique contribution by examining the relationship
between negative emotions, functional status, illness perception, and QoL in women with CVD.
Furthermore, age will be examined as a contributing factor to this relationship. This knowledge
will benefit nursing practice by identifying factors that affect functional status and QoL. This
will enable APN’s to target these factors for optimal healthy outcomes in women with CVD.

CHAPTER THREE
METHODOLOGY
Design
A cross-sectional correlational study design was used to explore the relationship between
symptoms (depression and anxiety), functional status (health-promoting behaviors), health
perceptions (illness perception), and QoL. A correlational design is appropriate for the
examination of the relationship between the key variables generated by the theoretical model at
one point in time (Polit & Beck, 2012). The strengths of cross-sectional studies are: there is no
waiting for the outcome, there is minimal if any participant attrition, they can serve as the first
step in a cohort or experimental study, and are relatively inexpensive to conduct (Hulley,
Cummings, Browner, Grady, & Newman, 2007). This design allowed for identifying the general
health perceptions of women with CVD by examining each individual’s personal cardiovascular
risk factors. Individual characteristics (age, race/ethnicity, gender, marital status, education,
socioeconomic status, and employment) were examined to determine the influence on health
outcomes. In addition, environmental characteristics (social support) were examined to
determine the influence on health outcomes. The cross-sectional study allowed obtaining
measurements at approximately the same time to describe and determine the relationships among
the variables.
Setting
The study was conducted at two large Midwestern suburban cardiology outpatient offices
47
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from August 2017 to March 2018. The cardiology offices provide healthcare to women of
various ages. Site A is a private practice which sees 232 females’ ages 43-90 years old per
month. Site B is a private practice which sees 218 females’ ages 54-94 years old per month.
The two settings were chosen to allow for women of various ages and to obtain the required
sample size. Women with known coronary artery disease receiving care from the cardiology
outpatient offices were the participants. The cardiology offices were located in the suburban
community and provide care to women of various socioeconomic status and age. Permission was
obtained from Advocate Medical Group (AMG) Cardiology to recruit participants at these sites.
Sample
A convenience sample of women who presented to the private outpatient cardiology
clinics for health care was the sampling strategy. Eighty one women completed the study.
Women were informed of the study while at their scheduled cardiology appointment and
participant recruitment flyers were posted in the cardiology clinics and waiting rooms.
Inclusion criteria for participation were women age 35 – 78 years, had a personal history of CAD
(MI, myocardial ischemia, PTCA, stent, fibrinolytic, CABG surgery), angina Canadian
Cardiovascular Society (CCS) Class I-III, ACCF/AHA Heart Failure Stage A, B, and C New
York Heart Association (NYHA) Class I, were able to speak, read, and write English, and were
able to participate in the informed consent process. The mean age for the study sample was
65.53 ( 7.78). The age range was based on the age women develop heart disease and the age of
women who presented to the cardiology clinics over the past year. Women have a longer life
expectancy and develop heart disease at an older age resulting in a higher prevalence of heart
disease over sixty-five years of age (Mozaffarian, 2015). The original age range for the study
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was 35 to 70 years. Initially, the upper age limit of 70 years was established on the assumption
that women in their 70s may have cognitive impairment. After discussing the cognitive function
of female patients aged 70 -78 years with the cardiologists and advanced practice nurses, it was
determined that the majority of women between the age of 70 to 78 years were cognitively intact.
A proposal modification was made that changed the inclusion criteria age range to 35 to 78
years. There were a large number of women with CAD over the age of 70 years at the
recruitment sites who met the study inclusion criteria. Expanding the upper age to 78 years
allowed women of older age to be represented in the study. In addition, there continues to be
limited inclusion of older women in CAD studies (Metha et al., 2016) and including women of
older age is a unique contribution to the study.
Exclusion criteria was angina CCS Class IV, ACCF/AHA Heart Failure stage C NYHA
Class II, III, IV and stage D, stroke, and end-stage renal disease, since these individuals may
have different perceptions of heart disease due to severity of symptoms and more frequent health
care visits. Interested participants were screened by the primary investigator to determine
eligibility to participate in the study.
Sample Size
The sample size proposed for this study was estimated using power analysis in an effort
to decrease the probability of making a Type I or Type II error and to increase the probability of
finding a statistically significant effect, which in this case is the probability of finding
associations among negative mood symptoms (depressive and/or anxiety), functional status
(health-promoting lifestyle behaviors), health perceptions (cardiac illness perception), and QoL.
The power analysis was calculated according to the research questions. The alpha (α) 0.05 and
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the beta (β) 0.20 (Power 0.80) levels were used regardless of the research question. The sample
size calculation was based on the minimum number per variable used in multiple regression
analysis and it was also calculated based on the relationship between depressive symptoms and
QoL and healthy promoting behaviors.
The first aim was to determine the relationship between negative mood symptoms, health
promoting behaviors, illness perception, and QoL. According to Cohen (1988) a moderate effect
size of .30, an alpha of 0.50, a power of 0.80 is used to determine significant correlations among
variables. The online power analysis G*Power 3 (Faul, Erdfelder, Land, & Buchnar, 2007;
G*Power 3, n.d.) was used to calculate a sample size of 84 using effect size .30, alpha 0.05, and
power 0.80.
In addition, stepwise multiple regression analyses were used to determine the variables
that predict QoL. Based on the recommendation of 10-15 participants per predictor variable
(depressive symptoms, anxiety symptoms, health promoting behaviors, illness perception
identity, illness perception coherence, illness perception emotional response, social support,
functional comorbidities) in multiple analyses, the minimal estimated sample size was 80 and the
maximum was 120 with eight predictor variables (Cohen, 1988). In addition, the online power
analysis G*Power 3 (Faul, Erdfelder, Land, & Buchnar, 2007; G*Power 3, n.d.) was used to
calculate a sample size of 109 using a moderate effect size (.15), alpha 0.05, and power 0.80, and
two predictors (depressive and anxiety symptoms).
In examining the relationship between depressive symptoms and QoL and health
promoting behaviors, a study by Savoy and Penckofer (2016) was reviewed. In this study, 125
participants were studied and depressive symptoms explained 43% of the variance in QoL using
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the Center for Epidemiologic Studies Depression Scale (CES-D). In addition, depressive
symptoms explained 25% of the variance in health promoting behaviors. G*Power 3 analysis
(Faul et al., 2007) was used to calculate the effect size based on the squared multiple correlation
value of .43 producing an effect size of .75. Using the article by Rudy and Kerr (1991), this
indicated that a large effect size can identify a significant relationship between depression and
QoL and a moderate effect size can identify a significant relationship between depression and
health-promoting behaviors. With an effect size of .75 (large effect size), an alpha of 0.05, a
power of 0.80 and 4 predictors, G*Power 3 calculated that 26 subjects would be the sample size.
Using the variance that depressive symptoms explained health promoting behaviors, a G*Power
analysis was used to calculate the effect size based on the squared multiple correlation value of
.25 producing an effect size of .33, a moderate effect size. With an effect size of .25, an alpha of
0.05, a power of 0.80 and four predictors, G*Power 3 calculated that 42 subjects would be the
sample size.
The second research aim was to determine whether age is a factor contributing to
negative mood symptoms, functional status, health perceptions, and QOL after controlling for
social support. An independent t-test was used to determine whether there was a difference
between two age groups and the key variables. In additional to the above sample size methods,
the G*Power 3 was used to calculate the sample size of 55 for independent t-test using a
moderate effect size (.15), an alpha 0.50, a power of 0.80. Using these techniques for estimating
sample size, the range of recommended subjects was from 26 to 84 for this aim.
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Recruitment of Study Participants
To begin the recruitment process, contact was established with the administrative and
medical director of the AMG–Cardiology, Advocate Health Care cardiology offices. The
Institutional Review Board (IRB) forms were completed and submitted to the respective IRBs,
first to the Advocate Health Care IRB for approval and then to the Loyola University Health
Systems IRB for final approval. Approval was obtained from both Advocate Health Care IRB
and Loyola University Health Systems IRB prior to initiating the study. The PI met with the
cardiologists, office managers, advanced practice nurses, and medical technicians and reviewed
the study purpose, subject inclusion/exclusion criteria, and contact information for participating
in the study.
The recruitment process used study informational flyers and communication about the
study from health care providers. The PI contacted the office manager/director(s) to identify
ideal locations for posting flyers. The approved study flyers were posted in the cardiology
offices and waiting rooms. The flyer provided an abbreviated purpose for the study, the target
population, and instructed individuals to contact the investigator by phone number or email if
interested in participating in the study. To aid the recruitment process, participants would
receive a ten-dollar gift card after completing and submitting the questionnaire at the scheduled
office visit. In addition, a laminated card with study name, inclusion/exclusion criteria, and PI
contact information was provided to the cardiologists and advanced practice nurses.
The PI was present in the cardiology offices to promote the recruitment process by
informing the patients, physicians, advanced practice nurses, and medical technicians of the
study and to be available to answer any questions regarding the study.
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The PI was given a private office space at the cardiology offices to meet with women
who were interested in the study. The PI met with the interested participant and provided the
purpose of the study, explained and answered questions regarding the questionnaire booklet, and
the time required to complete the questionnaire booklet. Women who agreed to participate in the
study were screened for eligibility. Approximately fifty percent of the participants were
screened, consented, and completed the questionnaire booklet immediately after their cardiology
appointment. For those individuals who were not able to stay and complete the questionnaire
booklet, the PI scheduled a meeting time with the participant either sixty minutes before their
next cardiology office visit, or an agreed time to meet at the cardiology office, or a convenient
designated location identified by the participant to obtain consent and completion of the
questionnaire booklet. The women were given a flyer with the PI’s contact information and
encourage to call if they had any questions or needed to reschedule the appointment time. The
women who agreed to participate in the study and were scheduled a time to meet, received a
telephone call confirming the scheduled time to meet at the cardiology office or designated
location one week and one day before the scheduled appointment date. Individuals who were not
able to keep their appointment time, were rescheduled during that time and met at a place of
convenience for them.
Participants were assigned a unique identifier (number) that was be used to complete the
questionnaire booklet. The questionnaire booklet assessed symptoms of depression and anxiety
in individuals with CVD disease. The measures also included questions about their perceived
risk for CVD events, illness perception, health promoting behaviors, quality of life, and
sociodemographic information. On arrival to the office or designated meeting location the
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informed consent was obtained and the questionnaire booklet was completed by the participant.
The informed consent included if the patient has concerns about their mood they should talk to
their healthcare provider and would be given Advocate information about mental health. The PI
reviewed the questionnaire mood surveys for any missing data. Clarification for completing
unanswered questions in the questionnaire booklet was provided by the investigator. Some
participants may not want to answer every question if it makes them uncomfortable. Therefore,
the PI checked whether the participant was uncomfortable answering the question before asking
for more information to complete the questionnaire. Missing data was completed at this time and
the questionnaire booklet was collected. It took 30 – 45 minutes to complete the questionnaire
booklet. Once completed, the participant was compensated with a $10.00 gift card to a popular
area store prior to the leaving the office/convenient location.
The AMG-C patients are currently screened for depression using the Patient Health
Questionnaire-2 (PHQ-2). Those patients that answer “yes” to either question number one or
two on the PHQ-2 are referred to their primary care provider (PCP) for further assessment. The
PHQ-8 was the instrument used in the study to assess for depressive symptoms. The PHQ-2
questions are the first two questions on the PHQ-8. The AMG-C patients are screened for
depression using the PHQ-2 and there is a process in place to refer those individuals requiring
further assessment to their PCP. Thus, the PHQ-8 instrument was not scored at the time the
participant completed the questionnaire. Since the study questionnaire contained mood symptom
assessment tools, if the patient voices concern about their mood after completion of the
questionnaire, they were encouraged to contact their healthcare provider and would be given
Advocate information about mental health. A list of area psychological counseling services was
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obtained from Advocate Health Services. None of the women participants voiced concern about
their mood.
If needed, another strategy was identified to be used to recruit participants. This strategy
would consist of AMG-Cardiology (AMG-C) mailing a letter informing women about the study
with information to contact the PI if interested in participating in the study. The PI would
provide a stamped envelope for the mailing and the patients address label would be applied by an
AMG employee. This strategy was not used for recruitment because the sample was obtained
through recruiting in the cardiology offices.
Measurements
The measurements were organized according to the revised Wilson and Cleary’s
Model of HRQoL that was used to guide the study. A list of the study variables and how they
were measured are depicted in Table 1 and the measurement tools are included in Appendix A.
Table 1. Study Variables and Measurements
Variable

Measurement

Characteristics of the
Individual

Demographics

Biological Function

CVD Risk Factors

Age, race, ethnicity, marital
status, education, income,
employment
Framingham Recurrent Risk
Model
Functional Comorbidity
Index (FCI)
Patient Health Questionnaire8 (PHQ-8)
Generalized Anxiety
Disorder-7 (GAD-7)
Health Promotion Lifestyle
Profile-II (HPLP-II)

Comorbidities
Symptoms

Depression
Anxiety

Functional Status

Health Promoting Behaviors
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General Health Perceptions

Illness Perception

Overall Quality of Life

Satisfaction with Life

Characteristics of the
Environment

Social Support

Illness Perception
Questionnaire-Revised
Cardiac (IPQ-R-Cardiac)
QoL-Index Cardiac Version
IV (QLI)
Medical Outcomes Survey -8
(MOS-SS)

Characteristics of the Individual
Demographics were assessed for each individual and included the measurement of age,
gender, ethnicity/race, marital status, education, socioeconomic status, and employment. This
information allowed examining whether there were differences or similarities among these
variables and identified patterns in relationships to other variables studied. Examining
differences among age in relation to symptoms and functional status made this information
mandatory to obtain.
Biological Function
The two variables, cardiovascular risk factors and comorbid diseases, were assessed in
order to determine the effect of biological function on symptoms, functional status, health
perceptions, and QoL.
Cardiovascular risk factors. The Framingham Recurrent Risk Model was used to
assess recurrent CVD risk. The Framingham Recurrent Risk Model is a two-year risk prediction
for recurrent atherosclerosis cardiovascular disease (ASCVD) in individuals with CHD
(D’Agostino et al., 2000). The instrument measures the risk factors age, gender, SBP, tobacco
use, fasting total cholesterol (TC), HDL, and diabetes to determine the risk for a recurrent
cardiac event. The score obtained on the instrument correlates to the probability by percent for a
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CVD event in two years. For example, a score of 10 predicts a 2% probability of a CVD event in
the next two years.
The Framingham Risk Model is preferred for use in predicting female CVD mortality
compared to other CVD risk score models, such as the SCORE risk, HeartScore, and QRISK
score models (Goh, Dhaliwal, Lee, Bertolatti, & Della, 2013). The instrument is preferred over
the other risk score models because the instrument has a female risk score and high reliability
and validity (Coke, 2016; D’Agostino, Pencina, Massaro, & Coady, 2013; Goh, Dhaliwal, Lee,
Bertolatti, & Della, 2013). The reliability and validity of the Framingham Recurrent Risk Model
is evident by high sensitivity (67%) and specificity (98%) measures (Coke, 2016). The
limitation of the tool is that it does not include relevant risk factors to predict CVD mortality for
women, such as obesity, physical activity, alcohol consumption, and use of antihypertensive
medications (Goh et al., 2013). Overall, the Framingham Recurrent Risk Model is a successful
tool to identify the probability of a subsequent cardiovascular event in those who have CVD.
Comorbid diseases. Several comorbidity indices have been developed to predict
mortality or cost outcomes, such as length of hospital stay. The Functional Comorbidity Index
(FCI) was developed to measure comorbid conditions that have an impact on physical function.
Physical activity (exercise) is a health promoting behavior that reduces the risk for CAD or
worsening of one’s cardiac illness (Hammond et al., 2007; Mosca et al., 2006). Therefore, the
FCI instrument was used to assess for chronic comorbid conditions in this study. The FCI
consists of eighteen comorbid conditions. The eighteen comorbid conditions were derived from
an extensive literature review, focus group studies, and two large data bases that identified
conditions associated with a decline in physical functional. Physical function was identified
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using the Medical Outcome Study (MOS) 36-item Short Form Survey (SF-36) physical function
subscale. The SF-36 is a widely used reliable and valid instrument that is used to identify
general health status and includes a reliable physical function subscale (Cronbach’s alpha 0.93).
The SF-36 physical function subscale is made up of ten items related to walking, climbing stairs,
lifting, vacuuming, bathing, and dressing (Ware & Sherbourne, 1992). The FCI uses binary
scoring (0 = disease not present and 1 = disease is present) for each comorbid condition. The
scores range from 0 (the lowest score) to 18 (the highest score). The final FCI score is the sum
of the individual’s comorbidities. A higher FCI score indicates greater comorbidity and is
associated with greater impairment in physical function (Groll et al., 2005).
The reliability testing of the generic version has been previously reported for the generic
FCI instrument. There was a strong correlation of the FCI to the SF-36 physical function and
role function subscale scores (-.53, p < .0001, and -.31, p < .0001) respectively. Discriminant
analysis was used to determine the SF-36 physical function subscale score into “low function” if
the score was 66 or less, and “high function” for a score > 66 (Groll et al., 2005). The FCI
correctly classified individuals as “low function” or “high function” 76.6% of the time. The FCI
accounted for more variation in the physical function subscale scores compared to the Charlson
Comorbidity Index and Kaplan-Feinstein Comorbidity Index (R2 = 0.29, 0.18, and 0.07%
respectively (Groll et al., 2005).
Content validity was established by an extensive review of the literature, focus groups
and two large data bases to identify comorbid conditions. Independent comorbid variables
significantly associated (Spearman’s correlation coefficient, p < 0.1) with the physical function
subscale score were included in the regression analysis. Multiple regression linear models were
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used to identify the significant variables associated with physical function. In summary, the FCI
has demonstrated reliability and validity in measuring comorbidity using physical function as the
outcome (Groll et al., 2005; Haines, Berney, Warrillow, & Denehy, 2014).
Symptoms
The variables depression and anxiety were assessed in order to determine the effect
of symptoms on functional status, health perceptions, and QoL.
Depression. The PHQ-8 was used to measure depressive symptoms. The PHQ-8
originated from the Primary Care Evaluation Mental Disorders (PRIME-MD) instrument that is
used to screen for five common mental disorders in the primary care and general population:
depression, anxiety, and somatoform, alcohol, and eating disorders. The PRIME-MD consists of
a self-administered 26-item questionnaire and a clinician-structured interview. The instrument
was proven reliable and valid in the primary care setting, although found to be time-consuming
for the clinician to perform the interview process. Therefore, the PRIME-MD Patient Health
Questionnaire (PHQ) was developed. The PRIME-MD PHQ is a three-page, self-administered
questionnaire that is used to identify the five common mental disorders. The Patient Health
Questionnaire-9 (PHQ-9) is the depression module of the PHQ. The nine items on the PHQ-9
were selected from the Diagnostic and Statistical Manual of Mental Disorders, fourth edition
(DSM-4) diagnostic criteria for depression (Kroenke, Spitzer and Williams, 2001). The DSM-4
diagnostic criteria for depression remain current with the Diagnostic and Statistical Manual of
Mental Disorders, fifth edition (DSM-5) (American Psychiatric Association, 2013). The PHQ-8
instrument consists of eight of the nine items on the PHQ-9, omitting the ninth item. The ninth
item on the PHQ-9 assesses suicidal or self-injury thoughts. Researchers have found the ninth
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item was the least frequently endorsed item on the PHQ-9 and fairly uncommon in the general
population (Kroenke & Spitzer, 2002; Lee, Schulberg, Raue, & Kroenke, 2007; Razykov,
Ziegelstein, Whooley, & Thombs, 2012). The ninth item on self-harm was be omitted for
sensitivity reasons.
The PHQ-8 uses the same scoring criteria as the PHQ-9. The PHQ-8 measures the
severity of depressive symptoms using a 4-point Likert scale with 0 = not at all, 1 = several days,
2 = more than half the days, and 3 = nearly every day. Total scores range from 0-24, with higher
scores indicating more severe depressive symptoms. The level of depressive severity scores
consists of five ranges: minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19),
and severe (20-24). The cut-off point of 10 was established by identifying that most individuals
with a score ≥ 10 had either a depressive disorder or core depressive symptoms (sensitivity 88%
and specificity 88%) (Kroenke et al., 2009). A score < 5 is associated with the absence of a
depressive disorder, whereas scores ≥ 15 usually indicate major depressive disorder.
The reliability of the original PHQ-9 was psychometrically tested on a sample of 6,000
patients from eight primary care clinics and seven obstetrics-gynecology (ob-gyn) clinics. The
internal reliability is strong with a Cronbach’s alpha of 0.89 in the primary care setting and 0.86
in the ob-gyn setting. Participants completed the questionnaire and were interviewed 48 hours
later by a mental health provider to determine the stability of the instrument. The test-retest
reliability was r = 0.84 with nearly identical mean scores (5.08 vs. 5.03).
In terms of validity, criterion validity of the PHQ-9 was established by using a structured
psychiatric interview by a mental health professional to determine the presence of major
depression using the DSM-IV diagnostic criteria. Likelihood ratios confirmed the association
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between increasing PHQ-9 scores and the likelihood of major depression. The positive
likelihood ratios of the PHQ-9 scores of 0-4, 5-9, 10-14, 15-19, and 20-27 for major depression
were 0.04, 0.5, 2.6, 8.4, and 36.8, respectively. The positive likelihood ratio of these same
scoring intervals for major or other depressive disorder was 0.12, 1.3, 4.9, 15.7, and 38.0
respectively. ROC analysis confirmed that the PHQ-9 discriminates well between persons with
and without major depression by showing the area under the curve for diagnosing major
depression was 0.95. Construct validity was assessed by examining the correlations of the PHQ9 with the six subscales (physical functioning, role functioning, social functioning, mental health,
health perceptions, and pain) of the 20-item Short Form Health Survey (SF-20) examining
functional status. The PHQ-9 correlated the strongest with mental health (r = 0.73), followed by
health perceptions (r = 0.55), social functioning (r = 0.52), role functioning (r = 0.43), physical
functioning (r = 0.37), and pain (r = 0.33). There was a strong association between PHQ-9
severity scores and worsening function in all six SF-20 scales. Construct validity was also
assessed by examining the association between the PHQ-9 severity levels and disability days,
clinic visits, and the general amount of difficulty patients attribute to their symptoms. The PHQ9 correlated the strongest with symptom-related difficulty (r = 0.55), followed by disability days
(r = 0.39), and clinic visits (0.24). The greater levels of depression severity were associated with
an increase in symptom-related difficulty in activities and relationships, disability days, and
health care utilization (Kroenke et al., 2001). External validity was established by replicating the
findings from the 3,000 primary care patients using a second sample of 3,000 ob-gyn patients.
Generalizability to other populations has been established, including the cardiac population
(Holzapfel et al., 2007; Ruo, Rumsfeld, Hlatky, Liu, Browner, & Whooley, 2003; Haddad et al.,
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2013; van der Zwaan et al., 2016). In addition, the American Heart Association recommends the
use of the PHQ-9 instrument for depression screening in patients with coronary heart disease
(Lichtman et al., 2008). The scoring thresholds and the reliability and validation of the PHQ-9
apply for the PHQ-8 (Kroenke & Spitzer, 2002).
Anxiety. The GAD -7 tool was used to assess for general anxiety symptoms within the
past two weeks. The instrument was developed because most tools measuring anxiety were
seldom used because of their length and because they required administration by a health care
clinician, rather than patient self-report. The GAD-7 instrument was developed by using nine
items that reflected all the DSM-IV generalized anxiety disorder (GAD) symptoms criteria and
four items from existing anxiety scales (Spitzer, Kroenke, Williams, & Lowe, 2006). These nine
items reflecting GAD in the DSM-IV remain current in the DSM-5 (2013). The GAD-7
measures the frequency of anxiety symptoms using a 4-point Likert scale with 0 = not at all, 1 =
several days, 2 = more than half the days, and 3 = nearly every day. Total scores range from 021, with higher scores indicating more severe anxiety symptoms. The level of anxiety severity
scores fall into one of four categories: minimal (0-4), mild (5-9), moderate (10-14) and severe
(15-21). The cut-off point of 10 was established by determining most individuals with GAD had
GAD-7 scores of 10 or greater (sensitivity 89% and specificity 82%) and those without GAD had
scores less than 10. GAD scores greater than10 showed higher specificity, but the sensitivity
decreased significantly with the greater score.
The reliability testing of the original GAD 13-item tool was psychometrically tested on a
sample of 1,654 patients from fifteen family practice and two internal medicine sites. The
internal consistency of the instrument was strong with a Cronbach’s alpha 0.92 (Spitzer et al.,
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2006). Participants completed the questionnaire a second time to determine stability of the
instrument. The one week test-retest stability coefficient was adequate with an interclass
correlation (r = 0.83) using the same questionnaire.
In terms of validity, a random sample of 965 subjects from the initial sample was
interviewed by a mental health professional one week after completing the questionnaire to show
procedural validity with an intra-class correlation (r = 0.83). Factor analysis identified the seven
items that correlated the highest on the 13-item scale (r = 0.75-0.85) (Spitzer et al., 2006). The
GAD-7 items were combined with the eight items of the PHQ-8 depression scale and
confirmatory factor analysis identified two separate factors: factor 1 = depression and factor 2 =
anxiety. All the depression items loaded onto factor 1 (0.58-0.75) and the anxiety items loaded
onto factor 2 (0.69-0.81). Convergent validity was assessed by examining the correlations of the
GAD-7 with the Beck Anxiety Inventory (BAI) (r = 0.72) and the Symptom Checklist-90 anxiety
subscale (r = 0.74). The data analysis resulted in identifying the seven items on the tool.
The PHQ-8 and the GAD-7 were used to measure depressive and anxiety symptoms in
the study which was examined in relation to functional status, health perception, and QOL. Both
instruments reflect the principle that the higher the score, the higher the level of symptoms.
Functional Status
CVD involves adopting healthy behaviors to decrease the progression of CVD or
recurrent CVD events. The HPLP-II tool was used to assess CVD risk-reducing behaviors. The
original Health-Promoting Lifestyle Profile (HPLP) tool (Walker, Sechrist, & Pender, 1987) was
used to identify patterns and determinants of a health-promoting lifestyle and the effect that
interventions have to change one’s lifestyle. The HPLP-II was developed from the original tool
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to better reflect the more recent health-promoting behaviors to advance health promotion science
(Walker & Hill-Polerecky, 1996). The tool is a 52-item questionnaire consisting of six subscales
that measure the components of a healthy lifestyle: health responsibility, physical activity,
nutrition, interpersonal relations, spiritual growth, and stress management. The participant
chooses from four Likert choices ranging among 1 (never), 2 (sometimes), 3 (often), and 4
(routinely). HPLP-II scores may be obtained by adding up all responses to the items and
subscale scores may be obtained by adding up the responses to the subscales. Higher scores
represent greater health promotion behaviors.
The reliability testing of the HPLP original tool using a sample of 952 Midwestern adults
resulted in a Cronbach’s alpha of 0.92 while the six subscales were self-actualization (r = 0.90),
health responsibility (r = 0.81), exercise (r = 0.80), nutrition (r = 0.75), interpersonal support (r =
0.80), and stress management (r = 0.70) (Walker et al., 1987). Reliability testing of the revised
HPLP II resulted in a Cronbach’s alpha of the six subscales: health responsibility (r = 0.86),
physical activity (r = .85), nutrition (r = 0.80), spiritual growth (r = 0.86), interpersonal relations
(r = 0.87), and stress management (r = 0.79). The internal reliability of the HPLP-II revised tool
was stronger than the original HPLP tool. The HPLP-II has been found to be reliable in research
studying risk perception and CVD risk reduction behaviors with reported Cronbach’s alpha 0.95
(Oliver-McNeil & Artinian, 2002; Thanavaro, Moore, Anthony, Narsavage, & Delicath, 2006).
In terms of validity, content validity of the HPLP-II was established by a literature review
and evaluation by content experts. Factor analysis supported construct validity that identified six
subscales of health-promoting lifestyle (health responsibility, physical activity, nutrition,
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spiritual growth, interpersonal relations, and stress management) (Walker, Sechrist, & Pender,
1995).
General Health Perceptions
A major component of an individual’s perception of their overall general health is
influence by that individual’s perception of illness or disease (Weinman, Petrie, Moss-Morris, &
Horne, 1996). The variable illness perception was used to measure general health perceptions to
determine if there is a relationship to functional status.
Illness perception. The IPQ-R-Cardiac version was used to measure an individual’s
perception of illness that includes risk perception. The IPQ-R was adapted for use in CVD by
replacing the word “illness” with “heart disease”. Items relevant to the identity of heart disease
in women were identified from a literature review and inserted into the questionnaire. The IPQR originated from the Illness Perception Questionnaire (IPQ) that assessed five cognitive
components of illness: identity (label used to describe the illness and the symptoms),
consequences (expected outcome of the illness), cause (ideas about cause of illness), timeline
(how long the illness will last), and cure /control (recovery from or control of the illness) (Lau &
Hartman, 1983; Leventhal et al., 1984). The IPQ was used across many different populations,
including but not limited to the following: heart disease, cancer, arthritis, diabetes,
musculoskeletal, and including spouses/caregivers of individuals with medical illnesses. The
IPQ-R was developed to improve measurement reliability and expand the scope of its use by
adding more subscales to extend the original tool: cyclic timeline, illness coherence, and
emotional representation (Moss-Morris et al., 2002). The instrument has shown strong internal
reliability, test-retest reliability, and discriminant and descriptive validity in 711 patients from
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eight different illness groups (asthma, diabetes, rheumatoid arthritis, chronic pain, acute pain,
MI, multiple sclerosis, and human immunodeficiency virus (HIV)) (Moss-Morris et al., 2002).
The IPQ-R consists of three domains and nine representations of illness perception. The first
domain is identity that measures perceived symptoms and their possible relationship to the
illness. The second domain is beliefs and includes seven representations of illness: acute/chronic
timeline, cyclical timeline, consequences, personal control, treatment control, illness coherence,
and emotions. The acute/chronic and cyclical timeline represent the perceived changeability of
the illness. The consequences represent the perceived short- and long-term effects on physical,
psychological, and social functioning. The personal and treatment control represent the perceived
controllability and curability of the illness. Illness coherence represents understanding of the
illness. The emotional representation identifies the emotions caused by the illness. The third
domain is cause, representing the individual’s perceived responsibility and curability of the
illness.
The IPQ-R used a nominal scale to measure the subscale identity with 1 = yes and 2 = no.
A 5-point Likert scale was used to measure the individual’s responses to the items on the
subscales: timeline acute/chronic, consequences, personal control, treatment control, illness
coherence, timeline cyclical, emotional representations, and causes. The Likert scale responses
were 1 = strongly disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 =
strongly agree. The subscales of the IPQ-R are scored individually. High scores on the identity,
timeline acute/chronic, timeline cyclical, and consequences represent stronger beliefs about the
number of symptoms attributed to the illness, the chronicity/cyclicality of the illness, and the
negative consequences of the illness. High scores on personal control, treatment control, and
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illness coherence represent positive beliefs about the personal understanding of the condition and
controllability of the illness.
The IPQ-R is a common and reliable instrument use to measure illness perception. The
IPQ-R has strong internal reliability with a Cronbach’s alpha of each subscale: identity (r =
0.75), timeline acute/chronic (r = 0.89), timeline cyclical (r = 0.79), consequences (r = 0.84),
personal control (r = 0.81), treatment control (r = 0.80), illness coherence (r = 0.87), and
emotional representation (r = 0.88). The cause subscale consists of four subscales with a
Cronbach’s alpha of each subscale: psychological attributes (r = 0.86), risk factors (r = 0.77),
immunity (r = 0.67), and accident/chance (r = 0.23). The accident/chance subscale consisted of
two items with low correlation and which may contribute to the low Cronbach’s alpha. Threeweek test-retest stability coefficients of the subscales ranged from 0.46-0.89 with the personal
control being the only scale with a correlation less than 0.50. The six-month test-retest stability
coefficients of the subscales ranged from 0.35-0.82 with the timeline cyclical being the only
scale with a correlation less than 0.5.
In terms of validity, principal component analysis (PCA) was conducted to identify the
seven factors (acute/chronic timeline, cyclical timeline, consequences, personal control,
treatment control, coherence, and emotion) of the second domain with item loadings greater than
0.5. Another PCA was computed on the causal items identifying four factors (psychological
attributions, risk factors, immunity, and accident/chance) with item loadings greater than 0.50.
Validity of the identity subscale was established using a sample paired t-test that identified a
significant difference between somatization and identity of illness (t(15.94), p < .001). In
summary, the IPQ-R has demonstrated reliability and validity and has been used successfully to
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measure illness perception in the cardiovascular population (Alsen et al., 2010; Moss-Morris et
al., 2002; Schoormans et al., 2014).
Quality of Life
The outcome variable of QoL in individuals with CVD was measured by using an
adapted version of Ferrans and Powers Quality of Life Index (QLI). The generic QLI was
developed to measure satisfaction in four areas of life with the participant placing value on those
areas. QLI-Cardiac IV was used to measure QoL in individuals with CVD (Ferrans & Powers,
2010). There are four subscales assessed with this tool: health and functioning, psychological
and spiritual, social and economic, and family. Part one of the questionnaire consists of thirtyfive statements measuring satisfaction where the participant chooses from six Likert choices
ranging from 1 (very dissatisfied) to 6 (very satisfied) (Ferrans & Powers, 1992). Part two
consists of thirty-five statements measuring value where the participant chooses from six Likert
choices ranging from 1 (very unimportant) to 6 (very important). Scores range from 0 to 30 with
higher scores indicating higher perceived overall QoL. A score less than 19 indicates a poorer
QoL (Personal Communication from Dr. C. Ferrans, October 16, 2018).
The reliability testing of the generic version using a sample of 349 hemodialysis patients
resulted in a Cronbach’s alpha of 0.93 (Ferrans & Powers, 1992). Factor analysis confirmed four
distinct factors with corresponding Cronbach’s alpha as follows: health and functioning (r =
0.87), psychological and spiritual (r = 0.90), socioeconomic (r = 0.82), and family (r = 0.77).
Forty-eight studies report reliability of the overall tool to be a Cronbach’s alpha 0.73-0.99.
These studies report reliabilities for each four factor as follows: health and functioning (r = 0.700.94), psychological and spiritual (r = 0.78-0.96), social and economic (r = 0.71-0.92), and
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family (r = 0.63-0.92) (Ferrans & Powers, 1992). Two-week and four-week test-retest stability
coefficients of 0.87 and 0.81, respectively, are strong.
Two items on the generic QLI tool were revised for the Cardiac-IV version. The revised
items were: the amount of chest pain (angina) that you have, and having no chest pain (angina).
Four items were added to the generic QLI tool to create the Cardiac-IV version. These items are:
the ability to breathe without shortness of breath, the changes in your life that you have had to
make because of your heart problem, having no shortness of breath, and the changes in your life
that you have had to make because of your heart problem. These items are more specific to QoL
in patients with CVD. The cardiac version has been used in ten studies confirming Cronbach’s
alpha ranging from 0.86-0.98 (Bliley & Ferrans, 1993; Carroll & Hamilton, 2005; Carroll,
Hamilton, & McGovern, 1999; Delunas & Potempa, 1999; Deshotels, Planchock, Dech, &
Prevost, 1995; Dougherty, Dewhurst, Nichol, & Spertus, 1998; Ferrans & Powers, 2010;
Papadantonaki, Stotts, & Paul, 1994; Penckofer, Ferrans, Fink, Barrett, & Holm, 2005; Scott,
2000; Scott, Setter-Kline, & Britton, 2004).
Content validity was established by an extensive review of the literature and patients’
reports of their quality of life (Ferrans & Powers, 1995). Convergent validity of the QLI had
strong correlations (r = 0.61-0.93) between the overall score and measure of life satisfaction
(Bliley & Ferrans, 1993; Campbell, Converse, & Rodgers, 1976). The QLI-Cardiac IV is an
important outcome variable in the study.
The satisfaction section (Part 1) of the QLI questionnaire will only be utilized for this
study to reduce respondent burden with permission of Dr. Carol Ferrans (Personal
Communication, December 16, 2016).
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Characteristics of the Environment
Social support was measured using the MOS-SS. The MOS-SS is a 20-item survey that
was originally developed for chronically ill patients in the Medical Outcomes Survey (MOS)
(Sherbourne & Stewart, 1991). The instrument is unique from other social support instruments
by measuring an individual’s perceived availability of social support. The MOS-SS contains one
item on structural support (number of close friend and relatives) and four subscales of functional
support: emotional/informational (expression of positive affect, empathetic understanding,
encouragement of feelings, and providing good advice, information, guidance or feedback);
tangible (provision of material aid or behavioral assistance); affection (expressions of love and
affection); and positive social interaction (availability of other people to do fun things with you).
The structural support item obtains a numerical value of the number of close friends and relatives
and is not included in scoring the instrument. Each subscale consists of items ranked on a 5point Likert scale with 1 = none of the time, 2 = a little of the time, 3 = some of the time, 4 =
most of the time, and 5 = all of the time, for how often each support was available. The scores
ranged from 0 (the lowest score) to 100 (the highest score). The higher the score the more
frequent the perceived social support. The items on the instrument are short, simple, and easy to
understand, promoting ease of use in patients of all ages with a chronic disease (McDonald,
2006).
In terms of reliability, this has been reported for the generic version using a sample of
2,987 adult patients with one or more chronic disease (CAD, hypertension, diabetes, and
depression), resulting in an overall Cronbach’s alpha of 0.97 and the subscale Cronbach’s
alpha’s as follows: emotional/information (r = 0.96), tangible (r = 0.92), affection (r = 0.91), and
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positive social interaction (r = 0.94). Test-retest reliability of the instrument one year later was
high, with strong overall correlations (r = 0.78) and subscales correlations (r = 0.72 – 0.76).
In terms of validity, item scale correlations confirmed convergent criterion validity of the
subscales: emotional/informational (r = 0.72-0.87), tangible (r = 0.80-0.86), affection (r = 0.820.90), and positive social interaction (r = 0.87-0.88). Discriminant validity was established by all
items in each subscale correlating two standards of error with their own scale than with any other
subscale. The single item of structural support showed low correlations with the four subscale
scores (r = 0.18-0.24). Factor analysis confirmed one item on structural support and four distinct
subscales of functional support: emotional/informational, tangible, affection, and positive social
interaction.
Human Subjects
Institutional Review Board
The research study was submitted for IRB approval through the data collection site
(AMG–Cardiology Advocate Health Care) and to Loyola University Heath System IRB before
beginning data collection. The IRB reviews assured that the study design was scientifically
secure and the protection of human subjects and ethical conduct was clearly defined. A letter of
organizational support for the research study (Appendix E) was obtained from AMG-Cardiology,
Advocate Health Care giving permission to recruit study participants from the cardiology offices.
Study Explanation to Prospective Participants
Women who were interested in participating in the study were explained the study
purpose, the procedure, the anticipated risks and benefits before asking them to read and sign the
consent form (Appendix F). The consent form contains the following items: a description of the
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purpose of the study, the study procedures, time required to complete the questionnaire booklet,
voluntary participation, description of the risks and benefits, compensation, and confidentiality.
The consent includes contact information for the PI and the Advocate Health Care IRB office.
During the consent process, prospective participants were informed they may refuse
and/or withdraw from participating in the study at any time without penalty and there would be
no impact on the health care they receive at Advocate Heath Care. The participants were
informed that all data would be collected and maintained to protect their confidentiality. In
addition, the participants were informed that the study questionnaire and information gathered
from their electronic medical record would be used for purposes of the research study only. To
maintain confidentiality of data collected and anonymity, the subject participants were assigned a
number rather than using their name. A master list of the subjects’ names and their code
numbers were secured in a locked file cabinet and electronic information was password protected
on the investigator’s computer.
Potential Risks
Risks for participating in the study included 1) time required to complete the
questionnaire and 2) discomfort in answering some questions on the PHQ-8 and GAD-7
measurements. As mentioned previously, the AMG-C patients are currently screened for
depression using the PHQ-2 and there is a process in place to refer those individuals requiring
further assessment to their PCP. Since the study questionnaire contained depressive and anxiety
symptom assessment tools, it was anticipated that some women may find the mood questions
disconcerting. Therefore, the PI asked at the completion of the questionnaire booklet if the
participant had any concerns about their mood. None of the women participants voiced concern
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about their mood. The risks to the subjects were minimal for obtaining knowledge of the
association of depressive and/or anxiety symptoms with health promoting behaviors, illness
perception, and QoL in women with CAD of younger and older age groups.
There were no known benefits for participating in the study. However, the knowledge
obtained through this study may support the importance to screen for depressive and anxiety
symptoms in women with CAD, provide treatments/interventions (anti-depressants, anti-anxiety
medication, cognitive behavioral therapy, illness perception intervention), to promote health
promoting behaviors and improve QoL. In addition, significant results from the study will
support the need for future studies to test interventions for improving depressive and anxiety
symptoms in women with CAD which can be a benefit to this population. The overall benefit
could be a positive impact on women’s CVD health and QoL. This could potentially result in
reduced future cardiovascular events which could translate to significant cost savings to the
healthcare system.
Data Analysis
The data was analyzed using Pearson’s correlations, multiple regression analysis,
independent t-test, and analysis of covariance (ANCOVA). Specific analysis for each aim is
identified below.
Aim 1: To determine the relationship of symptoms (depression, anxiety) to functional status
(health-promoting behaviors), health perceptions (illness perception) and QOL.
Hypothesis 1: Negative mood symptoms (depression, anxiety) will be associated with fewer
health-promoting behaviors, less perception of risk (illness), and poorer QOL.
In order to test this hypothesis, the analysis began by computing descriptive statistics on
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all study variables. The data were examined for potential outliers and their impact on the
outcomes. Next, correlations were examined to determine the relationships among the variables
described in the Wilson and Cleary Health-Related QoL model (as modified by Ferrans et al.,
2005). Given the relationships among these variables, a stepwise multiple regression model was
examined to identify the best model fit. The variables in the model were entered into the
regression equation in the order of which had the greatest account for the variance of the
dependent variable.
Aim 2: To determine whether age is a factor contributing to negative mood symptoms,
functional status, health perceptions, and QoL after controlling for social support.
Hypothesis 2: Women who are younger will have more negative symptoms, fewer
health-promoting behaviors, less perception of risk, and lower QoL than women who are older,
after controlling for social support.
The groups were divided into two age groups for analysis. One group was individuals
age 35-64 years and the other group was women ≥ 65. Subsequently, independent t-test was
used to examine the difference between these age groups among key study variables. Previous
studies identified that social support is significant predictor of depressive symptoms, health
promoting behaviors, illness perception, and QoL. Therefore, analysis of covariance
(ANCOVA) for social support (the covariate) was performed to examine differences between
age groups among key study variables.

CHAPTER FOUR
RESULTS
This chapter will discuss the analysis and results of the study. Descriptive statistics on
the sample will be provided along with the key variables in the study. Following will be the
results from the analysis of the study aims. The purpose of the study was to examine whether
negative mood symptoms (depression, anxiety) contribute to the lack of successful change in
healthy behaviors in women with known CVD. The first aim of the study was to identify the
relationship of symptoms (depression, anxiety) to functional status (health-promoting behaviors),
health perceptions (illness perception), and QoL. The second aim of the study was to determine
whether age is a factor contributing to negative mood symptoms, functional status, health
perceptions, and QOL after controlling for social support.
Enrollment
Women (n=81) were recruited from two suburban communities located approximately
sixteen miles from each other (Figure 2). It was expected that the sample would closely
resemble the racial and ethnic composition of the surrounding community. The majority of the
patients (n = 61, 75%) participating in the study came from within 14 miles of the study settings
located in one county. The racial composition for the primary county site is 68.6% White, 13.9%
Hispanic, and 10.8% Asian, and 4.6% Black (Census Bureau: American Community Survey,
2015).
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Figure 2. Enrollment Diagram

Flyers Posted in the Clinic

Verbally Informed of Study

Discussed the Study with
Women in the Clinic

Enrolled Participants
Site 1 = 73
Site 2 = 8
n = 81

Data Security
Data were abstracted from the completed study questionnaire booklets. Data from the
questionnaire booklet was stripped of all individual identifiers and entered into a statistical
software database (SPSS Mac Version 25, SPSS, Chicago, Il.) All data were checked manually
for errors and data entry errors were corrected. The database was stored in a password-protected
file and a protected backup system. Participant codes were used to identify the raw data and the
data was entered only using the de-identifier codes. All participant consents were secured in a
locked cabinet in the Advocate Medical Group Cardiology research office. All other paper data
was secured in a locked cabinet in the researcher’s office.
Missing Data
Completion of the data were verified after the women completed the questionnaire and
before they left the study area. Data was considered missing if there was no response to an item.
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Two participants had missing data for income and reported their spouse handled their finances
and they were unaware of their income. The patterns of missing data on the QLI were the
children, sex life, spouse/partner/lover, and job question. The missing data were to be expected;
if you do not have children, then it is realistic to not answer the item. Scoring on these items
does not require the replacement of missing data. The data were manually screened for missing
or potentially erroneous data responses. Data entry errors were corrected and frequencies were
run before continuing the data analysis. Missing data were imputed for missing data on the
income question and QLI instrument.
Data Analysis
Each of the key study variables were analyzed for normality, outliers, and extreme scores
that may influence the study findings. Histograms were used to evaluate normality. Variables
that appeared skewed were also analyzed for significant skewness. The PHQ-8 and GAD-7 were
found to be significantly positively skewed. The QLI and MOS-SS were significantly negatively
skewed. Although these variables were skewed, data normality is not an assumption for
Pearson’s correlation analysis or for predictors used in multiple linear regression (Field, 2009),
therefore no data transformations were performed to correct skewness.
The next segments provide an analysis of the variables based on the modified Wilson and
Cleary Health-Related Quality of Life theoretical model: characteristics of the individual
(demographics), biological function (Framingham Recurrent Risk Model and FCI), symptoms
(PHQ-8, GAD-7), functional status (HPLP-II), general health perceptions (IPQ-R), overall QoL
(QLI), and characteristics of the environmental (MOS-SS).
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Characteristics of the Individual
Individual characteristics may impact QoL, therefore demographics on the women were
collected.
Description of the Sample
Eighty-one women completed the study. The study sample can be described as suburban,
Caucasian, married, having had high school diploma or college graduate, retired, and with
varying income. The socio-demographics of the study sample are summarized in Table 2.
Table 2. Demographics of Study Sample
Variable

N (Percent)

Age

65.53 ( 7.78)
67 (43 – 78)

Mean (Standard Deviation)
Median (Range)

Duration of CAD

8.2 years

CAD
Heart Attack
Angioplasty
Stent
CABG
Chest Pain
Ethnicity/Race
Caucasian
African American
Hispanic
Asian
Multiple Race/Other
Marital Status
Married
Divorced
Separated
Single living with partner

42 (52%)
32 (40%)
53 (65%)
19 (24%)
28 (35%)
66 (81.5%)
7 (8.6%)
3 (3.7%)
1 (1.2%)
4 (4.9%)
42 (51.9%)
6 (7.4%)
2 (2.5%)
1 (1.2%)
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Single not living with partner
Widowed
Education
High School
Associate degree
Trade, vocational, technical
College Degree
Graduate Degree
Income
< $20,000
$20,000 - $29,000
$30,000 – $39,000
$40,000 - $54,000
$55,000 - $64,000
$65,000 - $79,000
$80,000 - $94,000
>$95,000
Employment
Full time
Part time
Homemaker/student
Retired
Unemployed
Other (Disability)
Depression/Anxiety Medication
Antidepressant
Anti-anxiety

13 (16%)
17 (21%)
27 (33.3%)
17 (21%)
6 (7.45)
20 (24.7%)
11 (13.6%)
1 (1.2%)
6 (7.4%)
10 (12.3%)
14 (17.3%)
8 (9.9%)
12 (14.8%)
9 (11.1%)
19 (23.5%)
16 (19.8%)
8 (9.9%)
6 (7.45)
42 (51.9%)
3 (3.7%)
6 (7.4%)

12 (14.8%)
9 (11%)
Biological Function

Cardiovascular Risk Factors
The Framingham 2 Year Recurrent Risk Model for Women with CHD was used to
identify CV risk factors and calculate the probability of a secondary cardiac event in women in
the study. The probability value was obtained from age, TC, HDL, SBP, tobacco use, and
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diabetes. Table 3 summarizes the CVD risk factors assessed in the sample according to the
Framingham scoring system. The women scored a 3% risk for a secondary cardiac event. In
order to score a 3% risk a woman would have to obtain a total of 16 points using the
Framingham scoring system. For this sample, the majority of points were from elevated age
(mean = 65 years), elevated cholesterol levels, and diabetes (n = 30; 37%). Age and diabetes are
two scoring items that cannot be controlled. Higher points are assigned as the individual ages,
for example, age 55 – 59 receive 4 points, age 59 - 64 receive 5 points, age 65 – 69 receive 6
points. A diagnosis of diabetes is 8 points. The controllable low risk items for a secondary event
are non-tobacco use, normal cholesterol levels (TC < 200 mg/dl & HDL-C > 40 mg/dl) and
blood pressure control (SBP < 140 mmHg). The women had very low tobacco use (n = 5; 6.2%)
and controlled SBP < 134 mmHg (n = 61; 75.30%). Using the mean risk factor values for this
sample, a 65 year old woman with a TC of 177 mg/dl, an HDL-C of 47 mg/dl, who does not
smoke, does not have diabetes, and an SBP of 127 mmHg would get 6 points for age, 6 points for
TC/HDL-C, no points for smoking, no points for diabetes, and 4 points for SBP. Her total points
would be 16 giving her a 3% 2-year recurrent CVD Framingham risk score. Therefore, most of
the points were due to age and cholesterol level. In summary, the women on average had a 3%
risk for a recurrent CVD event that is considered “low risk” for a secondary cardiac event. A
risk score less than 10% is considered low risk for having a heart attack or dying from a coronary
disease (Jellinger et al., 2017).
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Table 3. Recurrent Risk for Cardiovascular Disease Event per Framingham Score System
CVD Risk Factor
Age Mean (Standard Deviation)
Median (Range)
40-49
50-54
55-59
60-64
65-69
70-78

N (Percent)
65.53 ( 7.78)
67 (43 – 78)
1 (1.2%)
7 (8.6%)
13 (16%)
15 (18.5%)
17 (21%)
28 (34.6%)

TC Mean (Standard Deviation)
Median
HDL-C Mean (Standard Deviation)
Median

177 ( 33.3)
160 (160 - 300)
47 ( 13.2)
50 (55 - 25)

Smoking
No
Yes
Diabetes
No
Yes
SBP Mean
Median
< 110
110-114
115-124
125-134
135-144
145-154
155-164
Framingham Risk Score
Mean

76 (93.8%)
5 (6.2%)
51 (63%)
30 (37%)
127 mmHg
120 (115 - 124)
3 (3.7%)
19 (23.5%)
22 (27.2%)
17 (21%)
13 (16%)
5 (2.5%)
2 (2.5%)
3%

Note. TC = total cholesterol; HDL-C = high density lipoprotein cholesterol; SBP = systolic blood pressure.

Functional comorbidity. Studies have shown that there is greater self-report of
depression in individuals with comorbid conditions that impact physical function. Greater

82

impairment in physical function is associated with poorer health related quality of life (Haines et
al., 2013). The FCI instrument was used to measure for diagnosed chronic illnesses, including
calculating a BMI for obesity, to determine physical function. The instrument uses a “yes” or
“no” response to each chronic disease on the instrument. The FCI total score is a sum of the
number of “yes” chronic disease checked items with a score range of 0 – 18. The higher the total
score the greater impairment of physical function. Table 4 lists the number (%) of individuals
that reported “yes” to having the chronic disease, as well as, normative data. The normative data
was obtained from men ( n = 84) and women (n = 17) of the approximate age group (40-84 years
old; mean age 63 years) with recent coronary artery bypass surgery (Parry, Arthur, Brooks,
Groll, Pavlov, 2012). The FCI total score (mean = 4.83) indicated low functional comorbidity
that implied greater physical function in the women. All women reported having either angina (n
= 18; 22.2%), heart disease (n = 45; 55.6%), or heart attack (n = 43; 53.1%). This is an expected
finding because heart disease was inclusion criteria for the study. The most common diagnoses,
in addition to the cardiac diagnoses, were obesity (n = 38; 46.9%), arthritis (n = 38; 46.9%),
diabetes (n = 30; 37%), and upper gastrointestinal disorders (n = 30; 37%). The women may not
have responded “yes” to the congestive heart disease (CHF)/heart disease item because they may
have perceived this indicated they had heart failure. Heart failure disease was exclusion criteria
for the study. It is important to mention that a history of depression (n = 21; 25.9%) was
reported by the women, although the study sample had an overall low score on the PHQ-8
depression instrument. This finding may be due to some women reported taking an
antidepressant (n = 12; 14.8%) and/or anti-anxiety (n = 9; 11%) medication. The most common
chronic diseases reported by the women in the study compared to the normative data in
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men/women of the approximate age with heart disease. The FCI instrument had a borderline
reliability ( = .61), therefore the data was only used as descriptive data to identify comorbidities
with the study sample women. The instrument is more an indication of low or high number of
functional comorbidity diseases reported versus internal consistency of the subscale. The FCI
instrument was developed to predict physical function on comorbidity data and had a correlation
coefficient of 0.53 with physical function that indicated the instrument could account for 53% of
variance in physical function. Although this variance is low, the instrument was comparable to
other instruments (Comorbidity Scales for Stroke Outcomes, Chronic Disease Score, and
General Medical Health Rating) that measured comorbidity association to mortality (Groll et al.,
2005).
Table 4. Functional Comorbidity Disease Frequency
Study Sample Women

Normative Data

n (%)

n (%)

(n = 81)

(n = 101)

Arthritis

38 (46.9%)

26 (26%)

Osteoporosis

12 (14.8%)

3 (3%)

Asthma

10 (12.3%)

9 (9%)

COPD

13 (16%)

19 (19%)

Angina

18 (22.2%)

73 (72%)

CHF/Heart Disease

45 (55.6%)

101 (100%)

Heart Attack

43 (53.1%)

55 (55%)

Neurologic Disease

3 (3.7%)

1 (1%)

TIA

6 (7.4%)

8 (8%)

Comorbid Disease

Peripheral Vascular Disease 9 (11.1%)

17 (17%)

Diabetes Types I & II

33 (33%)

30 (37%)
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Upper GI Disease

30 (37%)

39 (39%)

Depression

21 (25.9%)

11 (11%)

Anxiety or Panic Disorder

19 (23.5%)

5 (5%)

Visual Impairment

27 (33.3%)

11(11%)

Hearing Impairment

4 (4.9%)

4 (4%)

Degenerative Disc Disease

25 (30.9%)

9 (9%)

Obesity

38 (46.9%)

34 (34%)

Note. Normative data were obtained from men and women aged 40-84 years (mean = 63) post coronary artery
bypass graft surgery (Parry et al., 2012).

Symptoms
Depressive Symptoms
Depression severity was measured using the self-report PHQ-8 instrument. The PHQ-8
scoring is the simple sum of the item scores and can range from 0-24. The level of depressive
scores consists of five ranges: minimum (0-4), mild (5-9), moderate (10-14), moderately severe
(15-19), and severe (20-24). Higher scores reflect greater depressive symptoms. A score less
than 5 is associated with the absence of a depressive disorder, a score 5-9 is associated with mild
depressive symptoms, a score 10 is associated with a depressive disorder or moderately severe
depressive symptoms, and a score greater than 15 usually indicates major depressive disorder.
The score of 10 is the cut-off for determining the presence of a depressive disorder. Table 5 lists
the mean score for the total instrument, frequency response for each of the five ranges, and the
normative mean score. The normative mean score was obtained by women (n = 814) of the
approximate age group (18-94 years; mean age 60) with a history of a myocardial infarction
(Mallik et al., 2006). Using the PHQ-8 guidelines 64% of the women (n = 52) have no to
minimal symptoms, 33% (n = 27) have mild to moderate symptoms, and 3% (n = 2) have severe

85

depressive symptoms. Even though the women in the study had a lower PHQ-8 score compared
to the normative mean score, depressive symptoms were present in the sample. In summary,
while it is true that 64% of the women are healthy, there is another 36% who are with depressive
symptoms. The PHQ-8 had an alpha coefficient of .82 indicating high reliability with the study
sample.
Table 5. Patient Health Questionnaire-8 Mean Score and Frequency Results and Normative
Mean Score
Total
Mean Score
(Standard
Deviation)

Range Frequency
Minimum

Mild

Moderate

N (%)

N (%)

N (%)

3.87 ( 3.82)

52 (64%)

22 (27%)

5 (6%)

Moderately
Severe
N (%)
2 (3%)

N (%)

Normative
Total Mean
Score (Standard
Deviation)

0 (0%)

6.8 ( 5.8)

Severe

Note. Normative mean scores were obtained from women aged 18-94 years (mean = 60 years) with Myocardial
Infarction (Mallik et al., 2006).

Anxiety Symptoms
The GAD-7 is a self-report instrument that was used to measure anxiety symptoms using
a 4-point Likert scale of 0 (not at all) to 3 (nearly every day). The GAD-7 scoring is the sum of
the item scores and ranges from 0-21. Higher scores reflect greater anxiety symptoms. The level
of anxiety scores consists of four ranges: minimum (0-4), mild (5-9), moderate (10-14), and
severe (15-21). The score >10 is associated with generalized anxiety disorder. Table 6 lists the
mean scores for the total and each of the four ranges, as well as the normative mean score.
Using the GAD-7 guidelines, 73% (n = 59) of the women have no to minimal anxiety, 25% (n =
20) have mild anxiety, and 3% (n = 2) have severe anxiety symptoms. The normative mean
score (6.1) was obtained by women (n = 1780) of approximate age group (18-95; mean age 47.5)
from primary care settings (Spitzer et al., 2006). Spitzer et al. (2006) tested the reliability and
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validity of the GAD-7 instrument and found anxiety scores similar in women aged < 47 years
and those aged > 47 years. Lowe et al. (2008) conducted a study to establish normative data of
the GAD-7 in the general population and found women (n = 2678) with a mean age of 48 years
had a normative mean score of 3.20 (SD= 3.52). Even though the women in this study had a
lower GAD-7 total mean score compared to the normative total mean score identified in the
primary care and/or general population, anxiety symptoms were present in the study sample. In
summary, although 73% of the women are healthy, there are 28% who are with anxiety
symptoms. The GAD-7 had an alpha coefficient of .89 indicating high reliability of the
instrument.
The data from the GAD-7 showed the mean score was 2.74 (SD = 3.38) with a median of
1.00. It is important to note that the standard deviation (SD) was greater than the mean score.
Knowing that the SD is only affected by how much each data point is away from the average
value, it is very likely that data dispersion accounted for the high SD. The data from the GAD-7
was widely dispersed which likely accounts for the high SD value. The GAD-7 instrument
scores range from 0 to 21, and the frequency of scores from the study ranged from 0 to 18. The
GAD-7 frequency scores can be found in Table 7. Figure 3 displays the dispersion of scores
using a histogram for easier visualization. Although the majority of the women reported
minimal (score 0-4) symptoms, there were others that scored mild (score 5-9), or severe anxiety
symptoms (score 15-21). The SD greater than average (mean) identifies that the data points are
widely dispersed with several extreme values. Although the extreme scores are unusual values,
and not ideal from a statistical perspective, the values reflect those women who participated in
the study.
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Table 6. Generalized Anxiety Disorder-7 Mean Score and Frequency Results and Normative
Mean Score
Mean Score
(Standard
Deviation)

Range Frequency

2.74 ( 3.38)

Minimum

Mild

Moderate

Severe

N (%)

N (%)

N (%)

N (%)

59 (73%)

20 (25%)

0 (0%)

2 (3%)

Normative
Mean Score

6.1

Note. Normative mean score was obtained from women aged 18-95 years (mean = 47  15.5 years) from primary
care settings (Spitzer et al., 2006).

Table 7. GAD-7 Item Frequency Scores
Score
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

Frequency (N/Percent)
28/34.6%
13/16%
8/9.9%
4/4.9%
6/7.4%
7/8.6%
7/8.6%
2/2.5%
3/3.7%
1/1.2%
0/0%
0/0%
0/0%
0/0%
0/0%
1/1.2%
0/0%
0/0%
1/1.2%
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Figure 3. Histogram display of GAD-7 frequency scores distribution

Functional Status
Health-Promoting Behaviors
Health promoting behaviors were measured by the HPLP-II. Table 8 lists the frequency
response for the HPLP-II total and subscale scores. Table 9 lists the alpha coefficients and the
mean scores for the total and subscales, as well as the normative mean scores. The mean score
for the total and for each six subscales are based on a Likert scale of 1 (“never”), 2
(“sometimes”), 3 (“often”), and 4 (“routinely”). Higher scores reflect greater health promoting
behaviors. The HPLP-II total mean score of 3.23 indicates that on average the sample performed
health promoting behaviors in the often-to-routinely range. The highest scoring subscales were
interpersonal relations (mean = 3.64) and spiritual growth (mean = 3.46). These scores indicate
that on average the women were “often” to “routinely” performing these health promoting
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behaviors. The nutrition (mean = 3.20), health responsibility (mean = 3.09), and stress
management (mean = 3.09) subscales indicate that on average the women were “often”
performing healthy nutrition, health responsibility, and stress reducing activities. The women
scored the lowest on the physical activity subscale (mean = 2.74) indicating that on average they
“sometimes” to “often” performed physical activity behaviors. The alpha coefficients (.74 - .88)
for the HPLP subscales confirmed reliability of the subscales. The normative mean scores were
obtained from women (n = 125) of a similar age group (48-67 years old; mean age = 57.7)
without CAD (Savoy & Penckofer, 2015). Oliver-McNeil & Artinian (2002) examined women
(n = 33) with heart disease and obtained similar HPLP-II mean scores (total mean score 2.44; SD
.50) compared to the normative scores provided from women without CAD. In summary, the
women in the study were above average in performing heath promoting behaviors compared to
other women of the same age that are with or without heart disease (Oliver-McNeil & Artinian,
2002; Savoy & Penckofer, 2015; Thanavaro et al., 2006).
Table 8. Health-Promoting Lifestyle Profile II (HPLP-II) – Frequency Results
Scale

Never (1)
N (%)

Total Score

Sometimes (2)
N (%)

Often (3)
N (%)

Routinely (4)
N (%)

0

6 (7.4%)

50 (61.7%)

25 (30.9%)

0

14 (17.3%)

46 (56.8%)

21 (25.9%)

33 (40.7%)

27 (33.3%)

18 (22.2%)

Subscales:
Health Responsibility
Physical Activity

3 (3.7%)

Nutrition

0

5 (6.2%)

54 (66.7%)

22 (27.2%)

Spiritual Growth

0

4 (4.9%)

36 (44.4%)

41 (50.6%)

Interpersonal Relations

0

1 (1.2%)

27 (33.3%)

53 (65.4%)

10 (12.3%)

51 (63%)

19 (23.5%)

Stress Management

1 (1.2%)
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Table 9. Health-Promoting Lifestyle Profile II (HPLP-II) and Subscale Scores

HPLP-II Total Score
Subscales
Health Responsibility
Physical Activity
Nutrition
Spiritual Growth
Interpersonal Relations
Stress Management

# of Alpha
Items Coefficient
52
.94

Mean Score Median
Normative
(SD)
(Range)
Mean Score(SD)
3.23 ( .576) 3.00 (2 – 4) 2.63 (.38)

9
8
9
9
9
8

3.09 ( .655)
2.74 ( .848)
3.20 ( .541)
3.46 ( .592)
3.64 ( .507)
3.09 ( .636)

.80
.88
.74
.85
.80
.76

3.00 (2 – 4)
3.00 (1 – 4)
3.00 (2 – 4)
4.00 (2 – 4)
4.00 (2 – 4)
3.00 (1 – 4)

2.6 (.52)
2.1 (.68)
2.7 (.60)
3.0 (.55)
3.1 (.50)
2.4 (.53)

Note. Normative mean scores were obtained from women aged 48-67 years (mean = 57.7 years) without CAD
(Savoy & Penckofer, 2015).

General Health Perceptions
Illness Perception
Illness perception was measured by the IPQ-R-Cardiac Version instrument that includes
eight subscales (identity, timeline acute/chronic, timeline cyclical, consequences, personal
control, treatment control, illness coherence, and emotional representation). The IPQ-R scores
are obtained from the individual subscales. The scores on the subscales provide knowledge on
whether the individual has a negative perception or a positive perception of the illness. It is
believed that individuals with negative illness perception may not manage their illness
effectively (Weinman, Petrie, Sharpe & Walker, 2000). High scores on the identity, timeline,
consequences, cyclical, and emotional representation subscales indicates the belief that there are
more symptoms related to the illness, the illness is chronic, the illness is permanent, the illness
has negative consequences, and the illness causes distress. More symptoms related to illness,
illness has negative consequences, and illness causes distress are all negative perceptions of
illness. High scores on the personal control, treatment control and coherence subscales indicate
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the belief the illness can be personally controlled, the illness can be treated, and there is a greater
understanding of the illness. These are all positive perceptions of illness. Individuals with a
positive illness perception would be expected to manage their illness more effectively (Weinman
et al., 2000). The causal subscale identifies the perceived cause of the illness.
The IPQ-R identify subscale assessed the experience of 20 symptoms: pain, sore throat,
nausea, breathlessness, weight loss, fatigue, stiff joints, sore eyes, wheeziness, headaches, upset
stomach, sleep difficulties, dizziness, loss of strength, chest pain, shortness of breath, loss of
appetite, weakness, unusually scared, and indigestion. For each symptom the subject indicates
“yes” or “no” if she believes the symptom is related to her CVD illness. “Yes” responses are
counted and averaged to yield a mean number of symptoms believe to be related to the CVD
illness. A higher mean score indicates a greater number of symptoms are believed to be attributed
to CVD illness. The IPQ-R subscales (timeline acute/chronic, consequences, personal control,
treatment control, illness coherence, timeline cyclical, and emotional representation, causal) use a
5-point Likert scale from 1 (strongly disagree) to 5 (strongly agree). Higher scores indicate a
strong belief that the illness will be chronic, illness symptoms will occur often, consequences of
the illness will be negative, the illness can be personally controlled, the illness can be treated, a
greater understanding of the illness, and the illness causes distress. The IPQ-R causal subscales
(psychological attributes, risk factors, immunity, and accident/chance) use a 5-point Likert scale
from 1 (strongly disagree) to 5 (strongly agree). High score on the subscale indicates belief the
specific causal factor caused the illness. Lower score on the subscale indicates there is no belief
the specific causal factor caused the illness. For example, high score on the psychological
attribute subscale indicates the belief that negative personality caused the illness.
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Thirteen items, IP1, IP4, IP8, IP15, IP17, IP18, IP19, IP23, IP24, IP25, IP26, IP27, and
IP36, are reversed-coded before tabulating the score. Eight aspects of illness perception were
assessed. Table 10 lists the alpha coefficient and mean subscale scores. Table 11 lists subscale
mean scores compared to normative mean scores obtained from women of the same age group
with CAD or diabetes (Alsen et al., 2010; Calvin et al., 2009 ; Fennessy, Devon, Ryan, Lopez &
Zerwic, 2011). Alsen et al. (2010) examined illness perception in women with a mean age of 64
years (n = 58) four months post MI. Fennessy at al. (2011) examined illness perception in men
and women with a mean age of 67 years (n = 51) with CAD either 30 days post PTCA or optimal
medical therapy. Calvin et al. (2009) studied illness perception in women with a mean age of 53
(n = 143) with chronic type 2 diabetes for approximately 2 years. These comparisons were made
to obtain a rough estimation on how the women in the study with CVD perceived their illness in
relation to other women with CAD or chronic illness. The women reported higher scores than
other women with CAD, MI or diabetes on timeline dimension (acute/chronic) and illness
coherence indicating they perceived their illness to be more chronic and had a greater
understanding of their illness compared with these groups. These findings may be due to the
women in the sample had a longer duration of CVD compared to the women in the comparison
studies. Otherwise, the reported subscale scores were similar to women of the same age group.
The IPQ-R instrument had acceptable reliability among this population, with the
exception of the treatment control subscale and causal subscales. Borderline reliability was
found with the treatment control subscale ( = 0.65). Low reliability in the treatment subscale
( = .60, .56, .50) has been found in other comparable studies (Byrne et al., 2005; Calvin et al.,
2009; Fennessy et al., 2011). The low reliability findings in the treatment control subscale may
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lead to the possibility that additional items or improvement in measurements may be needed for
the IPQ-R questionnaire. In addition, borderline reliability was found with the IPQ-R causal
subscales risk factors ( = .57), immunity ( = .60), and accident/chance ( = .59). The causal
subscale psychological attributes was the only causal subscale with acceptable reliability ( =
.85). The low reliability findings in the causal subscales may be due to the low number of items
in each subscale. The number of items on each subscale ranged from 2 - 7 items (psychological
attributes (6 items), risk factors (7 items), immunity (3 items), and accident/chance (2 items).
The women attributed a low number of symptoms to CVD (identity) (mean = 3.78, SD
3.79). Table 12 identifies the most frequently reported symptoms experienced and symptoms
believed to be related to CVD. There was a wide distribution of reported symptoms. Some
reported no symptoms and others reported sixteen symptoms. The most common symptoms
reported were fatigue, pain, sleep difficulties, stiff joints, and shortness of breath. It was an
expected finding that the women associated fatigue, pain, and shortness of breath symptoms with
CVD, as well as, the symptoms stiff joints were not related to CVD. Although, a concern is that
they did not perceive sleep difficulties were related to CVD. Sleep difficulties may indicate
heart disease, including cardiac arrhythmias, myocardial ischemia, and sleep apnea.
The women’s illness perception subscale mean scores indicate they believed CVD would
be more chronic (timeline acute/chronic) (mean = 24.26, SD 4.79), CVD symptoms would occur
often (timeline cyclical) (mean = 10.25, SD 3.28), CVD would have negative consequences
(consequences) (mean = 19.55, SD 4.77), and CVD caused emotional distress (emotional
representation) (mean = 15.79, SD 5.30). Despite negative illness perceptions of the duration
(timeline acute/chronic), chronicity (timeline cyclical), negative consequences (consequences),

94

and emotional distress (emotional representation), the sample women believed they could control
CVD (personal control) (mean = 24.86, SD 3.45), CVD could be treated (treatment control)
(mean = 18.52, SD 2.98), and understood CVD (illness coherence) (mean = 20.04, SD 3.92).
The women identified CVD risk factors and psychological attributes (causal subscale) as
the top causes for their CVD. Table 13 displays the most frequent reported causes for CVD.
The CVD risk factors the women most frequently reported were hereditary (mean = 4.07, SD
1.22), diet or eating habits (mean = 3.77, SD 1.06), my own behavior (mean = 3.56, SD 1.08),
and ageing (3.38, SD 1.13). The psychological attributes most frequently reported were stress or
worry (mean = 3.56, SD 1.27) and family problems or worries (mean = 3.02, SD 1.24). In
summary, the women had a strong perception that hereditary, ageing, health related behaviors,
and psychological attributes caused their CVD. In their review of the literature, Al-Samadi et al.
(2016) found that most women report hereditary and psychological attributes, not health related
behaviors, as causes for their CVD. Whereas, men most frequently report health related
behaviors as the cause for CVD.
Table 10. Illness Perception Questionnaire-Revised Subscale Mean Scores

# of Alpha Range of
Items Coeff. Scores
Subscales
Identity
Timeline (Acute/Chronic)
Timeline Cyclical
Consequences
Personal Control
Treatment Control
Illness Coherence
Emotional Representation

20
6
4
6
6
5
5
6

.85
.87
.80
.73
.79
.65
.85
.89

0 – 20
6 – 30
4 – 20
6 – 30
6 – 30
5 – 25
5 – 25
6 – 30

Mean Score
(SD)
3.78 (3.79)
24.26 (4.79)
10.25 (3.28)
19.55 (4.77)
24.86 (3.45)
18.52 (2.98)
20.04 (3.92)
15.79 (5.30)

95

Table 11. IPQR Subscale Mean Scores (SD) Compared With Reference Women Populations
IPQR Subscales
Timeline
(acute/chronic)
Timeline Cyclical
Consequences
Personal Control
Treatment Control
Illness Coherence
Emotional
Representation

Study Sample
(N = 81)
24.26 (4.79)

Stable CADa
MIb
(N = 51)
(N = 58)
18.2 (3.2)
19.30 (4.66)

Type 2 Diabetesc
(N = 143)
17.03 (5.21)

10.25 (3.28)
19.55 (4.77)
24.86 (3.45)
18.52 (2.98)
20.04 (3.92)

6.9 (3.2)
12.7 (2.1)
18.1 (3.6)
21.9 (.83)
17.4 (5.2)

11.93 (2.78)
18.38 (4.60)
20.53 (4.00)
17.88 (2.84)
17.42 (3.74)

11.7 (2.97)
20.36 (3.57)
25.42 (2.35)
20.36 (1.70)
15.96 (4.15)

15.79 (5.30)

10.6 (1.8)

16.73 (4.40)

16.88 (3.93)

Note. CAD = coronary artery disease; MI = myocardial infarction. a Published means by Fennessy et al. (2011); b
Published means by Alsen et al. (2010); c Published means by Calvin et al. (2009).

Table 12. IPQR Identity Subscale Frequency Scores
______________________________________________________________________________
Symptom Experienced
Symptom Related to CVD
(n = 81)
Fatigue
71.6%
63.8%
Pain
64.2%
44.2%
Sleep Difficulties
59.3%
29.2%
Stiff Joints
58%
10.6%
Shortness of Breath
53.1%
79.1%
Table 13. IPQR Causal Subscale Mean Scores
Causes for CVD
n = 81
Hereditary
Diet or Eating Habits
My Own Behavior
Stress or Worry
Ageing
Family Problems or Worries

Mean (SD)
4.07 (1.22)
3.77 (1.06)
3.56 (1.08)
3.56 (1.27)
3.38 (1.13)
3.02 (1.24)
Quality of Life

QoL was measured using the QLI Cardiac-IV instrument that includes a total score and
four subscales (health and functioning, social and economic, psychological/spiritual, and family).
The QLI Cardiac-IV uses a 6-point Likert scale from 1 (very dissatisfied) to 6 (very satisfied).
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The higher the score the greater perceived QoL. The mean score for the QLI total and for each
four subscales were based on the possible range of scores from 0-30. A review of the mean
scores for the women gives a sense of the overall status of QoL with a score less than 19
indicating poorer QoL (Personal Communication from Dr. C. Ferrans on October 16, 2018).
Table 14 lists the mean scores and number scoring less than 19 for the total and subscales, as
well as normative mean scores. The normative mean scores were obtained from women without
CAD of the same age group (30-75 years; mean age 57.7) (Savoy & Penckofer, 2015). The QLI
total mean score of 23.74 indicates that on average the sample perceived above average
satisfaction with QoL. On the Likert scale the sample scored in the “slightly to moderately
satisfied” range. An overall greater satisfaction with QoL is reflected by the low number of
women with a total score of less than 19 (n = 12). The highest scoring subscale was social and
economic (mean = 24.58) with 12.3% scoring less than 19. This score indicates that on average,
the women were “moderately to very satisfied” with their social and economic status. The
psychological/spiritual growth subscale (mean = 24.19) had 17.3% women scoring less than 19.
This score indicates that on average, the women were “moderately satisfied” with their personal
self and spirituality. The family subscale (mean = 24.13) was not the highest mean score,
although had the least women (9.9%) scoring less than 19. This score indicates that on average,
the women were “moderately satisfied” with their family life. The women scored the lowest on
the health and functioning subscale (mean = 23.01), with 21% of the women scored less than 19.
This score indicates that on average the women were “slightly to moderately satisfied” with their
health and functional status. Some of the items in the function domain included ability to
independently care for oneself, perform everyday activities, take care of family responsibilities.
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Other studies with women with or without heart disease of the same age group found similar
scores for the overall QLI and health functioning, social economic, psychological/spiritual and
family subscales (Carroll & Hamilton, 2005; Savoy & Penckofer, 2015). The QLI Cardiac IV
instrument alpha coefficient was .90 confirming strong reliability of the instrument with the
study sample. Overall, the women scored favorable satisfaction with the various aspects of
quality of life.
Table 14. Quality Life Index Cardiac-IV (QLI) and Subscale Scores and Normative Mean Score
______________________________________________________________________________
Mean Score
(SD)
QLI Cardiac IV Total Score 23.74 (4.64)

Median
(Range)
24.75 (5-30)

Number Scoring
Normative
Less Than 19 (%) Mean Score (SD)
12 (14.8%)
22.4 (4)

Subscales
Health and Functioning
Social and Economic
Psychological/Spiritual
Family

23.01 (4.98)
24.58 (4.94)
24.19 (5.25)
24.13 (5.55)

23.60 (3-30)
25.71 (7-30)
25.72 (8-30)
25.20 (4-30)

17 (21%)
10 (12.3%)
14 (17.3%)
8 (9.9%)

21.5 (4.6)
22.7 (4.5)
23.2 (4.9)
23.0 (5.3)

Note. Normative mean scores were obtained from women aged between 30-75 years (mean 57.7 years) (Savoy &
Penckofer, 2015).

Characteristics of the Environment
Social support was examined because it is an environment factor that may impact the
QoL in women with heart disease.
Social Support
The MOS-SS was used to measure perceived social support. The MOS-SS uses a 5-point
Likert scale of 1 (none of the time), 2 (little of the time), 3 (some of the time), 4 (most of the
time), and 5 (all of the time). The higher the score the greater perceived social support. Social
support was evaluated because the literature identifies this variable as a potential covariate
biasing the accuracy of self-report depression surveys. Lett et al., (2005) studied individuals
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with heart disease and found an association between low social support and the development of
depression or worsening depression. Whereas, high levels of social support predicted low
depressive symptoms (Frasure-Smith et al., 2000). The MOS-SS item #1 (number of close
friends/relatives) measures structural support and is omitted when scoring the instrument. Table
15 lists the mean scores for the total and subscales, as well as, the normative mean scores. The
normative mean scores were obtained from patients with chronic disease (HTN, CHD, diabetes,
depression) with a mean age of 55 years (Sherbourne & Stewart, 1991). It is important to note
that the study sample from where the normative scores were obtained included men (39%) and
women with a lower mean age (mean age = 55 years) than the women (mean age = 65 years) in
this study. This same study results found that men and older age (> 45 years) perceived greater
social support compared to women and younger age (Sherbourne & Stewart, 1991). The mean
score for the total, each four subscales, and one additional item were determined using a formula
that transforms the scale scores to a 0 – 100 scale (Social Support Survey Instrument Scoring
Instructions, Rand.org). The MOS-SS total mean score of 83.98 indicated that 87% of the study
sample perceived above average social support. On the Likert scale the study sample scored in
the “most of the time” range for having social support. The highest scoring subscale was
affectionate (mean = 90.02). This score indicates on average the women felt expression of love
and affection, scoring between “most of the time” and “all of the time” range for affectionate
support. The women scored above average in all of the subscales, emotional/informational
(mean = 82.90), tangible (mean = 81.10), positive social interaction (mean = 85.80), and the one
additional item (mean = 80.50). The one additional item was “having someone to do things
with”. The scores on these subscales indicates the women perceived having social support “most
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of the time” using the Likert scale. The women in the study perceived greater social support
compared to normative scores from other individuals with heart disease. Overall, the women
perceived having a strong social support network that may bias their self-report perceived
depression score indicating lower depressive symptoms. The MOS-SS had an alpha coefficient
of .96 confirming strong reliability of the instrument.
Table 15. Medical Outcomes Survey-Social Support (MOS-SS) and Subscale Scores
______________________________________________________________________________
# of Range of
Items Scores

Mean Score (SD)

Normative
Mean Score (SD)

MOS-SS Total Score
Subscales

19

19 - 95

83.98 (17.8)

70.1 (24.2)

Emotional/Informational
Tangible
Affectionate
Positive Social Interaction

8
4
3
3

8 - 40
4 - 20
3 – 15
3 – 15

82.90 (19.5)
81.10 (24.0)
90.02 (17.4)
85.80 (18.9)

69.6 (25.5)
69.8 (28.5)
73.7 (28.3)
69.8 (26)

Note. Range of Scores is possible lowest and highest score. Normative mean scores were obtained from patients
with a chronic disease (HTN, CHD, diabetes, depression) (Sherbourne & Stewart, 1991).

Data Analysis of Study Aims
Aim 1: To determine the relationship of symptoms (depression, anxiety) to functional
status (health promoting behaviors), health perceptions (illness perception), and QoL.
Hypothesis: Negative mood symptoms (depression or anxiety) will be associated with
fewer health-promoting behaviors, less perception of risk (illness), and poorer QOL.
The primary study aim was to examine whether there was a relationship between
depression/anxiety symptoms, health promoting behaviors, illness perception and QoL.
Pearson’s correlations were performed to assess the correlation between the variables. Table 16
lists the correlations between depressive symptoms, anxiety symptoms, health promoting
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behaviors, QoL, social support and functional comorbidities. There were statistically significant
correlations between depressive symptoms, anxiety symptoms, health promoting behaviors,
QoL, social support and functional comorbidities. More depressive symptoms were associated
with greater anxiety symptoms (r = .689, p < .01), less health promoting behaviors (r = -.366, p <
.01), poorer QoL (r = -.673, p < .01), less social support (r = -.380, p < .01), and greater
functional comorbidities (r = .431, p < .01). Anxiety symptoms demonstrated similar results.
More anxiety symptoms were associated with less health promoting behaviors (r = -.328, p <
.01), poorer QoL (r = -.687, p < .01), less social support (r = -.431, p < .01), and greater
functional comorbidities (r = .345, p <. 01). Better QoL was significantly associated with more
health promoting behaviors (r = .535, p < .01), greater social support (r = .490, p < .01) and less
functional comorbidities (r = -.471, p < .01). In summary, women with more depressive and/or
anxiety symptoms performed less health promoting behaviors, and had poorer QoL, less social
support, and greater functional comorbidities.
Table 16. Depression/Anxiety Correlations to Key Study Variables

PHQ-8
GAD-7
HPLP-II
QoL
MOS-SS
FCI

PHQ-8

GAD-7

HPLP-II

QoL

MOS-SS

--.698**
-.366**
-.673**
-.380**
.431**

---.328**
-.687**
-.431**
.345**

--.535**
.366**
-.172

--.490**
---.471** -.179

FCI

---

Note. PHQ-8 = depressive symptoms, GAD-7 = anxiety symptoms, HPLP = health promoting lifestyle profile, QoL
= quality of life, MOS-SS = social support, FCI = functional comorbidities, ** statistically significant at p < .01.

Examining the relationship between illness perception subscales and depressive
symptoms, anxiety symptoms, health promoting behaviors and QoL provided knowledge on
whether the individual had a positive or negative perception of their illness, as well as, the
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specific illness perception domain(s) that attributed to the negative/positive perception. There
were statistically significant correlations between certain domains of illness perception and
depressive symptoms, anxiety symptoms, health promoting behaviors and QoL. Table 17 lists
illness perception subscale correlations to depression, anxiety, health promoting behaviors, and
QoL. More depressive symptoms were significantly associated with the belief that CVD
attributed to a greater number of symptoms (r = .274, p < .05), difficulty understanding CVD (r =
-.340, p < .01), and CVD caused more distress (r = .431, p < .01). Similar to depressive
symptoms, more anxiety symptoms were significantly associated with CVD attributing a greater
number of symptoms (r = .246, p < .05), difficulty understanding CVD (r = -.332, p < .01), and
CVD caused more distress (r = .522, p < .01). These results indicate that women with more
depressive and/or anxiety symptoms were associated with a negative perception of their CVD.
Better QoL was significantly associated with lower number of symptoms attributed to CVD (r =
-.318, p < .01), CVD had less negative consequences (r = -.266, p < .05), better understanding of
CVD (r = .424, p < .01), and CVD did not cause distress (r = -.497, p < .01). Individuals with a
more positive perception of their illness were associated with better QoL. Better health
promoting behaviors were significantly associated with beliefs that CVD could be personally
controlled (r = .296, p < .01) and better understanding of CVD (r = .283, p < .05). In summary,
women who perceived CVD attributed to less symptoms, CVD had few negative consequences,
CVD could be personally controlled, and had a better understanding of CVD performed more
health promoting behaviors and had greater QoL. Unfortunately, women with greater depressive
and/or anxiety symptoms believed their heart disease attributed to more symptoms, had difficulty
understanding CVD, and CVD caused more distress and therefore performed less health
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promoting behaviors and had poorer QoL.
Table 17. Illness Perception Correlations to Depression, Anxiety, HPLP-II, and QoL
Illness Perception
Subscales
Identity
Timeline Acute-Chronic
Timeline Cyclical
Consequences
Personal Control
Treatment Control
Illness Coherence
Emotional Representation

Depression

Anxiety

HPLP-II

QoL

.274*
.013
.067
.178
-.111
-.022
-.340**
.431**

.246*
-.061
.156
.104
-.176
-.050
-.322**
.522**

-.019
.052
-.052
-.092
.296**
.195
.283*
-.171

-.318**
-.012
-.175
-.266*
.192
.115
.424**
-.497**

Note. * statistically significant at p < .05, ** statistically significant at p < .01.

Stepwise multiple regression method was used to determine the variables that predict
QoL. This method was used to identify the best model fit and because there were several
variables with a sample size of 81. Regression coefficients and standard errors can be found in
Table 18. Anxiety symptoms explained 46.5% of the variance in QoL, F(1, 79) = 70.468, p <
.001. Anxiety symptoms, health promoting behaviors, functional comorbidity, IPQR emotional
representation, and social support R2 for the overall model was 68.1% with an adjusted R2 of
66.0%, a large size effect according to Cohen (1988). Anxiety symptoms ( = -.324 (SE = .120,
t = -3.69, p < .001), health promoting behaviors ( = .292 (SE = .014, t = 4.08, p < .001),
functional comorbidities ( = -.257 (SE = .119, t = -3.68, p < .001), illness perception CVD
caused distress ( = -.215 (SE = .067, t = -2.80, p < .01) and social support ( = .152 (SE = .026,
t = 2.03, p < .05) were significant predictors of QoL. Greater anxiety symptoms, greater
functional comorbidities, and the belief that CVD caused distress predicted poorer QoL. Greater
health promoting behaviors and greater social support predicted greater QoL. Although
depressive symptoms were not a significant predictor of QoL, there was a trend ( = -.178 (t = -
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1.85, p = .069) toward poorer QoL. An important finding is that anxiety symptoms ( = -.324)
were a greater predictor of poorer QoL than depressive symptoms ( = -.178) in this sample of
women. The assumptions of regression were met. There was no evidence of multicollinearity, as
assessed by the variance inflation factor (VIF) less than 5, tolerance values greater than 0.1, and
no variables had high variance proportions for the eigenvalue.
Table 18. Multiple Regression with QoL as the Outcome
Variable
Intercept
Depression
Anxiety
Health Promoting Behaviors
Social Support
Functional Comorbidities
Illness Perception CVD
Symptoms
Illness Perception
Understanding CVD
Illness Perception Distress

b
17.263
-.444
.058
.052
-.440

-.188

SEB
2.93
.120
.014
.026
.119

.067



t

p

-.178
-.324***
.292***
.152*
-.257***

-1.85
-.369
4.078
2.03
-3.68

.069
.000
.000
.046
.000

-.129

-1.86

.067

.076
-.215**

1.03
-2.80

.306
.006

Note. aAnxiety, Health Promoting Behaviors, Functional Comorbidities, Illness Perception Distress, Social Support;
R2 = .681; adjusted R2 = .660; F(5,75) = 32.077; p < .001. b = unstandardized regression coefficient; SEB = Standard
error of the coefficient;  = standard coefficient. * p < .05; ** p < .01; *** p < .001.

In summary, anxiety symptoms were a stronger predictor of poorer QoL than depressive
symptoms. Depressive symptoms were trending toward predicting poorer QoL. Greater health
promoting behaviors and social support predict greater QoL. Greater functional comorbidities
and the belief CVD caused more distress predicted poorer QoL. Other studies found a prediction
between depressive/anxiety symptoms and health promoting behaviors (Huffman et al., 2013;
Bauer et al., 2012) and negative illness perception (Hermele et al., 2007; Le Grande et al., 2012).
Aim 2: To determine whether age is a factor contributing to negative mood symptoms,
functional status, health perceptions, and QoL after controlling for social support.
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Hypothesis: Women who are younger will have more negative symptoms, fewer healthpromoting behaviors, less perception of risk (illness), and lower QoL than women who are older
(≥ 65 years) after controlling for social support.
The second study aim was to determine whether age is a factor contributing to negative
mood symptoms, functional status, health perceptions, and QoL after controlling for social
support. There is evidence to support that social support is associated with negative mood
symptoms, healthy behaviors, illness perception, and QoL. Poor social support is associated with
greater depressive and anxiety symptoms, poorer healthy behaviors, greater perception of being
ill, and poorer QoL. Age was categorized into two separate groups with group one being younger
women (< 65 years) and group two being older women (≥ 65 years). There were thirty-six
individuals in the younger age group and forty-four individuals in the older age group.
The independent t-test was run to determine whether there was a difference between the
age groups among age, CVD duration, CVD related symptoms, social support, and functional
comorbidities (Table 19). The two-tailed statistical test was selected because there was no strong
theoretical basis for a directional hypothesis. The level of significance was set at an  of .05. The
assumptions for the independent t-test were met by the use of continuous dependent variables,
the variances in the populations being roughly equal and the scores are independent coming from
different people. The standard error means were low for all five dependent variables indicating
the group means value was an accurate estimate of the group mean (Table 19).
The t-test group statistics concluded there were slightly less number of individuals in the
younger group (n = 36) compared to the older group (n = 45). The mean age for the younger group
was 58.14 years and the mean age for the older group was 71.4 years. The duration for CVD in
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weeks was less in the younger group (M = 332.67, SE = 70.56) compared to the older women
group (M = 501.64, SE = 69.03) which was an expected finding. Less social support was found in
younger women (M = 79.19, SE = 2.45) than older women (M = 85.73, SE = 1.78), a statistically
significant difference, M = -6.54, 95% CI -12.58, -.497, t = (79) = -2.16, p < .05. The younger
group of women reported more symptoms were related to CVD (M = 4.52, SE = .675) than the
older group of women (M = 3.17, SE = .521). Although, this difference was not significant t(79) =
1.58, p > .05. Younger women had slightly less functional comorbidities (M = 4.63, SE = .480)
than the older women (M = 4.97, SE = .386). This difference was not significant t(79) = -.550, p >
.05. In summary, younger women had significantly less social support than older women. Although
younger women believe more symptoms were related to CVD, there was no significant difference
found between the younger and older women. An unexpected finding was the absence of a
significant difference between functional comorbidities between the younger and older women.
This may be due to the low number of functional comorbidities reported among the women.
Table 19. Independent t test Comparison of Variables Among Age Groups
______________________________________________________________________________
Variable
Age < 65
Age  65
t-statistic p value
95% CI
Mean (SE)
Mean (SE)
Age
58.14 (.785) 71.44 (.517
14.16
.000**
-15.11, -11.50
CAD duration
(weeks)

332.67(70.56) 501.64 (69.03) -1.71

.091

-365.5, -27.58

CVD related
Symptoms

4.52 (.676)

3.17 (.521)

1.58

.118

-.352, 3.05

Social Support 79.19 (2.45)

85.73 (1.78)

-2.16

.034*

-12.58, -.497

Functional
Comorbidities
4.63 (.480)
*p < .05, **p < .01

4.97 (.386)

.584

-1.57, .889

-.550

The independent t-test was also used to examine whether there was a difference between
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the age groups and specific health promoting behavior subscales (health responsibilities, physical
activity, nutrition, spiritual growth, interpersonal relations, and stress management). Younger
women had poorer nutrition, less interpersonal relations, less spiritual growth, and greater stress
compared to the older women (Table 20), although the differences were not statistically significant.
Table 20. Summary of Age Group Differences of HPLP-II Subscales
Variable

Age < 65
N = 36

Age  65
N = 45

23.55(.91)

23.53(.77)

18.72(1.11)

18.08(.93)

24.0(.77)

25.8(.67)

26.55(.94)

28.97(.68)

27.58(.82)

29.82(.58)

20.05(.84)

22.44(.61)

140.47(4.3)

148.68(3.03)

HPLP Health Responsibility
Mean (SE)
HPLP Physical Activity
Mean (SE)
HPLP Nutrition
Mean (SE)
HPLP Spiritual Growth
Mean (SE)
HPLP Interpersonal Relations
Mean (SE)
HPLP Stress Management
Mean (SE)
HPLP Total
Mean (SE)

ANCOVA was used to examine the statistical significance of among age groups and the
key variables while controlling for social support (Table 21). Previous studies identified that
social support influences mood, health promoting behaviors, and quality of life (Lett et al., 2005;
Stanuite et al., 2013).
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While controlling for social support, QoL was found to be significantly greater in older
women compared to younger women, F (1,78) = 5.82, p < .05. Anxiety symptoms (F(1,78) =
3.41, p = .068) and the belief that CVD causes distress (F(1,78) = 3.86, p = .053) are trending
toward a significant difference between younger and older women. The findings indicate that
younger women have greater anxiety symptoms and the belief that CVD causes distress
compared to older women. Younger women as compared to older women reported more
depressive symptoms, fewer health promoting behaviors, and related more symptoms to CVD;
however, the difference was not statistically significant between groups.
Table 21. ANCOVA for Social Support
Age  65
Mean (SE)
3.75 (.541)

F

p value

PHQ-8

Age < 65
Mean (SE)
4.04 (.606)

.112

.728

Anxiety

GAD-7

3.46 (.513)

2.17 (.457)

3.41

.068

Health Promoting
Behaviors

HPLP-II

142.60 (3.69)

146.99 (3.28)

.765

.384

CVD Related
Symptoms

IPQR
Identity

4.45 (.639)

3.24 (.569)

1.93

.169

Understanding
CVD

IPQR
Coherence

19.62 (.645)

20.37 (.575)

.745

.391

CVD Causes
Distress

IPQR
ER

17.08 (.868)

14.76 (.773)

3.86

.053

QoL

QLI

22.52 (.669)

24.71 (.596)

5.82

.018*

Functional
Comorbidities
*p < .05

FCI

4.49 (.455)

5.10 (.406)

.968

.328

Variable

Instrument

Depression

108

In conclusion, the hypothesis that women who are younger will have more negative
symptoms, fewer health promoting behaviors, less perception of (risk) illness, and lower QoL
than older women was partially supported. Overall, younger women with CVD reported worse
outcomes than older women. The QoL in younger women was somewhat lower than older
women (p = .018) which has been reported in the literature (Beckie et al., 2015; Leung et al.,
2014). However, overall the women reported good QoL. There was a trend for younger women
to have greater anxiety symptoms and the belief that CVD caused more distress. These findings
were supported by other researchers examining women with CVD (Beckie et al., 2015;
LeGrande et al., 2014). Although depressive symptoms and health promoting behaviors were
not significantly different among age groups, women who were younger reported more
symptoms and engaged in fewer health promoting behaviors.
Studies have found that negative mood is more prevalent in younger women (< 55 years)
with CVD compared to younger men or older women and the use of antidepressants or antianxiety medications improved their mood and QoL (Mazza et at. 2010; Wang, Hoffman &
Blumenthal, 2011). Other studies have found the use of antidepressants in younger women with
chronic disease improved their depression, as well as, engaging in self-care behaviors (Lustman,
Williams, Sayak, Nix & Clouse, 2007). Younger women with CVD are more likely to have
negative mood, altered illness perception, less healthy behaviors, and poorer QoL compared to
older women. These findings support the importance to target the younger women to treatments,
such as antidepressants, education on CVD illness, and health promoting behaviors to increase
their overall QoL.

CHAPTER FIVE
DISCUSSION
Overview
This chapter provides a discussion of the study findings, implications for nursing, and
recommendations for future research. This study was important to conduct to gather more
information on women with CVD to improve their overall QoL. CVD is a widespread chronic
illness that is the leading cause of death for women (Xu, Murphy, Kochanek, & Bastian, 2016).
Overall, there is an underrepresentation of women with CVD in studies that examined negative
mood, healthy behaviors, illness perception, and QoL. There are even fewer studies that
explored whether the association between these variables are different among younger and older
age groups. Depressive and anxiety symptoms are common in women with CVD and associated
with an increased risk for cardiac events leading to greater morbidity and mortality rates
(Lichtman et al., 2014; Gan et al., 2014; Roest, Martin, de Jonge, & Denollet, 2010). Studies
found that increased cardiac events were associated with less health promoting behaviors
(Kronish et al., 2006; Lichtman et al., 2014). Also, there is limited knowledge on whether
depressive/anxiety symptoms influence illness perception, that may influence healthy behaviors
and QoL. In addition, women with CVD report poorer QoL compared to men with CVD or
women without CVD (Broddadottir et al., 2009; Ford et al., 2008). This study was important to
conduct because it contributed data that provided a better understanding of the effect of
depressive/anxiety symptoms on health promoting behaviors, illness perception, and overall QoL
109
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in women with CVD. In addition, this study provided significant data that identified there was a
difference in the relationship of these variables between younger and older women.
This cross-sectional study explored the relationships between mood symptoms, functional
status, health perceptions, and QoL in women with CVD. The modified Wilson and Cleary
Health-Related Quality of Life Model guided the exploration of the study variables. For this, the
characteristics of the individual were measured by age, race/ethnicity, marital status, education,
socioeconomic status, and employment. Biological function was measured by the Framingham
Recurrent Risk Model and the FCI tools. The PHQ-8 and GAD-7 measured mood symptoms.
The functional status of the women was measured using the HPLP-II. General health
perceptions were measured by the IPQ-R-Cardiac instrument. The QLI was used to measure
overall QoL. The characteristics of the environment was measured using the MOS-SS
instrument.
Overall findings identified that in a group of women with CVD, that depressive and/or
anxiety symptoms were associated with less health promoting behaviors, poorer QoL, less social
support, and more comorbid condition. The relationship between depressive and/or anxiety
symptoms and the illness perception subscales was examined to determine whether there were
specific illness perception domains that were influenced by negative mood. The study findings
identified that depressive and/or anxiety symptoms were associated with greater illness
symptoms, less understanding of the illness, and the illness caused distress. The significant
predictors of QoL were less anxiety (-.324, p <.001), better HPB (.292, p <.001), fewer
comorbidities (-.257, p <.001), less distress in risk perception (-.215, p <.05) and more social
support (.152, p <.05) which explained 66% of the variance in the model. There was a trend for
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depression as a predictor (-.178, p = .069). ANCOVA indicated that QoL was higher in older
women (p = .018) and there was a trend for younger women to have more anxiety (p = .068) and
emotional distress for risk perception (p = .053).
Overall, findings support the need to target assessment of anxiety in all women
presenting with CVD to enhance health behavior, reduce distress and improve QoL. Women
who are less than 65 years of age need to be strongly targeted to reduce anxiety which may
include education, psychological therapy and/or possible medications since they will be at
greater risk for future CVD events.
Characteristics of the Individual
The sample consisted of 81 women with a diagnosis of CVD for a duration from one
week to 40 years, with a mean duration of 8.19 years. Over half (52%) had a prior history of MI,
65% had a percutaneous coronary intervention (angioplasty/stent), a quarter (24%) previously
underwent CABG, and over a third (35%) reported prior history of chest pain. The women were
between 35 to 78 years old with a mean age was 65.5 ( 7.78), with forty-four individuals age 
65 years and thirty-six individuals age < 65 years. The age range was similar to other samples
studying depressive and/or anxiety symptoms in women with CVD (Broddadottir et al., 2009;
Mallik et al., 2006; Rutledge et al., 2012; Shah et al., 2014; Spitzer et al., 2006). The women
were predominately white (81.5%), married (51.9%), college degree (38.3%), retired (51.9%),
and yearly income > $55,000 (59.3%). The racial composition of the sample corresponds to the
surrounding area around the recruitment sites. There is an under-representation of Hispanic and
Asian women compared to the county’s ethnic composition. There were a handful of Hispanic
women who were not eligible to participate in the study because they were unable to read or
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speak the English language. Inclusion criteria for the study required the ability to read and speak
the English language.
Women have a longer life expectancy and develop heart disease at an older age resulting
in a higher prevalence of heart disease over sixty-five years of age (Mozaffarian, 2015). The
original age range for the study was 35 to 70 years. The upper age limit of 70 years was based
on the assumption that women in their 70s may have cognitive impairment. Although, after
spending three weeks at the recruitment sites and discussing with the cardiologists and advance
practice nurses the cognitive function of the female patients aged 70 -78 years, it was found that
the majority of women between the age of 70 to 78 years were cognitively intact. The upper age
limit of 78 years was determined to exclude those women who may have cognitive impairment
due to older age. A proposal modification was made that changed the inclusion criteria age
range to 35 to 78 years. There were a large number of women with coronary heart disease over
the age of 70 years at the recruitment sites who met the study inclusion criteria. Expanding the
upper age to 78 years allowed women of older age to be represented in the study which also
aided in the testing of hypothesis 2.
Biological Function
Overall, women had low functional comorbidity. The Functional Comorbidity Index
identifies chronic comorbidities that decrease one’s level of physical function. The study sample
mean score of 4.83 indicated low functional comorbidity, indicating the women would be able to
engage in physical activities. Being physically active, such as walking, swimming, dancing, or
stretching, decreases one’s risk for CV events. The most frequent chronic illness identified, with
the exception of heart disease, was obesity (46.9%), arthritis (46.9%), diabetes (37%) and upper
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gastrointestinal disorders (37%). From a physical functioning standpoint, the study sample
women reported similar physical function compared to individuals with a history of CABG that
were of approximate age (Parry et al., 2012). Obesity and arthritis are known factors that can
reduce the ability to engage in physical activities due to pain or increased fatigue. Depression is a
known comorbid condition in individuals with diabetes (Penckofer, Doyle, Byrn & Lustman,
2014). Diabetes was found to be present in 37% of the women therefore increasing the risk for
depressive symptoms. Heart disease is another chronic illness that is associated with depressive
and/or anxiety symptoms and was present in 100% of the women. This study sample
contradicted the norm because there were less depressive and/or anxiety symptoms in the women
compared to related studies (Mallik at al., 2006; Spitzer et al., 2006). Although, with this sample
having low chronic illnesses it is expected to find a lower level of depressive symptoms.
In terms of their risk for a secondary cardiac event, women in this study had a low
probability, less than 4%, for a secondary cardiac event in the next two years. This probability
was determined by the Framingham 2-year Recurrent Risk Model for Women with CHD. The
Framingham Risk tool measures the risk factors age, total cholesterol, HDL, diabetes, tobacco
use, and systolic blood pressure to determine the risk for a CVD event. The instrument uses the
cutoffs of  10% is low risk, 10-20% is intermediate risk, and  20% is high risk. The majority
of points for this sample of women was age, elevated cholesterol level, and diabetes. SBP and
no tobacco use were not risk factors in the sample. The majority of the women 75.3% (n = 61)
had a SBP  134 mmHg. The goal SBP is < 140 mmHg. There was a significant number of
former smokers 51% (n = 41) that may have contributed to their initial cardiac event, although
only 6.2% (n = 5) were current smokers. The limitations of the Framingham Risk Model are the
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lack of taking in consideration the race or ethnic diversity, diastolic blood pressure, stroke, LDLC level, and age limit of 74 years (Nayor & Ramachandran, 2016). These risk factors are
substantial to include to determine the overall risk for a CV event and are included in some
modified Cardiac Risk instruments.
Symptoms
The symptoms explored in this study were depression as well as anxiety. The moods
reported by the women were inconsistent with previous studies identifying depression and
anxiety as prevalent findings in women with heart disease (Lichtman et al., 2014; Batelaan et al.,
2016). A cut-off score of 10 on the PHQ-8 was used to indicate the presence of depressive
symptoms or depressive disorder. In this study sample 36% of the women were with depressive
symptoms, with 9% scoring  10, indicating a depressive disorder. Even though the women in
this study had a lower PHQ-8 score compared to other studies of women with heart disease,
depressive symptoms were present in the sample.
The findings for the presence of anxiety symptoms were similar to depressive symptoms.
A cut-off score of 10 on the GAD-7 was used to indicate the presence of a generalized anxiety
disorder. Anxiety symptoms were present in 28% of the women, with 3% scoring  10.
Although the women in this study had a lower GAD-7 score compared to other women in the
primary care or general population, anxiety symptoms were present. The lower level of negative
mood found in the current study may be due to the small sample size (n = 81), the greater
number of women  65 years old (n = 45; 56%), married or living with a partner (n = 43; 53%),
retired (n = 42; 52%), had an average yearly income that was > $55,000 (N = 48; 59%), evidence
of strong social support (87%), and the absence of heart failure (n = 81; 100%). Previous studies
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have found that negative mood is greater in women < 65 years old, living alone, unemployed, of
lower socioeconomic status, lack of social support, and with heart failure (Alhurani et al., 2015;
Broddadottir et al., 2009; Gan et al., 2014). Heart failure was an exclusion criterion for this
study. Several of the women were living alone and commented how grateful they were to have
close friends to confide in and attend social events. The demographic characteristics of the
women may have contributed to the overall findings of lower depression and anxiety levels.
Despite the small sample size and composition, differences were noted between younger women
(< 65 years) and older women ( 65 years) with younger women having greater anxiety
symptoms, but this difference was not statistically significant for depressive symptoms.
Functional Status
Health Promoting Lifestyle Behaviors were used to assess the dimensions of functional
status. The findings from this study indicated that women were above average in performing
health promotion behaviors. The highest areas of health promotion were interpersonal
relationships (81%) and spiritual growth (78%), followed by nutrition (69%), stress management
(66%), and health responsibility (64%). The lowest area of health promotion was physical
activity (56%). This means a large number of the women reported they did not exercise. The
highest areas of health promotion in this sample of women is similar to other studies examining
women with and without heart disease (Oliver-McNeil et al., 2002; Savoy & Penckofer, 2016;
Thanavaro, Thanavaro & Delicath, 2010). The lowest area of health promotion (physical
exercise) was also a consistent finding with other research studies. Lack of physical exercise has
been found to be a common barrier to health promotion in several other research studies on
women with or without heart disease. Unhealthy life-style behaviors have placed women at an
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increased risk for secondary CVD events. The unhealthy behaviors include high fat diet,
sedentary lifestyle, and stress. In this study, older women (> 65) compared to the younger
women, reported better health behaviors in nutrition, spiritual growth, interpersonal
relationships, and stress management. There was no difference between the age groups in terms
of physical activity and health responsibility.
The current sample had fewer negative moods that may contribute to the overall above
average performance of health promoting behaviors. Negative mood has been found to
contribute to the lack of health promoting behaviors in women (McKenzie & Skelly, 2010;
Mommersteeg et al., 2013). In addition, studies have found that low education, low income, and
poor social support were significant predictors for poor healthy behaviors (Mochari-Greenberger
et al., 2010). The women in this study had above high school education (67%), income >
$55,000 (59%), and strong social support (87%) that provides additional support for the greater
engagement in health promoting behaviors.
General Health Perceptions
Illness perception was measured to examine the women’s health perception and included
the following: the view of their cardiac disease as an illness and whether illness perception was
related to mood and/or health promoting behaviors. The IPQ-R consists of several subscales to
explore illness perception. The subscales include illness identity, control, chronicity, coherence,
consequences and cause. The study women reported a low number of symptoms related to their
heart disease. The most common symptoms reported and believed to be related to their heart
disease were fatigue, pain, and shortness of breath. Although sleep difficulty was a common
reported symptom, it is of concern that the women did not perceive this symptom to be related to
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heart disease. The study women perceived their illness to be controllable, chronic,
asymptomatic, understandable, and have negative consequences. The perceived cause for their
heart disease were risk factors, that included genetic/hereditary, unhealthy diet, own behavior,
and aging, as well as, psychological attributes (stress, worry). Illness control consists of both
personal control and treatment control. The higher scores on personal control and treatment
control indicated the women had more positive beliefs about being able to control their cardiac
illness. Studies have found a significant correlation between depressive and/or anxiety
symptoms and lower perceived illness control (Grace et al., 2005; Hermele et al., 2007; Juergens
et al., 2010; Stafford, Berk, & Jackson, 2009). This sample of women had low scores for
depressive and/or anxiety symptoms that may reflect their more positive beliefs of illness
control. Heart disease is a chronic illness therefore it would be expected for individuals with
heart disease to identify the illness as chronic. Also, identifying an illness as chronic may
influence women to engage in health promoting behaviors to stay healthy and prevent worsening
of their heart disease.
There was a high perception of illness coherence found in this study. Illness coherence is
understanding of heart disease. The women acknowledged that they understood their heart
disease. Although, it was found that women with greater depressive and anxiety symptoms had
less understanding of CVD. Other studies found a significant correlation between greater
depressive/anxiety symptoms and low illness coherence (Fennessy et al., 2011; Alsen et al.,
2010; Calvin et al., 2009). This study sample had lower depressive/anxiety symptoms that may
have contributed to greater understanding of their heart disease, therefore, greater health
promoting behaviors.
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The participants in this study believed their illness had negative consequences on their
life, that included seriousness of the disease, financial consequences, major consequences on
their life, and caused difficulties for others close to them. Several studies found a significant
correlation between negative mood and negative consequences of the illness (Aalto et al., 2006;
Cherrington et al., 2004; Grace et al., 2005). It may be possible that perceiving heart disease has
negative consequences may contribute to depressive or anxiety symptoms. Dickens et al (2008)
found negative perception of heart disease in MI patients was associated with new onset of
depressive symptoms. This may be a significant factor in women’s perception of chronic illness
and engagement in health promoting behaviors. In addition, individuals who perceive their
illness has negative consequences may view their illness as a life threat and take action to change
behaviors. Viewing one’s illness as a life threat may influence greater health promoting
behaviors to reduce the threat.
Overall, the participants viewed their heart disease as asymptomatic. This may be
because most women did not have structural damage to the heart muscle that would result in
greater symptoms, such as heart failure. As mentioned earlier, heart failure was an exclusion
criterion for the sample. In addition, although the women had a history of coronary artery
disease, there usually are no symptoms unless there is significant coronary artery blockage or
spasm. The lack of symptoms may be another factor for greater engagement in health promoting
behaviors. Many studies on heart disease patients with symptoms (fatigue, shortness of breath,
chest pain), such as heart failure patients, found symptoms were associated with less engagement
in healthy behaviors due to heart impairment, as well as, lack of motivation and time (Klompstra,
Jaarsma & Stromberg, 2018).
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The sample of women identified risk factors for heart disease to be the greatest cause of
their illness. Health promoting behaviors are known to reduce risk factors for heart disease.
Therefore, it is an expected finding that the participants had strong health promoting behaviors to
reduce their risk for a secondary event. The participants identified that tobacco was a cause for
their heart disease and stopped tobacco use after their first cardiac event. The fact that these
women identified that risk factors caused their heart disease and adopted healthy behaviors was a
significant finding for the prevention of chronic disease complications and greater QoL.
Quality of Life
The study participants had overall above average satisfaction with QoL. The high QoL
rating was similar to other studies obtained from women with or without heart disease of the
approximate same age (Savoy & Penckofer, 2015; Carroll & Hamilton, 2005). Although, it has
been identified in other studies that women with heart disease had lower QoL compared to
women without heart disease (Broddadottir et al., 2009; Ford et al., 2008). This study sample
women had overall strong social support, economic stability, low negative mood, positive
outlook, few comorbidities, and stable cardiac condition. These study sample characteristics
correspond to a perceived higher QoL.
Characteristics of the Environment
The sample of women had overall a very strong perception of social support with above
average levels for all four domains: emotional, tangible, affection, and positive social
interaction. This means that the women felt love and affection, had positive social interactions,
had someone to care for them, and someone to do things with. The strong perception of social
support may reduce negative mood and promote health behaviors, alleviate chronic illness
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perception, and improve overall QoL (Broddadottir et al., 2007; Greco et al., 2014; FrasureSmith et al., 2000; Leifheit-Limson et al., 2010; Lett et al., 2005; Pragodpol & Ryan, 2013; Ruo
et al., 2003). Therefore, the strong social support reported by the women in the current study
may have contributed to their lower negative mood, increased healthy behaviors, less illness
perception (less perception of being ill), and greater QoL. It is important to note that social
support was significantly stronger in older women (> 65) compared to younger women. The
older women also had less negative mood, greater health promoting behaviors, less negative
illness perceptions, and greater QoL. This will be discussed in more detail in the study Aim 2
discussion section.
Discussion of Study Aims
There were two study aims and two study hypotheses for this research study.
Aim 1: The relationship of mood symptoms to functional status (healthy promoting
behaviors), health perceptions (illness perception), and QoL.
Hypothesis: Negative mood symptoms (depression or anxiety) will be associated with
fewer health-promoting behaviors, less perception of risk (illness), and poorer QoL.
The first study aim was to determine the relationship between negative mood symptoms
(depression/anxiety), health promoting behaviors, illness perception, and QoL in women with
heart disease. The hypothesis was that negative mood symptoms would be associated with fewer
health promoting behaviors, less perception of illness, and poorer QoL. The hypothesis was
partially supported. The findings revealed significant inverse relationships between depressive
symptoms and health promoting behaviors (r = -.366, p < .001), QoL (r = -.673, p < .001), and
social support (r = -.380, p < .001). This means that greater depressive symptoms were
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associated with less health promoting behaviors, poorer QoL, and less social support. There was
a positive relationship between depressive symptoms and functional comorbidities (r = .431, p <
.001). This finding indicates that greater depressive symptoms were associated with more
functional comorbidities. The same findings were found with anxiety symptoms. There was a
significant relationship between anxiety and health promoting behaviors (r = -.328, p < .001),
QoL (r = -.687, p < .001), and social support (r = -.431, p < .001). Anxiety had a positive
relationship to functional comorbidities (r = .345, p < .001). Therefore, women with more
anxiety symptoms performed less health promoting behaviors, had poorer QoL, less social
support, and greater functional comorbidities. Women who performed more health promoting
behaviors reported better QoL. The study findings that women with CVD with greater negative
mood performed less health promoting behaviors and had poorer QoL is supported by other
researchers (Savoy & Penckofer, 2015; Reigel et al., 2017; Pragodpol & Ryan, 2013). Huffman
et al. (2013) conducted a literature review on the associations between depression and health
promoting behaviors in CVD patients. The summary of findings concluded that individuals with
greater depressive symptoms were less likely to engage in health promoting behaviors (Bauer et
al., 2012; Casey, Hughes, Waechter, Josephson, & Rosneck, 2008; May et al., 2010; McGrady,
McGinnis, Badenhop, Bentle, & Rajput, 2009; Whooley et al., 2008; Ziegelstein et al., 2000).
Although, some researchers (Bauer et al., 2012; Kuhl et al., 2009) found that greater anxiety
symptoms were associated with less health promoting behaviors, others (Herrmann et al., 2000)
have found anxiety symptoms increased health promoting behaviors. These findings may
indicate that there is a dose response of anxiety symptoms that predict healthy behaviors.
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The illness perception subscales were examined to determine whether depressive/anxiety
symptoms, health promoting behaviors, and QoL were related to an individual’s positive or
negative perception of their illness, as well as, identify the specific illness perception domain(s)
that attribute to the negative/positive perception. The study findings revealed women with more
depressive and/or anxiety symptoms perceived more symptoms were related to their heart
disease, had difficulty understanding CVD, and believed that CVD caused greater distress
(worry, fear, anger). In this study, depressive and/or anxiety symptoms were not related to the
perception that CVD was chronic, CVD caused negative consequences, or CVD was
uncontrollable. These results of depressive/anxiety symptoms and illness perception were
partially supported in the literature. Researchers examining depressive and/or anxiety symptoms
and illness perception in CVD individuals found that greater negative illness perception (more
symptoms are related to the illness, the illness is chronic, symptoms are unpredictable, the illness
causes negative consequences, and the illness causes distress) was associated with greater
depressive and/or anxiety symptoms (Broadbent et al., 2009; Hermele et al., 2007; Le Grande et
al., 2012; Savoy & Penckofer, 2015; Stafford et al., 2009).
Other researchers have found that depression was predicted by the perception that CVD
caused negative consequences (Stafford, Berk & Jackson, 2009), CVD was difficult to
understand (Hermele, Olivo, Namerow & Oz, 2007), and CVD could not be controlled (Dickens
et al., 2008). In addition, a greater negative perception of illness predicted negative mood and
increased complications in MI patients (Cherrington, 2014). Le Grande et al (2012) examined
illness perception in heart disease patients and found greater depressive symptoms was
associated with the belief that CVD was a chronic disease and could not be cured (controlled).

123

In addition, they reported that younger individuals believed their illness to be chronic, treatment
to be in-effective, CVD caused distress, with resulting greater depressive symptoms and lower
QoL (Le Grande et al., 2012; Grace et al., 2005). The results from this study examining the
relationship between illness perception domains and depressive and/or anxiety symptoms may
differ from other research findings because only women were enrolled in this study, whereas
other researchers enrolled both men and women with most of participants being men. In
addition, the study women reported low depressive and anxiety symptoms that may impact the
relationship to other variables.
Illness perceptions have been found to differ between men and women with CVD. A
meta-analysis conducted by Al-Smadi et al (2016) examined illness perception in individuals
with CVD and included gender differences in illness perception. The analysis found that women
had higher perception of illness (belief that they were ill), as well as, a greater negative
perception of CVD compared to men. Women perceived CVD contributed to more symptoms,
CVD was chronic, and CVD caused more distress. On the other hand, men perceived CVD can
be controlled, CVD caused more negative consequences, and CVD was understandable. The
findings from the meta-analysis supports that gender may contribute to this study results
differing from other studies in the literature that included both genders. Illness perceptions in
individuals with CVD have been found to change based on the individual’s duration of the
disease, as well as, the severity of the disease (Alsen et al., 2010; Broadbent et al., 2008). In this
study, the majority of the women had CVD for eight years without heart failure. Heart failure is
associated with an increase in severity of disease.
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Research studies on heart disease patients have found that one’s perception or beliefs
about their CVD can predict negative mood, health promoting behaviors, and QoL (Alsen et at.,
2010; Cherrington, 2014; Kunschitz et al., 2016). In addition, women with depressive and/or
anxiety symptoms had a greater negative illness perception compared to women without
depressive and/or anxiety symptoms (Broadbent et al., 2009; Hermele et al., 2007; Le Grande et
al., 2012; Stafford et al., 2009). Review of the literature has identified that illness perception
varies among women with CVD and has an impact on the occurrence of negative mood, health
promoting behaviors, and QoL (Alsen et al., 2010). In addition, younger age contributes to
greater negative illness perceptions (Beckie et al., 2015; Le Grande et al., 2012). Therefore, the
current study findings support that illness perception is an important area for further
investigation among younger women with CVD to improve overall QoL.
Stepwise linear regression examined whether depressive/anxiety symptoms, health
promoting behaviors, illness perception, social support and functional comorbidities predict
QoL. The significant predictors of QoL were less anxiety, better HPB, fewer comorbidities, less
distress in risk perception, and more social support which explained 66% of the variance in the
model. In addition, there was a trend for greater depressive symptoms to be a predictor for
worse QoL. Other studies have found that less depressive and/or anxiety symptoms were
significant predictors of better QoL (Savoy & Penckofer, 2015; Alsen et al., 2010; Broddadottir
et al., 2009; Stafford et al., 2007).
Aim 2. To Determine Whether Age is a Factor Contributing to Negative Mood
Symptoms, Functional Status, Health Perceptions, and QoL After Controlling for Social Support.
Hypothesis: Women who are younger will have more negative symptoms, fewer health
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promoting behaviors, less perception of (risk) illness, and lower QoL than women who are older
( 65 years), after controlling for social support.
The second study aim was to determine whether age is a factor contributing to negative
mood symptoms, functional status, health perceptions, and QoL while controlling for social
support. The hypothesis was women who are younger will have more negative symptoms, fewer
health promoting behaviors, less perception of illness, and lower QoL than women who are older
( 65 years). The younger and older age groups were almost evenly distributed with thirty-six
individuals in the younger age group and forty-four individuals in the older age group.
ANCOVA was used to compared the two groups while controlling for social support and the
findings indicated that QoL was higher in older women and there was a trend for younger
women to have more anxiety, and perceive that CVD caused emotional distress.
To support these findings, researchers have found that negative mood (depressive and/or
anxiety symptoms) is more prevalent in younger women (< 55 years) with or without CVD
compared to men or older women (Beckie, Fletcher, Groer, Kip & Ji, 2015; Broddadottir et al.,
2009; Fang et al., 2018; Huffman et al., 2013; Mazza et al., 2010; Mallik et al., 2006; Wang,
Hoffman & Blumenthal, 2011; Shah et al., 2014). Few studies were identified that reported the
age difference in women with CVD and anxiety symptoms. Beckie et al (2015) examined
women with CVD (n = 252) who were enrolled in cardiac rehabilitation, after acute coronary
syndrome or MI, and found anxiety and depressive symptoms to be greater in younger women (<
55 years) compared to older women. Young women reported significantly greater anxiety
symptoms (41.7, SD  14.1 vs. 33.3; SD  11.0) and depressive symptoms (24.5, SD 13.4 vs.
15.5, SD 9.9) compared to the older women (Beckie et al., 2015). Todaro et al (2007) examined
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anxiety symptoms in men and women with CVD and found anxiety symptoms greater in women
(58.8%) compared to men (25.5%), although age was not reported. Fang et al (2018) studied
anxiety symptoms in men and women with a MI and found anxiety symptoms were greater in
younger women and men, although there was no difference between genders.
The current study found greater depressive symptoms were reported by women < 65
years, although the finding was not statistically significant. Research studies have found
significantly greater depressive symptoms in younger women compared to older women with
CVD (Beckie et al., 2015; Shah et al., 2014). Shah et al (2014) studied whether depression was
associated with higher incident and greater adverse outcomes in men (n = 2136) and women (n =
1100) undergoing coronary angiogram for the evaluation of CVD. The study results found that
younger women age < 55 years had more depressive symptoms (27%), than women age 56-64
(18% depressive symptoms), or women  65 years (12% depressive symptoms) (Shah et al.,
2014). The small sample size of the current study may contribute to the lack of significant
findings in predicting greater depressive symptoms in younger women.
The sample of younger women perceived more symptoms related to their CVD, less
understanding of CVD, and CVD caused more distress. Although the difference between
younger and older women were not statistically significant, other researchers have found results
indicating issues with younger women. A review of the literature found two studies that reported
illness perception differences between younger and older individuals with heart disease. These
researchers identified that younger individuals with CVD reported greater negative illness
perceptions compared to older individuals (Beckie et al., 2015; Le Grande et al., 2012). Beckie
et al. (2015) found younger women (< 55 years) with CVD reported significantly worst health
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perceptions (perceived themselves to be more ill) compared to older women. Le Grande et al
(2012) found that younger individuals (mean age = 63) believed that CVD severely impacted
their life, would last their lifetime, treatment would be ineffective, caused severe distress, had
greater depressive symptoms, and poorer QoL. The older individuals (mean age = 69) believed
their disease to be chronic and treatment was ineffective, although they had fewer depressive
symptoms and greater QoL. Further investigation on examining the differences in illness
perception among younger and older age groups is needed to identify and implement illness
perception interventions that are specific to the individuals’ health needs. Individuals with
greater negative illness perceptions have been found to have greater depressive symptoms,
engage in less healthy behaviors, and have poorer QoL. The results of the current study support
the need to target the younger women with CVD and provide interventions to decrease their
negative illness perceptions. In addition, decreasing one’s negative perception of being ill may
minimize depressive and/or anxiety symptoms and promote greater QoL.
Younger women had somewhat lower QoL compared to older women in the current
study. There are several studies in the literature that support QoL is poorer in women with CVD
compared to women without CVD (Ford et al., 2008; Norris et al., 2010). In the literature, there
is limited research examining differences in QoL among age groups in women with CVD. The
few studies that did examine QoL in men and women with CVD found that younger patients (<
65 years) had poorer QoL compared to older patients ( 65 years), and women reported poorer
QoL compared to men (Beckie, Fletcher, Groer, Kip & Ji, 2015; Xiu, Wu, Zheng, Sullivan, Zhan
& Labarthe 2008; Leung et al., 2014). The lack of studies reporting women with CVD age group
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differences with negative mood, health promoting behaviors, illness perception, and QoL may be
due to the limited inclusion of older women in CVD studies (Mehta et al., 2016).
The current sample of younger women reporting poorer QoL compared to older women
may have been influenced by their perception of more symptoms related to CVD, less
understanding of CVD, CVD caused more distress, and greater negative mood symptoms,
although these differences were not statistically significant. In addition, poorer QoL in younger
women may be explained by the fact that CVD may have a stronger impact on patients in their
productive years than those who are retired. CVD may restrict younger individuals from
performing or pursuing their professional goals and social roles as opposed to older retired
individuals. This restriction may contribute to poorer QoL.
In the current study, health promoting behaviors were found to be less in younger women
(142.6, SE 3.68 vs. 146.9, SE 3.28) compared to older women, although the difference was not
found to be statistically significant. The findings that younger women perform less health
promoting behaviors is supported in the literature. There is evidence in the literature that
younger women perceived specific barriers to health promoting behaviors that included time
constraints, stress, depression, family obligations, and ambivalence to behavior change (Mosca et
al., 2013; Galbraith, Mehta, Veledar, Vaccarino & Wenger, 2011). In the current study, younger
women reported equal physical activity and health responsibilities (i.e. knowledge of heart
disease) compared to older women. Although, unhealthy diet, lower social support, less spiritual
growth, and greater stress was found in the younger women versus the older women. The study
findings, although not significant, were similar to findings in the literature examining healthy
behaviors in women with heart disease (Beckie et al., 2015; Mehta et al., 2016; Mosca et al.,
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2013). Mehta et al (2016) conducted a comprehensive review of the literature on
biopsychosocial mechanisms in women with a history of MI. In this review, findings support
that younger women performed less healthy behaviors that included poorer stress management,
less physical function, and less social support compared to men. Beckie et al (2015) found
greater stress, lower social support, greater anxiety symptoms, and lower enrollment or
sustainability in cardiac rehabilitation in younger women compared to older women.
Summary of Major Findings
The correlational analyses demonstrated that greater depressive and anxiety symptoms
were associated with fewer healthy behaviors, poorer QoL, less social support and more
functional comorbidities. Illness perception was also associated with healthy behaviors and
QoL. Women who perceived CVD attributed to less symptoms, CVD had few negative
consequences, CVD could be personally controlled, and CVD was understandable were
associated with more health promoting behaviors and greater QoL. In addition, the perception
that more symptoms are related CVD, CVD caused distress, and CVD was difficult to
understand were associated with greater depressive and/or anxiety symptoms.
In terms of regression analyses, the significant predictors of QoL were less anxiety, better
HPB, fewer comorbidities, less distress in risk perception, and more social support. Although
anxiety was a stronger predictor of poorer QoL than depressive symptoms, there was a trend for
depressive symptoms as a predictor. Greater health promoting behaviors and social support
predict greater QoL. Greater functional comorbidities and the belief CVD caused more distress
predicted poorer QoL.
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Younger women with CVD reported worse outcomes than older women. Younger
women had poorer QoL than older women and there was a trend for younger women to have
more anxiety and the belief that CVD caused more emotional distress. Although depressive
symptoms and health promoting behaviors were not significantly different among age groups,
women who were younger had greater depressive symptoms, fewer health promoting behaviors,
and less social support.
Limitations
The non-experimental design of the study affects the internal validity of the findings and
was perhaps the greatest limitation of this study. As a cross-sectional correlational design study,
no causal relationships can be established. However, the study did identify the relationship of
depressive and/or anxiety symptoms, health promoting behaviors, and illness perceptions to
overall quality of life, therefore, added knowledge to the health status of women with CVD.
Participation selection bias also occurred because a convenient nonrandom sample of women
was used. The sampling technique did not allow for an equal number of participants for the
younger and older age groups. Although the groups were almost equal, there were more older
women than younger women and the difference in age groups may have contributed to the
findings. Another threat to internal validity was instrumentation. The use of self-report
questionnaires relies on honest reporting and accurate self-assessment. It is impossible to know
if the study participants over or under-estimated negative mood, health promoting behaviors,
illness perception, social support, or QoL. In addition, testing was a concern due to the length of
time it took to complete the questionnaires. Response burden may have occurred because the
average length to complete the questionnaire was 45 minutes, although others took over an hour.
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Questionnaires that are long and time consuming may negatively impact the motivation and
effort to answer the items accurately. To address this potential limitation, the participants were
informed of the time required to complete the questionnaire prior to consenting to participate in
the study. There was minimal amount of missing data from the self-report questionnaires. In
order to reduce missing data, the questionnaires were reviewed after they were completed by the
participant to reduce this error. There was one item, annual income, on the demographic
questionnaire that was missing data from two participants, otherwise there was no other missing
data. Participants were recruited from two separate sites that may have also been a potential
threat to internal validity. However, the two site locations had similar demographics and
received treatment from the same cardiology group practitioners. They also had the same
practice standards and education material at both site locations, thus minimizing this threat.
Using a convenience sample, there is selection bias which is a threat to external validity
by reducing the generalizability to the general population. The majority of the participants
(75%) came from within 14 miles of the recruitment sites in the same county. The racial
composition of the county was 68.6% White, 13.9% Hispanic, 10.8% Asian, and 4.6% Black
(Census Bureau: America Community Survey, 2015). The racial composition of the study
participants were largely White (81.5%) and there was less minority representation (3.7%
Hispanic, 1.2% Asian, and 8.6% Black). Lack of enrollment of more Hispanic women may be
due to the study inclusion criteria to be able to read and speak the English language. Increase in
ethnic participation is a challenge in clinical research, however, this should be a consideration for
future researchers conducting this type of work. Overall, the study sample was not racially
diverse. Sample subjects were economically stable, well educated, had a high level of social
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support, and experienced few depressive/anxiety symptoms. Finally, study exclusion criteria
may have been a threat to external validity. The results of this study may not apply to women
with heart failure, previous cerebral vascular accident, end-stage renal disease, and non-English
speaking or reading women because these were identified exclusion criteria. This study’s
limitations should be noted when interpreting the study findings.
Nursing Implications
This study was conducted to gain more knowledge on the impact that depressive and/or
anxiety symptoms have on health promoting behaviors, illness perception, and QoL in women
with CVD. The findings from the study found that there was a trend for anxiety symptoms and a
negative perception of CVD illness to be greater in younger women. In addition, younger
women reported less social support compared to older women. This is an important finding
because social support is associated with greater QoL. A key finding from this study was that
negative mood was a barrier to illness perception by its relationship to perceiving more
symptoms were related to CVD, less understanding of CVD, and CVD caused more distress
(worry, fear, anger). Other researchers found that negative mood altered illness perception by its
association to perceiving CVD was chronic, CVD caused more negative consequences, and CVD
could not be controlled (Dickens et al., 2008; Le Grande et al., 2012; Stafford et al., 2009). The
findings from this study support the importance to initiate anxiety screening and continue
depression screening for early detective of negative mood. As well as, examine illness
perceptions of women with CVD. Once early detection of negative mood is established, the
appropriate strategies can be discussed with the patient and implemented by a nurse driven team
of health care professionals. The strategies should be tailored to the individual’s need, and may
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include medication, cognitive therapy, illness perception interventions, education on CVD,
healthy behavior interventions, and social support. Overall, these strategic interventions will be
to treat negative mood symptoms, promote healthy behaviors, address illness perceptions of
CVD, and promote social support in women with CVD, with the ultimate goal of greater QoL.
Most nurse practitioners focus on behavioral changes to health (e.g. medication
adherence, diet, physical activity), however, these may not be effective if there is not detection
and resolution of the emotional responses to the disease. Nurse practitioners have the
opportunity to establish evidence-based guidelines that address a more holistic approach to
address the biopsychosocial needs of women with negative mood using a collaborative care
model. Evidence-based collaborative care models have been developed for effective
improvement in the treatment of both depression and health care in patients with depression and
chronic disease, including CVD (Ludman et al., 2013; Katon et al., 2010; Rosenberg, Lin,
Peterson, Ludman, VonKorff, & Katon, 2013). The advanced practice nurse is the manager of
the collaborate care program who works jointly with the patient and primary care physician and
specialist physician(s) (cardiologists, psychiatrist, and psychologist) to improve depression,
medical disease control, and patient self-management. Since the development of a team care
approach to address depression and chronic disease, other research has shown the effectiveness
of the collaborative care model with other negative moods, including anxiety (Bickett & Tapp,
2016; Celano et al., 2016; Huffman et al., 2014). Researchers have found that collaborative care
programs for the delivery of care to individuals with negative mood and CVD are more effective
in improving negative mood, healthy behaviors, and QoL, as well as, cost effective and
associated with fewer hospitalizations (Celano et al., 2016; Katon et al., 2012). In addition to
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developing, implementing, and managing collaborative care models, the advanced practice nurse
must work with other health care professionals to develop methods for evaluating the
effectiveness of the program. This would include evaluating changes in negative mood, illness
perceptions, healthy behaviors, and QoL, as well as, the cost effectiveness of the program.
Overall, findings from this study support the need to identify early detection of negative
mood and implement interventions to promote engagement in healthy behaviors and improve
QoL. Collaborative care models, managed by advanced practice nurses, have been shown to be
more effective in improving negative mood, healthy behaviors, and QoL in patients with CVD.
Ultimately, advanced practice nurses have the opportunity to develop evidence-based practice
guidelines to develop and implement a collaborative care approach to improve women’s CVD
health and QoL. The overall benefit could potentially reduce CVD secondary events that
translate to cost savings to the health care system.
Also important for nurses to address when caring for women with CVD is that younger
women had trended toward greater anxiety symptoms and negative perceptions of their CVD
illness, but experienced a lower QoL compared to older women that was statistically significant.
Whether this has clinical significance may be of question. They also had more depressive
symptoms and poorer healthy behaviors than older women, but these findings were not
statistically significant. Of key importance, however, is that younger women with CVD have an
increased risk for poorer health outcomes or a secondary cardiac event (i.e. MI). Studies have
found that greater depressive and/or anxiety symptoms are found in younger women and the use
of anti-depressants or anti-anxiety medications have improved their mood, engagement in
healthy behaviors, and QoL (Berkman et al., 2003; Lustman, Williams, Sayak, Nix & Clouse,
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2007; Mavrides & Nemeroff, 2015; Mazza et al., 2010; Wang, Hoffman & Blumenthal, 2011).
In addition, cognitive behavior therapy and stress management have been found to improve
depressive and/or anxiety symptoms in CVD patients (Berkman et al., 2003; Dau et al., 2011;
Freedland et al., 2009; Mavrides & Nemeroff, 2015). In the literature, there has been discussion
on the safety and efficacy of selective serotonin uptake inhibitors (SSRI’s) to treat depression in
CVD patients. Mayrides & Nemeroff (2015) literature review on the treatment of depression in
CVD found fourteen clinical trials demonstrating the efficacy and safety of anti-depressant
medication and psychotherapy (cognitive behavioral therapy and interpersonal therapy) in heart
disease patients. Cognitive behavioral therapy focus on altering cognitions and behavioral
activations, whereas, interpersonal therapy focus on resolving interpersonal issues that are
characteristic of depression (Scherrer et al., 2011). These are important research findings to
support that health care providers need to target the younger women to treatments (antidepressants, anti-anxiety medication, illness perception interventions, healthy behavior
education, stress management, and cognitive behavioral therapy) because it appears the older
women have less risk for poorer health outcomes. Additional research examining whether there
are age group differences with negative mood, health promoting behaviors, illness perception,
and QoL in women with CVD may provide more knowledge on age groups to target for
treatment. As well as, research examining the effectiveness of the treatments/interventions for
health care outcomes, including QoL, in women with CVD.
Future Research
In 2008, the American Heart Association (AHA) advisory recommended screening for
depression and referral to treatment when depression is detected (Lichtman et al., 2008). The
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AHA advisory has not recommended routine screening of anxiety in CVD patients, although
anxiety symptoms are present in CVD patients and associated with increased mortality and CV
adverse events, as well as, reduced healthy behaviors, altered perception of being ill, and poorer
QoL (Frasure-Smith et al., 2008; Foxwell et al., 2013; Kuhl et al., 2009; Martens et al., 2010;
Roest et al., 2012). There are currently not enough randomized clinical trials demonstrating that
anxiety screening is safe, cost effective and is associated with clinical benefits, that include the
reduction of anxiety symptoms and improved clinical outcomes (Bunevicius et al., 2013).
Current research being conducted is the Understanding the Benefits of Exercise and
Escitalopram in Anxious Patients With Coronary Heart Disease (UNWIND) randomized clinical
trial that is examining the efficacy of treating anxiety in CVD patients for reducing symptoms
and improving clinical outcomes (Blumenthal et al., 2016). Although, over the past few years
there has been an increase number of research studies identifying an association between anxiety,
CVD, healthy behaviors and QoL, additional clinical trials are warranted to determine whether
routine anxiety screening and treatment will improve anxiety symptoms and QoL. In addition,
further research is needed examining both depressive and anxiety symptoms and the association
between healthy behaviors, illness perceptions, and QoL in women of younger and older age
groups with CVD. The current study identified differences among younger and older women,
with younger women trending toward more anxiety symptoms, greater negative perceptions of
being ill, and statistically significant poorer QoL. The results from this study identified that
health care providers need to target the younger women to strategic interventions to improve
mood, healthy behaviors, illness perception, and QoL.
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The American Heart Association (AHA) Council on Cardiovascular and Stroke Nursing
(CVSN) is charged to promote the AHA 2020 strategic goal of improving CV health and
reducing mortality (AHA, 2017). In 2018, the AHA Council on CVSN identified CV nursing
science priorities for future CVD research. Based on the results of the current study and the
AHA Council on CVSN recommendations for future research, it would be realistic to design a
longitudinal interventional study that evaluated the effectiveness of using collaborative care
models to implement evidence-based interventions (antidepressants, anti-anxiety medications,
cognitive behavioral therapy, illness perception interventions, healthy behavior education, stress
management) to address the biopsychosocial needs of women with CVD for improved QoL. The
evaluation would need to include consistent measurement of the current study key variables,
depressive and/or anxiety symptoms, healthy behaviors, illness perception, and QoL. Further
research is needed examining illness perception and whether it predicts healthy behaviors or
negative mood. It would be interesting to identify whether increased knowledge on CVD would
alter the individual’s illness perception and whether the change in illness perception would
reduce depressive and/or anxiety symptoms and increase healthy behaviors. Further research is
needed examining the effect that treatment/interventions have on the key variables and whether
this treatment predicts a change in the associations between these variables.
Another area for future research is to assess and validate existing instruments or develop
instruments that can be used to evaluate these key variables. Participant response burden from
lengthy questionnaires can be avoided by using short form instruments. This is important to
consider especially with longitudinal studies obtaining repeated measurements of the variables.
The current study used the PHQ-8 (8 items) to measure depressive symptoms, the GAD-7 (7

138

items) to measure anxiety symptoms, and the IPQR-cardiac (76 items) to measure illness
perceptions. Shorter versions of each of these instruments, PHQ-2 (2 items), GAD-2 (2 items),
and Brief IPQ (11 items), have been found to be reliable and valid tools and could be used to
prevent response burden. Ongoing assessment and validation of instruments may lead to the
development of new instruments that are shorter in length, reliable, and valid tools.
The findings of this study are important in considering future research that will determine
ways to minimize negative mood and improve QoL in women with CVD, especially younger
women. This study found that younger women trended toward greater anxiety symptoms and a
negative perception of CVD illness which may have contributed to their poorer QoL, although it
is not clear whether this is clinically significant. Future nursing research should focus on
discovering early detection of negative mood and treatments/interventions that will improve
mental health, healthy behaviors, illness perceptions and QoL in women with CVD. In addition,
it would be important to identify whether a positive alteration of these key variables is associated
with a reduction of secondary cardiac events.
Finally, while designing future research studies on women with CVD, there needs to be
an increased effort to obtain representation of vulnerable populations. Although there are limited
studies on women with CVD, there are even less studies that include non-white female
participants. Strategies to recruit more women of ethnicity/race needs to be a priority for future
studies. This is particularly important as there is evidence that women of Hispanic, Asian,
American Indian, Alaska Native ethnicity and African American women are underserved,
understudied and at greatest risk for CVD. Heart disease is the leading cause of death in African
American and Hispanic women and the second leading cause of death in Asian, American Indian
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and Alaska Native women (Benjamin et al., 2018). Cultural beliefs may vary among women of
different ethnicity/race. These cultural beliefs may have a strong influence on heathy behaviors
and illness perceptions that may increase the risk for CVD. Future research including women
from vulnerable populations will help identify the most effective interventions for decreasing
ethnic/racial disparities in preventing CVD and improving QoL.

APPENDIX A
INSTRUMENTS
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Demographic and Health History Information
Date:____________________ ID#: _____________ MRN#:_________________
Zip code: _________________
Please fill out the information below:
1. Age: _____________
2. History of Heart Disease (please circle all that you have)
o Heart attack
o Angioplasty
o Stent
o Coronary artery bypass surgery
o Chest pain symptoms from blocked arteries in your heart
3. How long have you had heart disease?__________________________________
4. Ethnicity/Race: (please circle one)
o African American
o Caucasian
o Hispanic
o Asian
o Pacific Islander
o American Indian
o Alaska Native:______________
o Other:__________________________
5. Marital Status (please circle one)
o Married
o Divorced
o Separated
o Single, and living with partner
o Single, and not living with partner
o Widowed
6. Education Status: (please circle the highest level of education)
o High school
o Associate degree
o Trade, vocational, technical
o College degree
o Graduate degree
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7. Household income: (please circle one)
o < $20,000
o $20,000 - $29,999
o $30,000 - $39,999
o $40,000 – $54,999
o $55,000 – $64,999
o $65,000 - $79,999
o $80,000 - $94,999
o > $95,000
8. Employment Status: (please circle one )
o Full time
o Part time
o Homemaker/Student
o Retired
o Unemployed
o Other____________________
9. Please list any prescribed medications you are currently taking:
_____________________

______________________

________________________

_____________________

______________________

________________________

_____________________

______________________

________________________

_____________________

______________________

________________________

_____________________

______________________

________________________

10. Over the counter medications (including vitamins and supplements):
_____________________

______________________

_________________________

_____________________

______________________

_________________________

_____________________

______________________

_________________________
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THE FUNCTIONAL COMORBIDITY INDEX
Have you ever been told by a doctor that you have any of the following? If yes, Circle YES. If no, Circle NO.

1

Arthritis (rheumatoid and osteoarthritis)

YES NO
YES NO

2

Osteoporosis

YES

NO

3

Asthma

YES

NO

4

Chronic Obstructive Pulmonary Disease (COPD), respiratory distress syndrome, or

YES

NO

emphysema
5

Angina

YES

NO

6

Congestive Heart Failure (or heart disease)

YES

NO

7

Heart Attack (Myocardial Infarct)

YES

NO

8

Neurological Disease (such as Multiple Sclerosis or Parkinson’s)

YES

NO

9

Stroke or TIA

YES

NO

10

Peripheral Vascular Disease

YES

NO

11

Diabetes Types I and II

YES

NO

12

Upper Gastrointestinal Disease (ulcer, hernia, reflux).

YES

NO

13

Depression

YES

NO

14

Anxiety or Panic Disorders

YES

NO

15

Visual Impairment (such as cataracts, glaucoma, macular degeneration)

YES

NO

16

Hearing Impairment (very hard of hearing, even with hearing aids)

YES

NO

17

Degenerative disc disease (back disease, spinal stenosis, or severe chronic back

YES

NO

pain)
18

Obesity and/or Body Mass Index >30 (weight in kg /( height in meters)2 )
height_____________________(cm or inches?)
weight_____________________(kg or lbs?)

BMI =

If the FCI is self-administered question 18 can be modified to read:
What is your current height___________ weight________________
And then BMI is calculated by the researchers. If BMI is greater then 30, 1 point is added for obesity.
Groll, D. L., To, T., Bombardier, C. & Wright, J. G. (2005). The development of a comorbidity index with physical function as
the outcome. Journal of Clinical Epidemiology, 58, 595-602.
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Functional Comorbidity Index (FCI)
Scoring Guidelines
The eighteen items are scored as a no or yes:

No

=0

Yes

=1

The scale score ranges from 0 – 18.
The score for FCI is obtained by calculating and adding each item to obtain a total score.
The higher the FCI score indicated greater comorbidity and is associated with greater impairment
in physical function.
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Patient Health Questionnaire-8 (PHQ-8)
Over the past few weeks, how often have you been bothered by any of the following? Place an “X” in the box to
indicate your answer.

Kroenke, K., Spitzer, R. L. & Williams, J. B. W. (2001). The PHQ-9: Validity of a Brief Depression Severity Measure. Journal
of General Internal Medicine, 16, 606-613.
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The items are scored as:

Patient Health Questionnaire-8 (PHQ-8)
Scoring Guidelines
Not at all
=0
Several days
=1
More than half the days
=2
Nearly every day
=3

The scale score ranges from 0 – 24
The score for depressive symptoms is obtained by calculating by adding each item score to
obtain a total score. A score of ≥ 10 is the cutoff score for the possible diagnosis of depressive
disorder and confirm by further evaluation.
Interpreting the Score:
Total Score
0-4
5-9
10-14
15-19
20-24

Level of Depression Severity
Minimal
Mild
Moderate
moderately severe
Severe

Kroenke, K., Spitzer, R. L. & Williams, J. B. W. (2001). The PHQ-9: Validity of a Brief Depression Severity Measure. Journal
of General Internal Medicine, 16, 606-613.
Kroenke, K., Strine, T. W., Spitzer, R. L., Williams, J. B. W., Berry, J. T. & Mokdad, A. H. (2009). The PHQ-8 as a measure of
current depression in the general population. Journal of Affective Disorders, 114, 163-173.
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Generalized Anxiety Disorder – 7 (GAD-7)

Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Lowe, B. (2006). A brief measure for assessing generalized
anxiety disorder: the GAD-7. Archives of Internal Medicine, 166(10), 1092-1097.
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Generalized Anxiety Disorder – 7 (GAD-7) Scale
Scoring Guidelines
The items are scored as:

Not at all
Several days
More than half the days
Nearly every day

=
=
=
=

0
1
2
3

The scale score ranges from 0 - 21
The score for GAD is obtained by calculating the adding each item score to obtain a total score.
A score ≥ 10 is the cutoff score for the possible diagnosis of GAD and confirm by further
evaluation.
Interpreting the Score:
Total Score
0-4
5-9
10-14
15-21

Level of Anxiety Severity
Minimal
Mild
Moderate
Severe

Spitzer, R. L., Kroenke, K., Williams, J. B. W. & Lowe, B. (2006). A brief measure for assessing generalized
anxiety disorder: GAD-7. Archives of Internal Medicine, 166, 1092-1097.
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Health Promoting Lifestyle Profile –II (HPLP-II)
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HEALTH-PROMOTING LIFESTYLE PROFILE II
Scoring Instructions

Items are scored as:

Never (N)
Sometimes (S)
Often (O)
Routinely (R)

=
=
=
=

1
2
3
4

A score for overall health-promoting lifestyle is obtained by calculating a mean of the
individual's responses to all 52 items; six subscale scores are obtained similarly by calculating a
mean of the responses to subscale items. The use of means rather than sums of scale items is
recommended to retain the 1 to 4 metric of item responses and to allow meaningful
comparisons of scores across subscales.
The items included on each scale are as follows:
Health-Promoting Lifestyle 1 to 52
Health Responsibility 3, 9, 15, 21, 27, 33, 39, 45, 51
Physical Activity 4, 10, 16, 22, 28, 34, 40, 46
Nutrition 2, 8, 14, 20, 26, 32, 38, 44, 50
Spiritual Growth 6, 12, 18, 24, 30, 36, 42, 48, 52
Interpersonal Relations 1, 7, 13, 19, 25, 31, 37, 43, 49
Stress Management 5, 11, 17, 23, 29, 35, 41, 47

3/95: snw
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Illness Perception Questionnaire – Revised (IPQ-R) Cardiac Version
Perceived Heart Risk (4 items)

YOUR VIEWS ABOUT YOUR HEART DISEASE
Listed below are a number of symptoms that you may or may not have experienced since your heart
disease. Please indicate by circling Yes or No, whether you have experienced any of these symptoms
since your heart disease, and whether you believe that these symptoms are related to your heart disease.
I have experienced this
symptom since my heart disease

This symptom is related to my
heart disease

Pain

Yes

No

_____________

Yes

No

Sore Throat

Yes

No

_____________

Yes

No

Nausea

Yes

No

_____________

Yes

No

Breathlessness

Yes

No

_____________

Yes

No

Weight Loss

Yes

No

_____________

Yes

No

Fatigue

Yes

No

_____________

Yes

No

Stiff Joints

Yes

No

_____________

Yes

No

Sore Eyes

Yes

No

_____________

Yes

No

Wheeziness

Yes

No

_____________

Yes

No

Headaches

Yes

No

_____________

Yes

No

Upset Stomach

Yes

No

_____________

Yes

No

Sleep Difficulties

Yes

No

_____________

Yes

No

Dizziness

Yes

No

_____________

Yes

No

Loss of Strength

Yes

No

_____________

Yes

No

Chest Pain

Yes

No

_____________

Yes

No

Shortness of Breath

Yes

No

_____________

Yes

No

Loss of Appetite

Yes

No

_____________

Yes

No

Weakness

Yes

No

_____________

Yes

No

Unusually Scared

Yes

No

_____________

Yes

No

Indigestion

Yes

No

_____________

Yes

No
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We are interested in your own personal views of how you now see your current heart disease.
Please indicate how much you agree or disagree with the following statements about your heart
disease by ticking the appropriate box.

Views About Your Heart
Disease

Strongly Disagree Neither
Disagree
Agree nor
Disagree

Agree Strongly
Agree

Strongly
Disagree

Agree Strongly
Agree

IP1 My heart disease will last a short
time
IP2 My heart disease is likely to be
permanent rather than temporary
IP3 My heart disease will last for a
long time

Views About Your Heart
Disease
IP4*
IP5*
IP6
IP7
IP8*
IP9
IP10
IP11

IP12
IP13

IP14

This heart disease will pass
quickly
I expect to have this heart disease
for the rest of my life
My heart disease is a serious
condition
My heart disease has major
consequences on my life
My heart disease does not have
much effect on my life
My heart disease strongly affects
the way others see me
My heart disease has serious
financial consequences
My heart disease causes
difficulties for those who are
close to me
There is a lot which I can do to
control my symptoms
What I do can determine whether
my heart disease gets better or
worse
The course of my heart disease
depends on me

Disagree

Neither
Agree
nor
Disagree
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IP15
*
IP16
IP17
*
IP18
*
IP19
*
IP20
IP21

IP22
IP23
*

IP24
IP25
IP26
IP27
IP28
*
IP29
IP30
IP31
IP32

IP33
IP34

Nothing I do will affect my heart
disease
I have the power to influence my
heart disease
My actions will have no affect on
the outcome of my heart disease
My heart disease will improve in
time
There is little that can be done to
improve my heart disease
My treatment will be effective in
curing my heart disease
The negative effects of my heart
disease can be prevented
(avoided) by my treatment
My treatment can control my
heart disease
There is nothing which can help
my condition
The symptoms of my condition
are puzzling to me
My heart disease is a mystery to
me
I don’t understand my heart
disease
My heart disease doesn’t make
any sense to me
I have a clear picture or
understanding of my condition
The symptoms of my heart
disease change a great deal
My symptoms come and go in
cycles
My heart disease is very
unpredictable
I go through cycles in which my
heart disease gets better and
worse
I get depressed when I think
about my heart disease
When I think about my heart
disease I get upset
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IP35
IP36
*
IP37
IP38

My heart disease makes me feel
angry
My heart disease does not worry
me
Having this heart disease makes
me feel anxious
My heart disease makes me feel
afraid

Causes of My Heart Disease
We are interested in what you consider may have been the cause of your heart disease. As
people are very different, there is no correct answer for this question. We are most interested in
your own views about the factors that caused your heart disease rather than what others including
doctors or family may have suggested to you. Below is a list of possible causes for your heart
disease. Please indicate how much you agree or disagree that they were causes for you by
ticking the appropriate box.

Possible Causes
C1
C2
C3
C4
C5
C6
C7
C8
C9
C10
C11*
C12*
C13*
C14*
C15*
C16*
C17*
C18*

Stress or worry
Hereditary – it runs in my family
A Germ or virus
Diet or eating habits
Chance or bad luck
Poor medical care in my past
Pollution in the environment
My own behavior
My mental attitude e.g. thinking
about life negatively
Family problems or worries
Overwork
My emotional state e.g. feeling
down, lonely, anxious, empty
Ageing
Alcohol
Smoking
Accident or injury
My personality
Altered immunity

Strongly Disagree Neither
Disagree
Agree nor
Disagree

Agree

Strongly
Agree
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In the table below, please list in rank-order the three most important factors that you now believe
caused YOUR heart disease. You may use any of the items from the box above, or you may
have additional ideas of your own.
The most important causes for me:
1.______________________________________________________
2. ______________________________________________________
3. ______________________________________________________
Reference
Moss-Morris, R., Weinman, J., Petrie, K.J., Horne, R., Cameron, L.D. & Buick, D. (2002). The
Revised Illness Perception Questionnaire(IPQ-R). Psychology and Health, 17(1), 1-16
Using and Scoring the IPQ-R Subscales
It is advisable to have a good read of the IPQ-R paper before you use the questionnaire. The
paper can be downloaded from this website. As outlined in the paper, the questionnaire can be
adapted for particular groups. Items relevant to the identity and causes of the illness can readily
be inserted into the questionnaire.
The pdf English version of the IPQ-R on this website asks the questions in relation to illness.
Wherever possible, the word illness should be replaced with the name of the particular illness or
condition under study e.g. diabetes, chronic fatigue syndrome.

SCORING THE IPQ-R
Please note:
High scores on the identity, timeline, consequences, and cyclical dimensions represent strongly
held beliefs about the number of symptoms attributed to the illness, the chronicity of the
condition, the negative consequences of the illness, and the cyclical nature of the condition.
High scores on the personal control, treatment control and coherence dimensions, represent
positive beliefs about the controllability of the illness and a personal understanding of the
condition.
Coding: for identity scale yes = 1; no = 0
strongly disagree =1, disagree =2, neither agree or disagree = 3, agree = 4, strongly agree = 5
Reverse score: IP1, IP4, IP8, IP15, IP17, IP18, IP19, IP23, IP24, IP25, IP26, IP27, IP36
1. Identity: sum yes-rated symptoms in column 2 (this symptom is related to my illness) on p. 1
2. Timeline (acute/chronic): sum items IP1 - IP5 + IP18

158

3. Consequences: sum items IP6 - IP11
4. Personal control: sum items IP12 - 1P17
5. Treatment control items: sum items IP19 – IP23
6. Illness coherence items: sum items IP24 – IP28
7. Timeline cyclical: sum items IP29 – IP32
8. Emotional representations: sum items IP33 – IP38
9. Causes: items C1 - C18
Do not use these as a scale. Start analysis with separate items - used as grouping variables
(ie those who do/do not believe in a specific causal factor). With a sufficient sample size
(n=85 or more), factor analysis can be used to identify groups of causal beliefs (eg lifestyle;
stress etc) which can then be used as sub-scales (see the following papers for examples).
References
Moss-Morris, R., Weinman, J., Petrie, K.J., Horne, R., Cameron, L.D. & Buick, D. (2002). The
Revised Illness Perception Questionnaire (IPQ-R). Psychology and Health, 17(1), 1-16.
Weinman, J., Petrie, K., Sharpe, N. & Walker, S. (2000). Causal attributions in patients and
spouses following a heart attack and subsequent lifestyle changes. British Journal of
Health Psychology, 5, 263-273.
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The Satisfaction Section (Part 1) will only be used to measure QOL.
STEPS FOR CALCULATING QLI SCORES FOR THE SATISFACTION SECTION
ONLY:
When using the Satisfaction Section only, insert a “6” score for all the important responses in
Section 2 of the Quality of Life Index Cardiac Version-IV. Conceptually this will make all items
equally important (scoring instructions obtained by Dr. Carol Ferrans on 12/9/2016).
Using SPSS
1.
2.
3.

Subtract the number 1 from the response for each satisfaction item.
Multiply each item by the number 6.
Sum the appropriate items for the scale (these are listed on the QLI under Questionnaires and
Scoring Subscale Items). This is on the QLI website at www.uic.edu/orgs/qli.
4. Divide the sum obtained in step 3 by the number of items answered by that person. This can be
accomplished by calculating a mean for EACH individual person (NOTE: this is different from a
mean for the group).

165
MOS SOCIAL SUPPORT SURVEY
Next are some questions about the support that is available to you.
1. About how many close friends and close relatives do you have (people you feel at ease with
and can talk to about what is on your mind)?
Write in number of close friends

number of close relatives

People sometimes look to others for companionship, assistance, or other types of support.
How often is each of these following types of support available to you if you need it?
Circle one number on each line
None
Of the
Time

A little Some
of the of the
Time
Time

Most
of the
Time

All
of the
Time

2. Someone to help you if you were confined to bed

1

2

3

4

5

3. Someone you can count on to listen to you when
you need to talk

1

2

3

4

5

4. Someone to give you good advice about a crisis

1

2

3

4

5

5. Someone to take you to the doctor if you needed it

1

2

3

4

5

6. Someone who shows you love and affection

1

2

3

4

5

7. Someone to have a good time with

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

10. Someone who hugs you

1

2

3

4

5

11. Someone to get together with for relaxation

1

2

3

4

5

8. Someone to give you information to help you
understand a situation
9. Someone to confide in or talk to about yourself or
your problems
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People sometimes look to others for companionship, assistance, or other types of support.
How often is each of these following types of support available to you if you need it?

Circle one number on each line
None
Of the
Time

A little Some
of the of the
Time
Time

Most
of the
Time

All
of the
Time

12. Someone to prepare your meals if you were unable
to do it by yourself

1

2

3

4

5

13. Someone whose advice you really want

1

2

3

4

5

14. Someone to do things with to help you get your
mind off things

1

2

3

4

5

15. Someone to help with daily chores if you were sick

1

2

3

4

5

16. Someone to share your most private worries and
fears with

1

2

3

4

5

17. Someone to turn to for suggestions about how to
deal with a personal problem

1

2

3

4

5

18. Someone to do something enjoyable with

1

2

3

4

5

19. Someone who understands your problems

1

2

3

4

5

20. Someone to love and make you feel wanted

1

2

3

4

5

Reference
Sherbourne, C. D. & Stewart, A. L. (1991). The MOS social support survey. Social Science
Medicine, 32(6), 705-714.
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Participants needed:
• Women with heart
disease
• Age 35 to 78
Does Mood Affect
Healthy Behaviors
and Quality of Life?

Questionnaire ~ 45
minutes

Call or Email Today!!!
Jacqueline Tulley
Doctoral Nursing Student at Loyola University Chicago
815-735-9824
jtulley1@luc.edu

Reimbursed for
time and effort $10
Target gift card

APPENDIX D
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April 3, 2017
Jacqueline Tulley, MSN, ACNP-BC, RN
Loyola University of Chicago
Nursing PhD Student
Dear Ms Tulley:
Thank you for choosing Advocate Medical Group Cardiology (Downers Grove, Naperville, and
Elmhurst locations) as the site for your nursing research project. We would like to extend this
letter of support to participate in your study “The Impact of Mood on Health Behaviors and
Quality of Life in Women with Cardiovascular Disease”. Our participation would be contingent
upon the approval of the Advocate Medical Group Cardiology Protocol Review Committee and
the Institutional Review Board at Advocate Health Care.
I will be your contact person at AMG and can be reached at 630-785-2661 or
lea.elder@advocathealth.com. If you have questions or we can provide you with additional
information, please do not hesitate to call. Again, thank you for choosing Advocate Medical
Group.
Sincerely,

Lea Elder, RN, MSN, MBA, CCRC

Director of Research
Advocate Medical Group, Cardiology
cc.

Lawrence Barr, MD
Wm Thomas Summerfelt, PhD
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Consent to Take Part in a Human Research Study
Title of Research Study: The Impact of Mood on Health Behaviors and Quality of Life in
Women with Cardiovascular Disease
Principal Investigator:
Jacqueline Tulley, MSN, ACNP, RN
Address:
Loyola University Chicago, Marcella Niehoff School of Nursing
2160 S. 1st Avenue / Maywood, Illinois 60153
Phone:
815-735-9824
Why am I being invited to take part in a research study?
You are being invited to take part in a research study because you are a woman with heart disease.
There is evidence that shows mood may contribute to the lack of successful change in healthy
behaviors in women with heart disease. In addition, mood may have an effect on one’s illness
perception and overall quality of life. There are few studies examining the effect of mood on
these factors in women with known heart disease, and thus the reason this study is being
conducted.
What should I know about a research study?
• Someone will explain this research study to you.
• Whether or not you take part is up to you.
• You can choose not to take part.
• You can agree to take part and later change your mind.
• Your decision will not be held against you.
• You can ask all the questions you want before you decide.
Who can I talk to?
If you have questions, concerns, or complaints, or think the research has hurt you, talk to the
research team at Advocate Health Care IRB.
This research has been reviewed, approved and will be monitored by the Institutional Review
Board (“IRB”) of Advocate Health Care and Loyola University Chicago. An IRB is a committee,
independent of the Loyola University Chicago investigators, that reviews and oversees research
studies to protect the rights and safety of participants. You may talk to them at 630-929-6148 or
email IRBMail@advocatehealth.com if:
• Your questions, concerns, or complaints are not being answered by the research team.
• You cannot reach the research team.
• You want to talk to someone besides the research team.
• You have questions about your rights as a research subject.
• You want to get information or provide input about this research.

IRB Approved 07/30/17 – 07/29/18
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Why is this research being done?
The purpose of this study is to see if mood impacts the perceptions of your health and whether
this may affect your ability to engage in healthy behaviors such as taking your medication,
exercise and diet. We know that being depressed can often affect how well you take care of
yourself. However, we don’t know if it affects how you perceive your health. Therefore, in
order to better understand these relationships, we are asking questions about your mood, health
perceptions, health behaviors, and quality of life.
How long will the research last?
You will only be in the study for the time it takes to complete the questionnaires which may be up
to one hour.
How many people will be studied?
We expect up to 128 people for the study.
What happens if I say yes, I want to be in this research?
• If you agree to participate in this study you will be required to fill out a packet of
questionnaires that describes your mood, illness perception, healthy behaviors, quality of
life and demographic information.
•

Jacqueline Tulley, the principal investigator who is also a doctoral student at Loyola
University, will contact you to schedule a date and time to meet at your cardiology
outpatient office or designated location for you to complete the questionnaire.

•

The questionnaire will take approximately 45 minutes to complete. You will only be
asked to complete the questionnaires one time.

•

In order to meet the goals of the research study, Jacqueline Tulley will collect information
on you from your Advocate Medical Group medical record (including, but not limited to,
history and physical exam notes, progress notes, consultation reports, laboratory test
results, and/or operative reports).

What are my responsibilities if I take part in this research?
If you take part in this research, you will be responsible for completing questionnaires and
allowing me to access your medical record to record your age, height, weight, blood pressure,
total cholesterol, HDL, smoking status, major diseases.
What happens if I do not want to be in this research?
You can leave the research at any time and it will not be held against you. Your decision whether
or not to participate will not affect your current or future relationship with Advocate Health Care.
What happens if I say yes, but I change my mind later?
You can leave the research at any time it will not be held against you. You can stop the survey at
IRB Approved 07/30/17 – 07/29/18
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any time without it affecting your medical care. The partially completed surveys will be kept to
determine reasons for partial completion and compare to those who completed the entire survey.
Is there any way being in this study could be bad for me?
Enrollment in this study may cause you to feel uncomfortable when answering some of the survey
questions. After completing the surveys if there are concerns about your mood, you should talk to
your healthcare provider and you will be provided Advocate information about mental health.
Will there be any costs to me if I participate?
There will not be any costs to you if you participate.
You will receive a $10 Target gift card as a thank you for your time participating in this study
when you complete the questionnaires.
Will being in this study help me in any way?
You will not benefit from participating in this study.
What happens to the information collected for the research?
Efforts will be made to limit the use and disclosure of your personal information, including
research study and medical records, to people who have a need to review this information. We
cannot promise complete confidentiality. Organizations that may inspect and copy your
information include the Advocate Health Care IRB and other representatives of this organization
involved in the monitoring and oversight of research.
Federal law provides additional protections of your medical records and related health information. That law is the Health Insurance Portability and Accountability Act (HIPAA). This study’s
HIPAA statement is provided below. You are providing your authorization if you sign this form.
HIPAA Authorization

How will my information be kept confidential?
Your identity will be protected as required by law and according to any policies described in the
Confidentiality section above. You should be aware that your study records (which include your
medical records, your signed consent form, and other identifiable information) will be shared as
needed for the purposes of the study. If this is a sponsored study, researchers may share your
information with representatives of the sponsor for the purposes of managing and overseeing the
study. Usually the health information sent to sponsors does not directly identify participants (for
example, by name or address). Instead initials and a code number are used. Some personal
information, such as date of birth, will usually be included but will not be used to identify you.
Additionally, governmental oversight authorities [e.g. the U.S. Food and Drug Administration
(FDA) or the Department of Health and Human Services Office for Human Research Protections
(OHRP)] may have access to your information. Representatives of the Institutional Review
Board overseeing this study may have access to your data.
Please note that the study doctor or study staff may also share personal information about you if
required by law (for example, if the study doctor or study staff suspects that you are going to
harm someone or yourself). If you have questions about this, please ask the study doctor.
IRB Approved 07/30/17 – 07/29/18
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How will my information be used and shared for this study?
This section explains who will use and share your health information if you agree to be in this
study. You must authorize this use and sharing of your information by signing this form or you
cannot be in the study.
The study principal investigator and study staff will collect, use, and share identifiable health
information about you, including any information needed to conduct the study. Information used
and shared may include:
• information from your medical records related to the research;
• information collected about you during the research and any follow-up concerning study
visits, tests, procedures, outcomes, etc.
Your information may be used and shared for some or all of the following purposes:
• to conduct this research;
• to review the study, and to check the safety and results of the study;
• to seek government approval of an investigational study drug, vaccine, device or product
if such was involved in the trial;
• to facilitate a public health authority that is authorized by law to collect or receive such
information for the purpose of preventing or controlling disease, injury, or disability, and
conducting public health surveillance, investigations, or interventions.
After your information is shared with the organizations listed above, the law may not require
them to protect the privacy of your information. To maintain the integrity of this research, you
might not have access to any health information developed as part of this study until it is
completed. At that point, you generally would have access to your health information.
You can cancel your authorization to use and share your information at any time by writing a
letter to the study doctor. If you cancel your authorization, you will not be able to continue in the
study. If some aspects of the study were optional, you may cancel your authorization for the
optional part(s) of the study and still remain in the main study.
If you cancel your authorization, the study doctor and study staff will still be able to use and share
your information that has already been collected to maintain the integrity of the study. No new
information will be collected without your permission. This authorization to use and share your
information has no expiration date. If study information is used for scientific publications or
educational purposes, all identifying information will be removed.
Signature Block for Capable Adult
Your signature documents your permission to take part in this research.
Signature of subject

Date

Printed name of subject
Signature of person obtaining consent
Printed name of person obtaining consent
IRB Approved 07/30/17 – 07/29/18
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Behavioral Health Service
Locations
Naperville Counseling &
Psychotherapy Center
Naperville
1555 Naperville Wheaton Road
Suite 212
Naperville, Illinois 60563
1-866-296-5262
Oak Brook Counseling &
Psychotherapy Center
Oak Brook
2625 Butterfield Rd
Suite 101N
Oak Brook, IL 60523
1-866-296-5262
Christian Counseling Center
Lombard
2020 Meyers Road
Lombard, IL 60148
1-800-361-6880
Linden Oaks Behavioral Health
Naperville
825 South West Street
Naperville, Il 60540
1-630-305-5027
New Prairie Counseling Services
Elmhurst
360 W. Butterfield Rd
Suite 120
Elmhurst, Il 60126
1-630-492-0404

Associates in Professional Counseling
Naperville
1804 N. Naper Blvd #370
Naperville, Il 60563
1-888-545-5707
Heritage Professional Associates
Hinsdale
120 East Ogden Ave
Suite 220
Hinsdale, Il 60521
1-630-325-5300
Wheaton
1737 S. Naperville Rd.
Suite 206
Wheaton, Il 60189
1-630-653-9700
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Depression and Coronary Artery Disease
There is a link between depression and coronary artery disease. People with heart disease are
more likely to get depression. And if a person has both depression and heart disease, they may
not stay as healthy as possible. They are less likely to take their medicines and get regular
exercise. And this may raise their risk of having a heart attack.

Watch for symptoms of depression
Depression causes you to feel sad and hopeless much of the time. It’s different from normal
feelings of sadness, grief, or low energy. Depression is a medical problem that needs treatment.
If you think you may be depressed, see your doctor for diagnosis and treatment right away.
Untreated depression may get worse. And your heart disease may get worse too.

Your doctor can help
If you have heart disease, your doctor will probably ask you some simple questions to check for
any symptoms of depression. But if you think you have symptoms of depression, do not wait to
ask for help. Your doctor can help find out if you are depressed and talk to you about your
options for treatment.
On your regular doctor visits, he or she might ask how often you have been bothered by any of
the following problems in the past 2 weeks:
• You don’t have interest or pleasure in doing things
• You feel down, depressed, or hopeless
If your doctor thinks you might have depression symptoms, he or she will ask you more about
your symptoms. Your doctor may refer you to another doctor who diagnoses and treats
depression.

Ask for help
If you think you might be depressed, talk to your doctor. The sooner you know if you are
depressed, the sooner you can get treatment. Treating depression is good for your health.
Many people have concerns about seeking treatment for a mental health problem. You might
feel too embarrassed to ask for help. Or maybe you think that you’ll get over depression on your
own. You may think it’s a sign of weakness, or you don’t want people to know about it. It’s
important to overcome these reasons for not seeking treatment.

Take care of yourself
If you have depression and heart disease, try hard to stay healthy. Having both of these
conditions can make it hard to take your medicines or do healthy things like exercise and eat
right.

For friends and family
If you think that someone you know is depressed, the best thing you can do is to get the person to
see a doctor. The sooner someone with depression gets treatment, the sooner he or she will feel
better.
©2006-2017 Healthwise, Incorporated. Care instructions adapted under license by your
healthcare professional. If you have questions about a medical condition or this instruction,
always ask your healthcare professional. Healthwise, Incorporated disclaims any warranty or
liability for your use of this information.
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Variables and Measurements of Study
Following the revised version of Wilson & Cleary’s (1995) conceptual model of Health-Related
Quality of Life (HRQoL), the following study variables and measurement tools will be used in
this study.

Biological Function

Symptom Status

Study Variable

Measurement Tool

Data collection method

Cardiovascular risk
factors
Co-morbidities
Age, height, weight
HDL, total cholesterol
Diabetes
Tobacco use
Systolic blood pressure
Cardiac history; mental
health history
Major Diseases
Cardiac Health Factors
medications
Depression

Framingham Recurrent
Risk Model

EMR

Functional Comorbidity
Index

Self Report

Demographic form
(created by researcher)
Patient Health
Questionnaire-8 (PHQ-8)
Generalized Anxiety
Disorder-7 (GAD-7)
Health Promoting
Lifestyle Behaviors-II
(HPLP-II)
Illness Perception
Questionnaire-Revised
Cardiac version (IPQ-Rcardiac)
Quality of Life-Index
Cardiac version (QLICardiac IV)
Demographic form
(created by researcher)
Demographic form
(created by researcher)
Demographic form
(created by researcher)
Demographic form
(created by researcher)
Demographic form
(created by researcher)
Demographic form
(created by researcher)
Medical Outcomes Study
Social Support Survey
(MOS-SS)

Self-report

Anxiety
Functional Status

Health Promoting
Behaviors

General Health
Perceptions

Illness perception

Overall Quality of Life

Satisfaction with life

Characteristics of the
Individual

Age
Race/Ethnicity
Marital status
Education status
Employment
Social economic status

Characteristics of the
Environment

Social support

Self-report
Self-report
Self-report

Self-report

Self-report

Self-report
Self-report
Self-report
Self-report
Self-report
Self-report
Self-report
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